Background  ||| S:24 E:43 ||| NNP
Glucocorticoids  ||| S:43 E:59 ||| NNPS
influence  ||| S:59 E:69 ||| VBP
a  ||| S:69 E:71 ||| DT
wide  ||| S:71 E:76 ||| JJ
spectrum  ||| S:76 E:85 ||| NN
of  ||| S:85 E:88 ||| IN
cellular  ||| S:88 E:105 ||| JJ
functions  ||| S:105 E:115 ||| NNS
through  ||| S:115 E:123 ||| IN
their  ||| S:123 E:129 ||| PRP$
action  ||| S:129 E:136 ||| NN
on  ||| S:136 E:139 ||| IN
soluble  ||| S:139 E:147 ||| JJ
intracellular  ||| S:147 E:169 ||| JJ
receptors ||| S:169 E:178 ||| NNS
.  ||| S:178 E:180 ||| .
In  ||| S:180 E:183 ||| IN
most  ||| S:183 E:188 ||| JJS
cells ||| S:188 E:193 ||| NNS
,  ||| S:193 E:195 ||| ,
unliganded  ||| S:195 E:206 ||| FW
glucocorticoid  ||| S:206 E:229 ||| FW
receptors  ||| S:229 E:239 ||| FW
( ||| S:239 E:240 ||| -LRB-
GR ||| S:240 E:242 ||| NNP
)  ||| S:242 E:244 ||| -RRB-
reside  ||| S:244 E:251 ||| JJ
predominately  ||| S:251 E:265 ||| NN
in  ||| S:265 E:268 ||| IN
the  ||| S:268 E:272 ||| DT
cytoplasm ||| S:272 E:281 ||| NN
,  ||| S:281 E:283 ||| ,
where  ||| S:283 E:297 ||| WRB
they  ||| S:297 E:302 ||| PRP
exist  ||| S:302 E:308 ||| VBP
as  ||| S:308 E:311 ||| IN
a  ||| S:311 E:313 ||| DT
heteromeric  ||| S:313 E:325 ||| JJ
complex  ||| S:325 E:333 ||| JJ
comprised  ||| S:333 E:343 ||| JJ
minimally  ||| S:343 E:353 ||| NN
of  ||| S:353 E:364 ||| IN
GR ||| S:364 E:366 ||| NNP
,  ||| S:366 E:368 ||| ,
90-kDa  ||| S:368 E:375 ||| NNP
and  ||| S:375 E:379 ||| CC
70-kDa  ||| S:379 E:386 ||| CD
heat  ||| S:386 E:391 ||| NN
shock  ||| S:391 E:397 ||| NN
proteins  ||| S:397 E:406 ||| NNS
( ||| S:406 E:407 ||| -LRB-
hsp90  ||| S:407 E:413 ||| NNP
and  ||| S:413 E:425 ||| CC
hsp70 ||| S:425 E:430 ||| CD
) ||| S:430 E:431 ||| -RRB-
.  ||| S:431 E:433 ||| .
Other  ||| S:433 E:439 ||| JJ
proteins  ||| S:439 E:448 ||| NNS
( ||| S:448 E:449 ||| -LRB-
i.e.  ||| S:449 E:454 ||| FW
p60 ||| S:454 E:457 ||| FW
/ ||| S:457 E:458 ||| FW
Hop ||| S:458 E:461 ||| NNP
,  ||| S:461 E:463 ||| ,
p23 ||| S:463 E:466 ||| NNP
,  ||| S:466 E:468 ||| ,
hsp40 ||| S:468 E:473 ||| NNP
,  ||| S:473 E:475 ||| ,
FKBP52 ||| S:475 E:481 ||| NNP
,  ||| S:481 E:491 ||| ,
and  ||| S:491 E:495 ||| CC
FKBP51 ||| S:495 E:501 ||| CD
)  ||| S:501 E:503 ||| -RRB-
have  ||| S:503 E:508 ||| VBP
been  ||| S:508 E:513 ||| VBN
implicated  ||| S:513 E:524 ||| VBN
in  ||| S:524 E:527 ||| IN
the  ||| S:527 E:539 ||| DT
assembly ||| S:539 E:547 ||| NN
/ ||| S:547 E:548 ||| CD
stabilization  ||| S:548 E:562 ||| NN
of  ||| S:562 E:565 ||| IN
the  ||| S:565 E:569 ||| DT
GR-hsp90-hsp70-complex  ||| S:569 E:592 ||| NN
in  ||| S:592 E:595 ||| IN
a  ||| S:595 E:605 ||| DT
form  ||| S:605 E:610 ||| NN
that  ||| S:610 E:615 ||| WDT
has  ||| S:615 E:619 ||| VBZ
high  ||| S:619 E:624 ||| JJ
affinity  ||| S:624 E:633 ||| NN
for  ||| S:633 E:637 ||| IN
agonist  ||| S:637 E:645 ||| NNS
[ ||| S:645 E:646 ||| -LRB-
for  ||| S:646 E:650 ||| IN
review ||| S:650 E:656 ||| NN
,  ||| S:656 E:658 ||| ,
see  ||| S:658 E:670 ||| VB
Ref.  ||| S:670 E:675 ||| CD
1 ||| S:675 E:676 ||| CD
,  ||| S:676 E:678 ||| ,
2 ||| S:678 E:679 ||| CD
,  ||| S:679 E:681 ||| ,
3 ||| S:681 E:682 ||| LS
] ||| S:682 E:683 ||| -RRB-
.  ||| S:683 E:685 ||| .
Upon  ||| S:685 E:690 ||| IN
agonist  ||| S:690 E:698 ||| JJ
binding ||| S:698 E:705 ||| NN
,  ||| S:705 E:707 ||| ,
the  ||| S:707 E:711 ||| DT
complex  ||| S:711 E:719 ||| JJ
undergoes  ||| S:719 E:737 ||| NNS
a  ||| S:737 E:739 ||| DT
transformation ||| S:739 E:753 ||| NN
,  ||| S:753 E:755 ||| ,
and  ||| S:755 E:759 ||| CC
the  ||| S:759 E:763 ||| DT
ligand  ||| S:763 E:770 ||| NN
bound  ||| S:770 E:776 ||| VBN
GR  ||| S:776 E:779 ||| NNP
translocates  ||| S:779 E:792 ||| NN
into  ||| S:792 E:805 ||| IN
to  ||| S:805 E:808 ||| TO
the  ||| S:808 E:812 ||| DT
nucleus  ||| S:812 E:820 ||| NN
in  ||| S:820 E:823 ||| IN
a  ||| S:823 E:825 ||| DT
manner  ||| S:825 E:832 ||| NN
that  ||| S:832 E:837 ||| WDT
is  ||| S:837 E:840 ||| VBZ
determined  ||| S:840 E:851 ||| VBN
by  ||| S:851 E:854 ||| IN
a  ||| S:854 E:856 ||| DT
nuclear  ||| S:856 E:872 ||| JJ
localization  ||| S:872 E:885 ||| JJ
sequence  ||| S:885 E:894 ||| NN
( ||| S:894 E:895 ||| -LRB-
NLS ||| S:895 E:898 ||| NNP
)  ||| S:898 E:900 ||| -RRB-
contained  ||| S:900 E:910 ||| VBD
in  ||| S:910 E:913 ||| IN
the  ||| S:913 E:917 ||| DT
receptor  ||| S:917 E:926 ||| NN
[  ||| S:926 E:928 ||| -LRB-
4 ||| S:928 E:929 ||| LS
] ||| S:929 E:930 ||| -RRB-
.  ||| S:930 E:940 ||| .
There  ||| S:940 E:946 ||| RB
the  ||| S:946 E:950 ||| DT
GR  ||| S:950 E:953 ||| NNP
acts  ||| S:953 E:958 ||| VBZ
as  ||| S:958 E:961 ||| IN
a  ||| S:961 E:963 ||| DT
ligand-activated  ||| S:963 E:980 ||| JJ
transcriptional  ||| S:980 E:1004 ||| JJ
stimulator  ||| S:1004 E:1015 ||| NN
or  ||| S:1015 E:1018 ||| CC
repressor  ||| S:1018 E:1028 ||| NN
of  ||| S:1028 E:1031 ||| IN
primary  ||| S:1031 E:1039 ||| JJ
response  ||| S:1039 E:1048 ||| NN
genes  ||| S:1048 E:1054 ||| NNS
by  ||| S:1054 E:1065 ||| IN
binding  ||| S:1065 E:1073 ||| VBG
to  ||| S:1073 E:1076 ||| TO
glucocorticoid  ||| S:1076 E:1091 ||| VB
hormone-responsive  ||| S:1091 E:1110 ||| JJ
elements  ||| S:1110 E:1119 ||| NNS
( ||| S:1119 E:1120 ||| -LRB-
GRE ||| S:1120 E:1123 ||| NNP
)  ||| S:1123 E:1133 ||| -RRB-
contained  ||| S:1133 E:1143 ||| VBD
in  ||| S:1143 E:1146 ||| IN
the  ||| S:1146 E:1150 ||| DT
promoter  ||| S:1150 E:1159 ||| NN
regions  ||| S:1159 E:1167 ||| NNS
of  ||| S:1167 E:1170 ||| IN
steroid-responsive  ||| S:1170 E:1197 ||| JJ
genes  ||| S:1197 E:1203 ||| NNS
and  ||| S:1203 E:1207 ||| CC
either  ||| S:1207 E:1214 ||| DT
facilitating  ||| S:1214 E:1227 ||| NN
or  ||| S:1227 E:1230 ||| CC
repressing  ||| S:1230 E:1241 ||| VBG
the  ||| S:1241 E:1245 ||| DT
formation  ||| S:1245 E:1263 ||| NN
of  ||| S:1263 E:1266 ||| IN
an  ||| S:1266 E:1269 ||| DT
active  ||| S:1269 E:1276 ||| JJ
transcriptional  ||| S:1276 E:1292 ||| JJ
complex ||| S:1292 E:1299 ||| NN
.  ||| S:1299 E:1309 ||| .
Although  ||| S:1309 E:1318 ||| IN
little  ||| S:1318 E:1325 ||| RB
is  ||| S:1325 E:1328 ||| VBZ
known  ||| S:1328 E:1334 ||| VBN
about  ||| S:1334 E:1340 ||| IN
the  ||| S:1340 E:1344 ||| DT
molecular  ||| S:1344 E:1354 ||| JJ
machinery  ||| S:1354 E:1372 ||| NN
that  ||| S:1372 E:1377 ||| WDT
regulates  ||| S:1377 E:1387 ||| VBZ
steroid  ||| S:1387 E:1395 ||| JJ
receptor  ||| S:1395 E:1404 ||| NN
movement  ||| S:1404 E:1413 ||| NN
through  ||| S:1413 E:1421 ||| IN
the  ||| S:1421 E:1433 ||| DT
cytoplasm  ||| S:1433 E:1443 ||| NN
and  ||| S:1443 E:1447 ||| CC
into  ||| S:1447 E:1452 ||| IN
the  ||| S:1452 E:1456 ||| DT
nucleus ||| S:1456 E:1463 ||| NN
,  ||| S:1463 E:1465 ||| ,
several  ||| S:1465 E:1473 ||| JJ
studies  ||| S:1473 E:1481 ||| NNS
suggest  ||| S:1481 E:1497 ||| VBP
that  ||| S:1497 E:1502 ||| DT
movement  ||| S:1502 E:1511 ||| NN
is  ||| S:1511 E:1514 ||| VBZ
influenced  ||| S:1514 E:1525 ||| VBN
by  ||| S:1525 E:1528 ||| IN
reversible  ||| S:1528 E:1539 ||| JJ
phosphorylation ||| S:1539 E:1554 ||| NN
.  ||| S:1554 E:1564 ||| .
Evidence  ||| S:1564 E:1573 ||| NN
for  ||| S:1573 E:1577 ||| IN
this  ||| S:1577 E:1582 ||| DT
originated  ||| S:1582 E:1593 ||| NN
from  ||| S:1593 E:1598 ||| IN
the  ||| S:1598 E:1602 ||| DT
studies  ||| S:1602 E:1610 ||| NNS
of  ||| S:1610 E:1613 ||| IN
Qi  ||| S:1613 E:1616 ||| NNP
et  ||| S:1616 E:1619 ||| FW
al.  ||| S:1619 E:1631 ||| FW
[  ||| S:1631 E:1633 ||| -LRB-
5 ||| S:1633 E:1634 ||| CD
,  ||| S:1634 E:1636 ||| ,
6 ||| S:1636 E:1637 ||| CD
] ||| S:1637 E:1638 ||| -RRB-
,  ||| S:1638 E:1640 ||| ,
which  ||| S:1640 E:1646 ||| WDT
revealed  ||| S:1646 E:1655 ||| VBD
that  ||| S:1655 E:1660 ||| IN
the  ||| S:1660 E:1664 ||| DT
hormone  ||| S:1664 E:1672 ||| NN
insensitivity  ||| S:1672 E:1694 ||| VBZ
produced  ||| S:1694 E:1703 ||| VBN
by  ||| S:1703 E:1706 ||| IN
cellular  ||| S:1706 E:1715 ||| JJ
transformation  ||| S:1715 E:1730 ||| NN
with  ||| S:1730 E:1735 ||| IN
v-mos  ||| S:1735 E:1741 ||| NNP
( ||| S:1741 E:1742 ||| -LRB-
a  ||| S:1742 E:1752 ||| FW
serine ||| S:1752 E:1758 ||| FW
/ ||| S:1758 E:1759 ||| FW
threonine  ||| S:1759 E:1769 ||| FW
protein  ||| S:1769 E:1777 ||| FW
kinase  ||| S:1777 E:1784 ||| FW
that  ||| S:1784 E:1789 ||| IN
acts  ||| S:1789 E:1794 ||| NNS
as  ||| S:1794 E:1797 ||| IN
an  ||| S:1797 E:1800 ||| DT
oncogene ||| S:1800 E:1808 ||| NN
)  ||| S:1808 E:1818 ||| -RRB-
results  ||| S:1818 E:1826 ||| NNS
from  ||| S:1826 E:1831 ||| IN
both  ||| S:1831 E:1836 ||| PDT
a  ||| S:1836 E:1838 ||| DT
decrease  ||| S:1838 E:1847 ||| NN
in  ||| S:1847 E:1850 ||| IN
the  ||| S:1850 E:1854 ||| DT
nuclear  ||| S:1854 E:1862 ||| JJ
retention  ||| S:1862 E:1872 ||| NN
of  ||| S:1872 E:1883 ||| IN
liganded  ||| S:1883 E:1892 ||| JJ
receptor  ||| S:1892 E:1901 ||| NN
and  ||| S:1901 E:1905 ||| CC
a  ||| S:1905 E:1907 ||| DT
decrease  ||| S:1907 E:1916 ||| NN
in  ||| S:1916 E:1919 ||| IN
the  ||| S:1919 E:1923 ||| DT
reutilization  ||| S:1923 E:1937 ||| NN
of  ||| S:1937 E:1940 ||| IN
GR  ||| S:1940 E:1951 ||| NNP
protein  ||| S:1951 E:1959 ||| NN
that  ||| S:1959 E:1964 ||| IN
cycles  ||| S:1964 E:1971 ||| NNS
back  ||| S:1971 E:1976 ||| RB
into  ||| S:1976 E:1981 ||| IN
the  ||| S:1981 E:1985 ||| DT
cytoplasm ||| S:1985 E:1994 ||| NN
.  ||| S:1994 E:1996 ||| .
Subsequently ||| S:1996 E:2008 ||| RB
,  ||| S:2008 E:2018 ||| ,
DeFranco  ||| S:2018 E:2027 ||| FW
et  ||| S:2027 E:2030 ||| FW
al.  ||| S:2030 E:2034 ||| FW
[  ||| S:2034 E:2036 ||| -LRB-
7 ||| S:2036 E:2037 ||| CD
]  ||| S:2037 E:2039 ||| -RRB-
reported  ||| S:2039 E:2048 ||| VBD
that  ||| S:2048 E:2053 ||| DT
treatment  ||| S:2053 E:2063 ||| NN
with  ||| S:2063 E:2068 ||| IN
okadaic  ||| S:2068 E:2084 ||| JJ
acid ||| S:2084 E:2088 ||| NN
,  ||| S:2088 E:2090 ||| ,
a  ||| S:2090 E:2092 ||| DT
potent  ||| S:2092 E:2099 ||| FW
ser ||| S:2099 E:2102 ||| FW
/ ||| S:2102 E:2103 ||| FW
thr  ||| S:2103 E:2107 ||| FW
protein  ||| S:2107 E:2115 ||| FW
phosphatase  ||| S:2115 E:2127 ||| FW
inhibitor ||| S:2127 E:2136 ||| FW
,  ||| S:2136 E:2138 ||| ,
also  ||| S:2138 E:2151 ||| RB
results  ||| S:2151 E:2159 ||| NNS
in  ||| S:2159 E:2162 ||| IN
inefficient  ||| S:2162 E:2174 ||| JJ
nuclear  ||| S:2174 E:2182 ||| JJ
retention  ||| S:2182 E:2192 ||| NN
of  ||| S:2192 E:2195 ||| IN
agonist-bound  ||| S:2195 E:2217 ||| NNP
GR  ||| S:2217 E:2220 ||| NNP
and  ||| S:2220 E:2224 ||| CC
the  ||| S:2224 E:2228 ||| DT
cytoplasmic  ||| S:2228 E:2240 ||| JJ
"trapping ||| S:2240 E:2249 ||| NN
"  ||| S:2249 E:2251 ||| ''
of  ||| S:2251 E:2254 ||| IN
GR  ||| S:2254 E:2257 ||| NNP
in  ||| S:2257 E:2260 ||| IN
a  ||| S:2260 E:2262 ||| DT
form  ||| S:2262 E:2267 ||| NN
that  ||| S:2267 E:2272 ||| WDT
is  ||| S:2272 E:2283 ||| VBZ
unable  ||| S:2283 E:2290 ||| JJ
to  ||| S:2290 E:2293 ||| TO
"recycle ||| S:2293 E:2301 ||| NNP
" ||| S:2301 E:2302 ||| ''
.  ||| S:2302 E:2304 ||| .
Recent  ||| S:2304 E:2311 ||| JJ
studies  ||| S:2311 E:2319 ||| NNS
with  ||| S:2319 E:2324 ||| IN
okadaic  ||| S:2324 E:2332 ||| JJ
acid  ||| S:2332 E:2345 ||| NNS
suggest  ||| S:2345 E:2353 ||| VBP
phosphorylation  ||| S:2353 E:2369 ||| RB
alters  ||| S:2369 E:2376 ||| VB
the  ||| S:2376 E:2380 ||| DT
high  ||| S:2380 E:2385 ||| JJ
affinity  ||| S:2385 E:2394 ||| JJ
binding  ||| S:2394 E:2402 ||| NN
of  ||| S:2402 E:2413 ||| IN
GR  ||| S:2413 E:2416 ||| NNP
to  ||| S:2416 E:2419 ||| TO
hsp-90 ||| S:2419 E:2425 ||| CD
,  ||| S:2425 E:2427 ||| ,
and  ||| S:2427 E:2431 ||| CC
that  ||| S:2431 E:2436 ||| IN
an  ||| S:2436 E:2439 ||| DT
intact  ||| S:2439 E:2446 ||| JJ
cytoskeleton  ||| S:2446 E:2459 ||| NN
is  ||| S:2459 E:2462 ||| VBZ
required  ||| S:2462 E:2479 ||| VBN
for  ||| S:2479 E:2483 ||| IN
ligand-activated  ||| S:2483 E:2500 ||| NNP
GR  ||| S:2500 E:2503 ||| NNP
translocation  ||| S:2503 E:2517 ||| NN
through  ||| S:2517 E:2525 ||| IN
the  ||| S:2525 E:2529 ||| DT
cytoplasm  ||| S:2529 E:2547 ||| NN
to  ||| S:2547 E:2550 ||| TO
the  ||| S:2550 E:2554 ||| DT
nucleus  ||| S:2554 E:2562 ||| NN
[  ||| S:2562 E:2564 ||| -LRB-
8 ||| S:2564 E:2565 ||| CD
] ||| S:2565 E:2566 ||| -RRB-
.  ||| S:2566 E:2576 ||| .
The  ||| S:2576 E:2580 ||| DT
ability  ||| S:2580 E:2588 ||| NN
of  ||| S:2588 E:2591 ||| IN
okadaic  ||| S:2591 E:2599 ||| JJ
acid  ||| S:2599 E:2604 ||| NN
to  ||| S:2604 E:2607 ||| TO
influence  ||| S:2607 E:2617 ||| VB
the  ||| S:2617 E:2629 ||| DT
intracellular  ||| S:2629 E:2643 ||| JJ
partitioning  ||| S:2643 E:2656 ||| NN
of  ||| S:2656 E:2659 ||| IN
GR  ||| S:2659 E:2662 ||| NNP
suggests  ||| S:2662 E:2671 ||| VBZ
that  ||| S:2671 E:2676 ||| IN
an  ||| S:2676 E:2679 ||| DT
okadaic  ||| S:2679 E:2695 ||| FW
acid  ||| S:2695 E:2700 ||| FW
sensitive  ||| S:2700 E:2710 ||| FW
ser ||| S:2710 E:2713 ||| FW
/ ||| S:2713 E:2714 ||| FW
thr  ||| S:2714 E:2718 ||| FW
protein  ||| S:2718 E:2726 ||| FW
phosphatase  ||| S:2726 E:2738 ||| FW
( ||| S:2738 E:2739 ||| -LRB-
PPase ||| S:2739 E:2744 ||| NNP
)  ||| S:2744 E:2754 ||| -RRB-
participates  ||| S:2754 E:2767 ||| VBZ
in  ||| S:2767 E:2770 ||| IN
the  ||| S:2770 E:2774 ||| DT
regulation  ||| S:2774 E:2785 ||| NN
of  ||| S:2785 E:2788 ||| IN
GR  ||| S:2788 E:2791 ||| NNP
movement ||| S:2791 E:2799 ||| NN
.  ||| S:2799 E:2801 ||| .
In  ||| S:2801 E:2804 ||| IN
vitro ||| S:2804 E:2809 ||| NN
,  ||| S:2809 E:2819 ||| ,
okadaic  ||| S:2819 E:2827 ||| JJ
acid  ||| S:2827 E:2832 ||| NN
acts  ||| S:2832 E:2837 ||| NNS
as  ||| S:2837 E:2840 ||| IN
a  ||| S:2840 E:2842 ||| DT
potent  ||| S:2842 E:2849 ||| JJ
inhibitor  ||| S:2849 E:2859 ||| NN
of  ||| S:2859 E:2862 ||| IN
serine ||| S:2862 E:2868 ||| FW
/ ||| S:2868 E:2869 ||| FW
threonine  ||| S:2869 E:2887 ||| FW
protein  ||| S:2887 E:2895 ||| FW
phosphatases  ||| S:2895 E:2908 ||| FW
type  ||| S:2908 E:2913 ||| NN
1  ||| S:2913 E:2915 ||| CD
( ||| S:2915 E:2916 ||| -LRB-
PP1 ||| S:2916 E:2919 ||| NNP
)  ||| S:2919 E:2921 ||| -RRB-
and  ||| S:2921 E:2925 ||| CC
2A  ||| S:2925 E:2928 ||| NNP
( ||| S:2928 E:2929 ||| -LRB-
PP2A ||| S:2929 E:2933 ||| NNP
)  ||| S:2933 E:2935 ||| -RRB-
[  ||| S:2935 E:2937 ||| -LRB-
9 ||| S:2937 E:2938 ||| CD
,  ||| S:2938 E:2940 ||| ,
10 ||| S:2940 E:2942 ||| CD
] ||| S:2942 E:2943 ||| -RRB-
.  ||| S:2943 E:2953 ||| .
Accordingly ||| S:2953 E:2964 ||| RB
,  ||| S:2964 E:2966 ||| ,
many  ||| S:2966 E:2971 ||| JJ
of  ||| S:2971 E:2974 ||| IN
the  ||| S:2974 E:2978 ||| DT
effects  ||| S:2978 E:2986 ||| NNS
produced  ||| S:2986 E:2995 ||| VBN
by  ||| S:2995 E:2998 ||| IN
the  ||| S:2998 E:3002 ||| DT
treatment  ||| S:3002 E:3020 ||| NN
of  ||| S:3020 E:3023 ||| IN
cells  ||| S:3023 E:3029 ||| NNS
with  ||| S:3029 E:3034 ||| IN
okadaic  ||| S:3034 E:3042 ||| JJ
acid  ||| S:3042 E:3047 ||| NNS
have  ||| S:3047 E:3052 ||| VBP
been  ||| S:3052 E:3057 ||| VBN
attributed  ||| S:3057 E:3068 ||| VBN
to  ||| S:3068 E:3071 ||| TO
the  ||| S:3071 E:3083 ||| DT
inhibition  ||| S:3083 E:3094 ||| NN
of  ||| S:3094 E:3097 ||| IN
these  ||| S:3097 E:3103 ||| DT
two  ||| S:3103 E:3107 ||| CD
enzymes ||| S:3107 E:3114 ||| NNS
.  ||| S:3114 E:3116 ||| .
However ||| S:3116 E:3123 ||| RB
,  ||| S:3123 E:3125 ||| ,
due  ||| S:3125 E:3129 ||| JJ
to  ||| S:3129 E:3132 ||| TO
toxicity  ||| S:3132 E:3149 ||| VB
and  ||| S:3149 E:3153 ||| CC
solubility  ||| S:3153 E:3164 ||| JJ
constraints ||| S:3164 E:3175 ||| NNS
,  ||| S:3175 E:3177 ||| ,
in  ||| S:3177 E:3180 ||| IN
living  ||| S:3180 E:3187 ||| VBG
cells  ||| S:3187 E:3193 ||| NNS
it  ||| S:3193 E:3196 ||| PRP
is  ||| S:3196 E:3199 ||| VBZ
difficult  ||| S:3199 E:3217 ||| JJ
to  ||| S:3217 E:3220 ||| TO
distinguish  ||| S:3220 E:3232 ||| VB
the  ||| S:3232 E:3236 ||| DT
actions  ||| S:3236 E:3244 ||| NNS
of  ||| S:3244 E:3247 ||| IN
PP2A  ||| S:3247 E:3252 ||| CD
from  ||| S:3252 E:3257 ||| IN
those  ||| S:3257 E:3263 ||| DT
of  ||| S:3263 E:3266 ||| IN
PP1  ||| S:3266 E:3270 ||| CD
using  ||| S:3270 E:3284 ||| VBG
okadaic  ||| S:3284 E:3292 ||| JJ
acid ||| S:3292 E:3296 ||| NN
.  ||| S:3296 E:3298 ||| .
Furthermore ||| S:3298 E:3309 ||| RB
,  ||| S:3309 E:3311 ||| ,
in  ||| S:3311 E:3314 ||| IN
humans ||| S:3314 E:3320 ||| NNS
,  ||| S:3320 E:3322 ||| ,
it  ||| S:3322 E:3325 ||| PRP
is  ||| S:3325 E:3328 ||| VBZ
now  ||| S:3328 E:3332 ||| RB
clear  ||| S:3332 E:3338 ||| JJ
that  ||| S:3338 E:3351 ||| IN
there  ||| S:3351 E:3357 ||| EX
are  ||| S:3357 E:3361 ||| VBP
four  ||| S:3361 E:3366 ||| CD
isoforms  ||| S:3366 E:3375 ||| NN
of  ||| S:3375 E:3378 ||| IN
PP1  ||| S:3378 E:3382 ||| NNP
[ ||| S:3382 E:3383 ||| -LRB-
PP1α ||| S:3383 E:3387 ||| NNP
,  ||| S:3387 E:3389 ||| ,
PP1δ ||| S:3389 E:3393 ||| NNP
,  ||| S:3393 E:3395 ||| ,
PP1γ  ||| S:3395 E:3409 ||| CD
1  ||| S:3409 E:3411 ||| CD
and  ||| S:3411 E:3415 ||| CC
PP1γ  ||| S:3415 E:3429 ||| CD
2  ||| S:3429 E:3431 ||| CD
[  ||| S:3431 E:3433 ||| -LRB-
11 ||| S:3433 E:3435 ||| CD
,  ||| S:3435 E:3437 ||| ,
12 ||| S:3437 E:3439 ||| CD
,  ||| S:3439 E:3441 ||| ,
13 ||| S:3441 E:3443 ||| CD
] ||| S:3443 E:3444 ||| -RRB-
,  ||| S:3444 E:3446 ||| ,
two  ||| S:3446 E:3450 ||| CD
isoforms  ||| S:3450 E:3459 ||| NN
of  ||| S:3459 E:3462 ||| IN
PP2A  ||| S:3462 E:3475 ||| NNP
( ||| S:3475 E:3476 ||| -LRB-
PP2A  ||| S:3476 E:3481 ||| CD
α  ||| S:3481 E:3483 ||| NNS
and  ||| S:3483 E:3487 ||| CC
PP2Aβ  ||| S:3487 E:3493 ||| NNP
[  ||| S:3493 E:3495 ||| -LRB-
14 ||| S:3495 E:3497 ||| CD
,  ||| S:3497 E:3499 ||| ,
15 ||| S:3499 E:3501 ||| CD
] ||| S:3501 E:3502 ||| CD
)  ||| S:3502 E:3504 ||| -RRB-
and  ||| S:3504 E:3508 ||| CC
four  ||| S:3508 E:3513 ||| CD
structurally  ||| S:3513 E:3526 ||| CD
related  ||| S:3526 E:3542 ||| JJ
phosphatases ||| S:3542 E:3554 ||| NN
,  ||| S:3554 E:3556 ||| ,
PP4  ||| S:3556 E:3560 ||| NNP
[  ||| S:3560 E:3562 ||| -LRB-
16 ||| S:3562 E:3564 ||| CD
] ||| S:3564 E:3565 ||| -RRB-
,  ||| S:3565 E:3567 ||| ,
PP5  ||| S:3567 E:3571 ||| NNP
[  ||| S:3571 E:3573 ||| -LRB-
17 ||| S:3573 E:3575 ||| CD
,  ||| S:3575 E:3577 ||| ,
18 ||| S:3577 E:3579 ||| CD
] ||| S:3579 E:3580 ||| -RRB-
,  ||| S:3580 E:3582 ||| ,
PP6  ||| S:3582 E:3586 ||| NNP
[  ||| S:3586 E:3588 ||| -LRB-
19 ||| S:3588 E:3590 ||| CD
]  ||| S:3590 E:3592 ||| -RRB-
and  ||| S:3592 E:3596 ||| CC
PP7  ||| S:3596 E:3600 ||| NNP
[  ||| S:3600 E:3610 ||| -LRB-
20 ||| S:3610 E:3612 ||| CD
] ||| S:3612 E:3613 ||| -RRB-
.  ||| S:3613 E:3615 ||| .
Although  ||| S:3615 E:3624 ||| IN
detailed  ||| S:3624 E:3633 ||| JJ
dose-response  ||| S:3633 E:3647 ||| JJ
studies  ||| S:3647 E:3655 ||| NNS
have  ||| S:3655 E:3660 ||| VBP
not  ||| S:3660 E:3664 ||| RB
been  ||| S:3664 E:3677 ||| VBN
reported  ||| S:3677 E:3686 ||| VBN
for  ||| S:3686 E:3690 ||| IN
native  ||| S:3690 E:3697 ||| JJ
PP5 ||| S:3697 E:3700 ||| NN
,  ||| S:3700 E:3702 ||| ,
PP6  ||| S:3702 E:3706 ||| NNP
and  ||| S:3706 E:3710 ||| CC
PP7 ||| S:3710 E:3713 ||| NNP
,  ||| S:3713 E:3715 ||| ,
studies  ||| S:3715 E:3723 ||| NNS
with  ||| S:3723 E:3728 ||| IN
PP4  ||| S:3728 E:3732 ||| NNP
[  ||| S:3732 E:3742 ||| -LRB-
21 ||| S:3742 E:3744 ||| CD
]  ||| S:3744 E:3746 ||| -RRB-
and  ||| S:3746 E:3750 ||| CC
recombinant  ||| S:3750 E:3762 ||| JJ
PP5  ||| S:3762 E:3766 ||| NNP
[  ||| S:3766 E:3768 ||| -LRB-
18 ||| S:3768 E:3770 ||| CD
]  ||| S:3770 E:3772 ||| -RRB-
indicate  ||| S:3772 E:3781 ||| VBP
they  ||| S:3781 E:3786 ||| PRP
are  ||| S:3786 E:3790 ||| VBP
also  ||| S:3790 E:3803 ||| RB
sensitive  ||| S:3803 E:3813 ||| JJ
to  ||| S:3813 E:3816 ||| TO
okadaic  ||| S:3816 E:3824 ||| VB
acid ||| S:3824 E:3828 ||| NN
.  ||| S:3828 E:3830 ||| .
Like  ||| S:3830 E:3835 ||| IN
calcineurin  ||| S:3835 E:3847 ||| NNS
( ||| S:3847 E:3848 ||| -LRB-
PP2B ||| S:3848 E:3852 ||| NNP
)  ||| S:3852 E:3854 ||| -RRB-
and  ||| S:3854 E:3866 ||| CC
PP2C ||| S:3866 E:3870 ||| NNP
,  ||| S:3870 E:3872 ||| ,
PP7  ||| S:3872 E:3876 ||| NNP
is  ||| S:3876 E:3879 ||| VBZ
apparently  ||| S:3879 E:3890 ||| RB
insensitive  ||| S:3890 E:3902 ||| VBN
to  ||| S:3902 E:3905 ||| TO
inhibition  ||| S:3905 E:3916 ||| VB
by  ||| S:3916 E:3927 ||| IN
okadaic  ||| S:3927 E:3935 ||| JJ
acid  ||| S:3935 E:3940 ||| NN
[  ||| S:3940 E:3942 ||| -LRB-
20 ||| S:3942 E:3944 ||| CD
] ||| S:3944 E:3945 ||| -RRB-
.  ||| S:3945 E:3955 ||| .
Recent  ||| S:3955 E:3962 ||| JJ
studies  ||| S:3962 E:3970 ||| NNS
indicate  ||| S:3970 E:3979 ||| VBP
that  ||| S:3979 E:3984 ||| IN
PP5  ||| S:3984 E:3988 ||| CD
associates  ||| S:3988 E:3999 ||| NNS
with  ||| S:3999 E:4004 ||| IN
the  ||| S:4004 E:4016 ||| DT
GR-hsp90  ||| S:4016 E:4025 ||| JJ
complex  ||| S:4025 E:4033 ||| NN
[  ||| S:4033 E:4035 ||| -LRB-
22 ||| S:4035 E:4037 ||| CD
,  ||| S:4037 E:4039 ||| ,
23 ||| S:4039 E:4041 ||| CD
]  ||| S:4041 E:4043 ||| -RRB-
suggesting  ||| S:4043 E:4054 ||| VBG
that  ||| S:4054 E:4059 ||| IN
PP5  ||| S:4059 E:4063 ||| NNP
may  ||| S:4063 E:4075 ||| MD
influence  ||| S:4075 E:4085 ||| VB
the  ||| S:4085 E:4089 ||| DT
actions  ||| S:4089 E:4097 ||| NNS
of  ||| S:4097 E:4100 ||| IN
GRs ||| S:4100 E:4103 ||| JJ
.  ||| S:4103 E:4105 ||| .
However ||| S:4105 E:4112 ||| RB
,  ||| S:4112 E:4114 ||| ,
studying  ||| S:4114 E:4123 ||| VBG
the  ||| S:4123 E:4135 ||| DT
cellular  ||| S:4135 E:4144 ||| JJ
roles  ||| S:4144 E:4150 ||| NNS
of  ||| S:4150 E:4153 ||| IN
PP5  ||| S:4153 E:4157 ||| NNP
has  ||| S:4157 E:4161 ||| VBZ
proven  ||| S:4161 E:4168 ||| VBN
difficult ||| S:4168 E:4177 ||| JJ
,  ||| S:4177 E:4179 ||| ,
in  ||| S:4179 E:4182 ||| IN
part ||| S:4182 E:4186 ||| NN
,  ||| S:4186 E:4196 ||| ,
because  ||| S:4196 E:4204 ||| IN
no  ||| S:4204 E:4207 ||| DT
physiological  ||| S:4207 E:4221 ||| JJ
substrates  ||| S:4221 E:4232 ||| NN
for  ||| S:4232 E:4236 ||| IN
PP5  ||| S:4236 E:4240 ||| NNP
have  ||| S:4240 E:4245 ||| VBP
been  ||| S:4245 E:4258 ||| VBN
identified ||| S:4258 E:4268 ||| VBN
.  ||| S:4268 E:4270 ||| .
In  ||| S:4270 E:4273 ||| IN
addition ||| S:4273 E:4281 ||| NN
,  ||| S:4281 E:4283 ||| ,
in  ||| S:4283 E:4286 ||| IN
crude  ||| S:4286 E:4292 ||| JJ
cell  ||| S:4292 E:4297 ||| NN
homogenates  ||| S:4297 E:4309 ||| NN
PP5  ||| S:4309 E:4321 ||| NN
resides  ||| S:4321 E:4329 ||| VBZ
predominately  ||| S:4329 E:4343 ||| VBN
in  ||| S:4343 E:4346 ||| IN
an  ||| S:4346 E:4349 ||| DT
inactive  ||| S:4349 E:4358 ||| JJ
state  ||| S:4358 E:4364 ||| NN
that  ||| S:4364 E:4369 ||| WDT
represents  ||| S:4369 E:4388 ||| VBZ
< ||| S:4388 E:4389 ||| SYM
1 ||| S:4389 E:4390 ||| CD
%  ||| S:4390 E:4392 ||| NN
of  ||| S:4392 E:4395 ||| IN
the  ||| S:4395 E:4399 ||| DT
measurable  ||| S:4399 E:4410 ||| JJ
PPase  ||| S:4410 E:4416 ||| JJ
activity ||| S:4416 E:4424 ||| NN
.  ||| S:4424 E:4426 ||| .
To  ||| S:4426 E:4429 ||| TO
characterize  ||| S:4429 E:4450 ||| VB
the  ||| S:4450 E:4454 ||| DT
cellular  ||| S:4454 E:4463 ||| JJ
roles  ||| S:4463 E:4469 ||| NNS
of  ||| S:4469 E:4472 ||| IN
PP5  ||| S:4472 E:4476 ||| NNP
we  ||| S:4476 E:4479 ||| PRP
have ||| S:4479 E:4483 ||| VBP
,  ||| S:4483 E:4485 ||| ,
therefore ||| S:4485 E:4494 ||| RB
,  ||| S:4494 E:4496 ||| ,
developed  ||| S:4496 E:4514 ||| VBD
chimeric  ||| S:4514 E:4523 ||| CD
antisense  ||| S:4523 E:4533 ||| CD
2 ||| S:4533 E:4534 ||| CD
' ||| S:4534 E:4535 ||| ''
-  ||| S:4535 E:4546 ||| :
O  ||| S:4546 E:4548 ||| NNP
- ||| S:4548 E:4549 ||| :
( ||| S:4549 E:4550 ||| -LRB-
2-methoxy ||| S:4550 E:4559 ||| NNP
)  ||| S:4559 E:4561 ||| -RRB-
ethylphosphothioate  ||| S:4561 E:4589 ||| JJ
oligonucleotides  ||| S:4589 E:4606 ||| JJ
capable  ||| S:4606 E:4614 ||| JJ
of  ||| S:4614 E:4617 ||| IN
inhibiting  ||| S:4617 E:4628 ||| VBG
the  ||| S:4628 E:4632 ||| DT
expression  ||| S:4632 E:4643 ||| NN
of  ||| S:4643 E:4654 ||| IN
human  ||| S:4654 E:4660 ||| JJ
PP5  ||| S:4660 E:4664 ||| NN
at  ||| S:4664 E:4667 ||| IN
nanomolar  ||| S:4667 E:4677 ||| JJ
concentrations ||| S:4677 E:4691 ||| NNS
.  ||| S:4691 E:4693 ||| .
Because  ||| S:4693 E:4701 ||| IN
the  ||| S:4701 E:4705 ||| DT
lead  ||| S:4705 E:4718 ||| JJ
compound  ||| S:4718 E:4727 ||| NN
targeting  ||| S:4727 E:4737 ||| VBG
PP5  ||| S:4737 E:4741 ||| NNP
( ||| S:4741 E:4742 ||| -LRB-
ISIS  ||| S:4742 E:4747 ||| NNP
15534 ||| S:4747 E:4752 ||| CD
)  ||| S:4752 E:4754 ||| -RRB-
acts  ||| S:4754 E:4759 ||| VBZ
via  ||| S:4759 E:4763 ||| IN
RNAase  ||| S:4763 E:4770 ||| NNP
H  ||| S:4770 E:4780 ||| NNP
mediated  ||| S:4780 E:4789 ||| JJ
degradation ||| S:4789 E:4800 ||| NN
,  ||| S:4800 E:4802 ||| ,
studies  ||| S:4802 E:4810 ||| NNS
with  ||| S:4810 E:4815 ||| IN
ISIS  ||| S:4815 E:4820 ||| NNP
15534  ||| S:4820 E:4826 ||| CD
do  ||| S:4826 E:4829 ||| VBP
not  ||| S:4829 E:4833 ||| RB
allow  ||| S:4833 E:4847 ||| VB
us  ||| S:4847 E:4850 ||| PRP
to  ||| S:4850 E:4853 ||| TO
assess  ||| S:4853 E:4860 ||| VB
how  ||| S:4860 E:4864 ||| WRB
rapid  ||| S:4864 E:4870 ||| JJ
changes  ||| S:4870 E:4878 ||| NNS
in  ||| S:4878 E:4881 ||| IN
PP5  ||| S:4881 E:4885 ||| CD
activity  ||| S:4885 E:4894 ||| NN
affect  ||| S:4894 E:4909 ||| VB
cellular  ||| S:4909 E:4918 ||| JJ
functions  ||| S:4918 E:4928 ||| NNS
( ||| S:4928 E:4929 ||| -LRB-
Northern  ||| S:4929 E:4938 ||| NNP
analysis  ||| S:4938 E:4947 ||| NN
indicate  ||| S:4947 E:4956 ||| VBP
that  ||| S:4956 E:4961 ||| IN
it  ||| S:4961 E:4972 ||| PRP
takes  ||| S:4972 E:4978 ||| VBZ
~  ||| S:4978 E:4980 ||| CD
6  ||| S:4980 E:4982 ||| CD
for  ||| S:4982 E:4986 ||| IN
the  ||| S:4986 E:4990 ||| DT
mRNA  ||| S:4990 E:4995 ||| JJ
degradation  ||| S:4995 E:5007 ||| NN
to  ||| S:5007 E:5010 ||| TO
occur  ||| S:5010 E:5016 ||| VB
and ||| S:5016 E:5019 ||| CC
,  ||| S:5019 E:5021 ||| ,
due  ||| S:5021 E:5025 ||| JJ
to  ||| S:5025 E:5028 ||| TO
the  ||| S:5028 E:5040 ||| DT
half-life  ||| S:5040 E:5050 ||| NN
of  ||| S:5050 E:5053 ||| IN
the  ||| S:5053 E:5057 ||| DT
preexisting  ||| S:5057 E:5069 ||| JJ
protein ||| S:5069 E:5076 ||| NN
,  ||| S:5076 E:5078 ||| ,
it  ||| S:5078 E:5081 ||| PRP
takes  ||| S:5081 E:5087 ||| VBZ
~  ||| S:5087 E:5089 ||| CD
24  ||| S:5089 E:5092 ||| CD
hours  ||| S:5092 E:5106 ||| NNS
for  ||| S:5106 E:5110 ||| IN
the  ||| S:5110 E:5114 ||| DT
protein  ||| S:5114 E:5122 ||| NN
levels  ||| S:5122 E:5129 ||| NNS
to  ||| S:5129 E:5132 ||| TO
fall  ||| S:5132 E:5137 ||| VB
[  ||| S:5137 E:5139 ||| -LRB-
24 ||| S:5139 E:5141 ||| CD
] ||| S:5141 E:5142 ||| -RRB-
.  ||| S:5142 E:5144 ||| .
Nonetheless ||| S:5144 E:5155 ||| RB
,  ||| S:5155 E:5157 ||| ,
ISIS  ||| S:5157 E:5170 ||| NNP
15534  ||| S:5170 E:5176 ||| CD
potently  ||| S:5176 E:5185 ||| NNS
inhibits  ||| S:5185 E:5194 ||| VBP
the  ||| S:5194 E:5198 ||| DT
expression  ||| S:5198 E:5209 ||| NN
of  ||| S:5209 E:5212 ||| IN
PP5  ||| S:5212 E:5216 ||| CD
in  ||| S:5216 E:5219 ||| IN
cultured  ||| S:5219 E:5236 ||| JJ
cells  ||| S:5236 E:5242 ||| NNS
for  ||| S:5242 E:5246 ||| IN
~  ||| S:5246 E:5248 ||| CD
48-72  ||| S:5248 E:5254 ||| CD
hours  ||| S:5254 E:5260 ||| NNS
( ||| S:5260 E:5261 ||| -LRB-
IC  ||| S:5261 E:5273 ||| NNP
50  ||| S:5273 E:5276 ||| CD
of  ||| S:5276 E:5279 ||| IN
< ||| S:5279 E:5280 ||| SYM
75  ||| S:5280 E:5283 ||| CD
nm ||| S:5283 E:5285 ||| CD
) ||| S:5285 E:5286 ||| -RRB-
,  ||| S:5286 E:5288 ||| ,
which  ||| S:5288 E:5294 ||| WDT
affords  ||| S:5294 E:5302 ||| VBZ
a  ||| S:5302 E:5304 ||| DT
~  ||| S:5304 E:5314 ||| CD
24-48  ||| S:5314 E:5320 ||| CD
hour  ||| S:5320 E:5325 ||| NN
window  ||| S:5325 E:5332 ||| NN
in  ||| S:5332 E:5335 ||| IN
which  ||| S:5335 E:5341 ||| WDT
the  ||| S:5341 E:5345 ||| DT
expression  ||| S:5345 E:5356 ||| NN
of  ||| S:5356 E:5359 ||| IN
PP5  ||| S:5359 E:5363 ||| NNP
is  ||| S:5363 E:5374 ||| VBZ
essentially  ||| S:5374 E:5386 ||| RB
ablated  ||| S:5386 E:5394 ||| JJ
[  ||| S:5394 E:5396 ||| -LRB-
24 ||| S:5396 E:5398 ||| CD
,  ||| S:5398 E:5400 ||| ,
25 ||| S:5400 E:5402 ||| CD
] ||| S:5402 E:5403 ||| -RRB-
.  ||| S:5403 E:5405 ||| .
More  ||| S:5405 E:5410 ||| RBR
importantly ||| S:5410 E:5421 ||| RB
,  ||| S:5421 E:5423 ||| ,
because  ||| S:5423 E:5439 ||| IN
ISIS  ||| S:5439 E:5444 ||| NNP
15534  ||| S:5444 E:5450 ||| CD
has  ||| S:5450 E:5454 ||| VBZ
no  ||| S:5454 E:5457 ||| DT
effect  ||| S:5457 E:5464 ||| NN
on  ||| S:5464 E:5467 ||| IN
the  ||| S:5467 E:5471 ||| DT
structurally  ||| S:5471 E:5484 ||| JJ
related  ||| S:5484 E:5492 ||| JJ
PPases  ||| S:5492 E:5507 ||| NN
[  ||| S:5507 E:5509 ||| -LRB-
24 ||| S:5509 E:5511 ||| CD
] ||| S:5511 E:5512 ||| -RRB-
,  ||| S:5512 E:5514 ||| ,
it  ||| S:5514 E:5517 ||| PRP
can  ||| S:5517 E:5521 ||| MD
be  ||| S:5521 E:5524 ||| VB
employed  ||| S:5524 E:5533 ||| VBN
to  ||| S:5533 E:5536 ||| TO
specifically  ||| S:5536 E:5549 ||| RB
inhibit  ||| S:5549 E:5557 ||| VB
the  ||| S:5557 E:5569 ||| DT
actions  ||| S:5569 E:5577 ||| NNS
of  ||| S:5577 E:5580 ||| IN
PP5  ||| S:5580 E:5584 ||| CD
by  ||| S:5584 E:5587 ||| IN
suppressing  ||| S:5587 E:5599 ||| CD
PP5  ||| S:5599 E:5603 ||| CD
protein  ||| S:5603 E:5611 ||| NN
levels  ||| S:5611 E:5618 ||| NNS
in  ||| S:5618 E:5629 ||| IN
cultured  ||| S:5629 E:5638 ||| JJ
human  ||| S:5638 E:5644 ||| JJ
cells ||| S:5644 E:5649 ||| NNS
.  ||| S:5649 E:5659 ||| .
To  ||| S:5659 E:5662 ||| TO
assess  ||| S:5662 E:5669 ||| VB
the  ||| S:5669 E:5673 ||| DT
role  ||| S:5673 E:5678 ||| NN
of  ||| S:5678 E:5681 ||| IN
PP5  ||| S:5681 E:5685 ||| CD
in  ||| S:5685 E:5688 ||| IN
the  ||| S:5688 E:5692 ||| DT
regulation  ||| S:5692 E:5703 ||| NN
of  ||| S:5703 E:5714 ||| IN
GR-mediated  ||| S:5714 E:5726 ||| JJ
events ||| S:5726 E:5732 ||| NNS
,  ||| S:5732 E:5734 ||| ,
binding  ||| S:5734 E:5742 ||| JJ
studies  ||| S:5742 E:5750 ||| NNS
were  ||| S:5750 E:5755 ||| VBD
conducted  ||| S:5755 E:5765 ||| VBN
with  ||| S:5765 E:5770 ||| IN
[  ||| S:5770 E:5780 ||| -LRB-
3H ||| S:5780 E:5782 ||| NNP
] ||| S:5782 E:5783 ||| -RRB-
dexamethasone  ||| S:5783 E:5797 ||| VBZ
before  ||| S:5797 E:5804 ||| RB
and  ||| S:5804 E:5808 ||| CC
after  ||| S:5808 E:5814 ||| IN
ISIS  ||| S:5814 E:5819 ||| NNP
15534-mediated  ||| S:5819 E:5842 ||| NNP
suppression  ||| S:5842 E:5854 ||| NN
of  ||| S:5854 E:5857 ||| IN
PP5  ||| S:5857 E:5861 ||| CD
expression ||| S:5861 E:5871 ||| NN
.  ||| S:5871 E:5873 ||| .
These  ||| S:5873 E:5879 ||| DT
studies  ||| S:5879 E:5887 ||| NNS
revealed  ||| S:5887 E:5896 ||| VBD
that  ||| S:5896 E:5909 ||| IN
the  ||| S:5909 E:5913 ||| DT
suppression  ||| S:5913 E:5925 ||| NN
of  ||| S:5925 E:5928 ||| IN
PP5  ||| S:5928 E:5932 ||| CD
expression  ||| S:5932 E:5943 ||| NN
had  ||| S:5943 E:5947 ||| VBD
no  ||| S:5947 E:5950 ||| DT
apparent  ||| S:5950 E:5959 ||| JJ
effect  ||| S:5959 E:5966 ||| NN
on  ||| S:5966 E:5977 ||| IN
dexamethasone  ||| S:5977 E:5991 ||| JJ
binding ||| S:5991 E:5998 ||| NN
,  ||| S:5998 E:6000 ||| ,
suggesting  ||| S:6000 E:6011 ||| VBG
that  ||| S:6011 E:6016 ||| IN
PP5  ||| S:6016 E:6020 ||| NNP
does  ||| S:6020 E:6025 ||| VBZ
not  ||| S:6025 E:6029 ||| RB
affect  ||| S:6029 E:6044 ||| VB
the  ||| S:6044 E:6048 ||| DT
formation  ||| S:6048 E:6058 ||| NN
of  ||| S:6058 E:6061 ||| IN
the  ||| S:6061 E:6065 ||| DT
high-affinity  ||| S:6065 E:6079 ||| JJ
ligand  ||| S:6079 E:6086 ||| JJ
binding  ||| S:6086 E:6094 ||| JJ
complex  ||| S:6094 E:6110 ||| NN
or  ||| S:6110 E:6113 ||| CC
hormone  ||| S:6113 E:6121 ||| NN
binding  ||| S:6121 E:6129 ||| VBG
to  ||| S:6129 E:6132 ||| TO
the  ||| S:6132 E:6136 ||| DT
GR  ||| S:6136 E:6139 ||| NNP
[  ||| S:6139 E:6141 ||| -LRB-
25 ||| S:6141 E:6143 ||| CD
] ||| S:6143 E:6144 ||| -RRB-
.  ||| S:6144 E:6146 ||| .
In  ||| S:6146 E:6149 ||| IN
contrast ||| S:6149 E:6157 ||| NN
,  ||| S:6157 E:6159 ||| ,
mobility  ||| S:6159 E:6176 ||| JJ
gel-shift  ||| S:6176 E:6186 ||| JJ
analysis  ||| S:6186 E:6195 ||| NN
revealed  ||| S:6195 E:6204 ||| VBD
that  ||| S:6204 E:6209 ||| DT
treatment  ||| S:6209 E:6219 ||| NN
with  ||| S:6219 E:6224 ||| IN
ISIS  ||| S:6224 E:6229 ||| NNP
15534  ||| S:6229 E:6243 ||| CD
produces  ||| S:6243 E:6252 ||| VBZ
a  ||| S:6252 E:6254 ||| DT
marked  ||| S:6254 E:6261 ||| JJ
increase  ||| S:6261 E:6270 ||| NN
in  ||| S:6270 E:6273 ||| IN
the  ||| S:6273 E:6277 ||| DT
association  ||| S:6277 E:6289 ||| NN
of  ||| S:6289 E:6292 ||| IN
GR  ||| S:6292 E:6295 ||| NNP
with  ||| S:6295 E:6308 ||| IN
GRE-containing  ||| S:6308 E:6323 ||| JJ
DNA ||| S:6323 E:6326 ||| NN
,  ||| S:6326 E:6328 ||| ,
and  ||| S:6328 E:6332 ||| CC
transient  ||| S:6332 E:6342 ||| JJ
transfection  ||| S:6342 E:6355 ||| JJ
studies  ||| S:6355 E:6371 ||| NNS
employing  ||| S:6371 E:6381 ||| VBG
a  ||| S:6381 E:6383 ||| DT
GR-responsive  ||| S:6383 E:6397 ||| JJ
reporter  ||| S:6397 E:6406 ||| NN
plasmid  ||| S:6406 E:6414 ||| VBZ
revealed  ||| S:6414 E:6423 ||| VBN
that  ||| S:6423 E:6436 ||| IN
the  ||| S:6436 E:6440 ||| DT
suppression  ||| S:6440 E:6452 ||| NN
of  ||| S:6452 E:6455 ||| IN
PP5  ||| S:6455 E:6459 ||| CD
expression  ||| S:6459 E:6470 ||| NN
activates  ||| S:6470 E:6480 ||| VBZ
GR-dependent  ||| S:6480 E:6501 ||| JJ
transcription  ||| S:6501 E:6515 ||| NN
in  ||| S:6515 E:6518 ||| IN
the  ||| S:6518 E:6522 ||| DT
absence  ||| S:6522 E:6530 ||| NN
of  ||| S:6530 E:6533 ||| IN
hormone  ||| S:6533 E:6541 ||| NN
[  ||| S:6541 E:6543 ||| -LRB-
25 ||| S:6543 E:6545 ||| CD
] ||| S:6545 E:6546 ||| -RRB-
.  ||| S:6546 E:6548 ||| .
When  ||| S:6548 E:6553 ||| WRB
A549  ||| S:6553 E:6566 ||| JJ
cells  ||| S:6566 E:6572 ||| NNS
were  ||| S:6572 E:6577 ||| VBD
treated  ||| S:6577 E:6585 ||| VBN
with  ||| S:6585 E:6590 ||| IN
ISIS  ||| S:6590 E:6595 ||| NNP
15534  ||| S:6595 E:6601 ||| CD
and  ||| S:6601 E:6605 ||| CC
then  ||| S:6605 E:6610 ||| RB
dexamethasone ||| S:6610 E:6623 ||| JJ
,  ||| S:6623 E:6633 ||| ,
the  ||| S:6633 E:6637 ||| DT
effect  ||| S:6637 E:6644 ||| NN
was  ||| S:6644 E:6648 ||| VBD
additive ||| S:6648 E:6656 ||| CD
,  ||| S:6656 E:6658 ||| ,
with  ||| S:6658 E:6663 ||| IN
maximal  ||| S:6663 E:6671 ||| FW
dexamethasone  ||| S:6671 E:6685 ||| FW
induced  ||| S:6685 E:6701 ||| FW
luciferase  ||| S:6701 E:6712 ||| FW
activity  ||| S:6712 E:6721 ||| NN
~  ||| S:6721 E:6723 ||| CD
10  ||| S:6723 E:6726 ||| CD
times  ||| S:6726 E:6732 ||| NNS
greater  ||| S:6732 E:6740 ||| JJR
than  ||| S:6740 E:6745 ||| IN
the  ||| S:6745 E:6749 ||| DT
maximal  ||| S:6749 E:6765 ||| JJ
dexamethasone-induced  ||| S:6765 E:6787 ||| JJ
response  ||| S:6787 E:6796 ||| NN
attainable  ||| S:6796 E:6807 ||| NN
in  ||| S:6807 E:6810 ||| IN
the  ||| S:6810 E:6814 ||| DT
presence  ||| S:6814 E:6831 ||| NN
of  ||| S:6831 E:6834 ||| IN
PP5  ||| S:6834 E:6838 ||| NNP
[  ||| S:6838 E:6840 ||| -LRB-
25 ||| S:6840 E:6842 ||| CD
] ||| S:6842 E:6843 ||| -RRB-
.  ||| S:6843 E:6845 ||| .
Together ||| S:6845 E:6853 ||| RB
,  ||| S:6853 E:6855 ||| ,
these  ||| S:6855 E:6861 ||| DT
studies  ||| S:6861 E:6869 ||| NNS
indicate  ||| S:6869 E:6878 ||| VBP
that  ||| S:6878 E:6883 ||| IN
PP5  ||| S:6883 E:6895 ||| CD
acts  ||| S:6895 E:6900 ||| NNS
as  ||| S:6900 E:6903 ||| IN
a  ||| S:6903 E:6905 ||| DT
suppressor  ||| S:6905 E:6916 ||| NN
of  ||| S:6916 E:6919 ||| IN
GR-induced  ||| S:6919 E:6930 ||| JJ
transcription ||| S:6930 E:6943 ||| NN
.  ||| S:6943 E:6953 ||| .
To  ||| S:6953 E:6956 ||| TO
further  ||| S:6956 E:6964 ||| RB
characterize  ||| S:6964 E:6977 ||| VB
the  ||| S:6977 E:6981 ||| DT
mechanism  ||| S:6981 E:6991 ||| NN
by  ||| S:6991 E:6994 ||| IN
which  ||| S:6994 E:7000 ||| WDT
PP5  ||| S:7000 E:7012 ||| NNP
affects  ||| S:7012 E:7020 ||| VBZ
GR  ||| S:7020 E:7023 ||| NNP
function ||| S:7023 E:7031 ||| NN
,  ||| S:7031 E:7033 ||| ,
in  ||| S:7033 E:7036 ||| IN
the  ||| S:7036 E:7040 ||| DT
present  ||| S:7040 E:7048 ||| JJ
study  ||| S:7048 E:7054 ||| NN
we  ||| S:7054 E:7057 ||| PRP
employed  ||| S:7057 E:7066 ||| VBD
a  ||| S:7066 E:7076 ||| DT
GR-GFP  ||| S:7076 E:7083 ||| JJ
fusion  ||| S:7083 E:7090 ||| NN
protein  ||| S:7090 E:7098 ||| NN
and  ||| S:7098 E:7102 ||| CC
fluorescent  ||| S:7102 E:7114 ||| JJ
microscopy  ||| S:7114 E:7125 ||| NN
to  ||| S:7125 E:7128 ||| TO
follow  ||| S:7128 E:7143 ||| VB
the  ||| S:7143 E:7147 ||| DT
movement  ||| S:7147 E:7156 ||| NN
of  ||| S:7156 E:7159 ||| IN
GR  ||| S:7159 E:7162 ||| NNP
in  ||| S:7162 E:7165 ||| IN
cells  ||| S:7165 E:7171 ||| NNS
treated  ||| S:7171 E:7179 ||| VBN
with  ||| S:7179 E:7184 ||| IN
dexamethasone  ||| S:7184 E:7198 ||| NN
and  ||| S:7198 E:7210 ||| CC
ISIS  ||| S:7210 E:7215 ||| NNP
15534 ||| S:7215 E:7220 ||| CD
.  ||| S:7220 E:7222 ||| .
These  ||| S:7222 E:7228 ||| DT
studies  ||| S:7228 E:7236 ||| NNS
indicate  ||| S:7236 E:7245 ||| VBP
that  ||| S:7245 E:7250 ||| IN
PP5  ||| S:7250 E:7254 ||| CD
mediated  ||| S:7254 E:7271 ||| JJ
suppression  ||| S:7271 E:7283 ||| NN
of  ||| S:7283 E:7286 ||| IN
GR-function  ||| S:7286 E:7298 ||| JJ
arises  ||| S:7298 E:7305 ||| NN
from  ||| S:7305 E:7310 ||| IN
the  ||| S:7310 E:7314 ||| DT
ability  ||| S:7314 E:7322 ||| NN
of  ||| S:7322 E:7325 ||| IN
PP5  ||| S:7325 E:7337 ||| CD
to  ||| S:7337 E:7340 ||| TO
suppress  ||| S:7340 E:7349 ||| VB
the  ||| S:7349 E:7353 ||| DT
nuclear  ||| S:7353 E:7361 ||| JJ
accumulation  ||| S:7361 E:7374 ||| NN
of  ||| S:7374 E:7377 ||| IN
GRs ||| S:7377 E:7380 ||| JJ
.  ||| S:7380 E:7404 ||| .
Results  ||| S:7404 E:7431 ||| NNP
Inhibition  ||| S:7431 E:7442 ||| NNP
of  ||| S:7442 E:7445 ||| IN
PP5  ||| S:7445 E:7449 ||| CD
by  ||| S:7449 E:7452 ||| IN
okadaic  ||| S:7452 E:7460 ||| JJ
acid  ||| S:7460 E:7475 ||| JJ
Okadaic  ||| S:7475 E:7483 ||| JJ
acid  ||| S:7483 E:7488 ||| NN
is  ||| S:7488 E:7491 ||| VBZ
widely  ||| S:7491 E:7498 ||| RB
employed  ||| S:7498 E:7507 ||| VBN
to  ||| S:7507 E:7510 ||| TO
inhibit  ||| S:7510 E:7518 ||| VB
PPase  ||| S:7518 E:7534 ||| JJ
activity  ||| S:7534 E:7543 ||| NN
in  ||| S:7543 E:7546 ||| IN
eukaryotic  ||| S:7546 E:7557 ||| JJ
cells ||| S:7557 E:7562 ||| NNS
,  ||| S:7562 E:7564 ||| ,
and  ||| S:7564 E:7568 ||| CC
the  ||| S:7568 E:7572 ||| DT
observed  ||| S:7572 E:7581 ||| JJ
effects  ||| S:7581 E:7599 ||| NNS
are  ||| S:7599 E:7603 ||| VBP
often  ||| S:7603 E:7609 ||| RB
attributed  ||| S:7609 E:7620 ||| VBN
to  ||| S:7620 E:7623 ||| TO
the  ||| S:7623 E:7627 ||| DT
inhibition  ||| S:7627 E:7638 ||| NN
of  ||| S:7638 E:7641 ||| IN
PP1  ||| S:7641 E:7645 ||| NNP
and  ||| S:7645 E:7649 ||| CC
PP2A ||| S:7649 E:7653 ||| NNP
.  ||| S:7653 E:7665 ||| .
However ||| S:7665 E:7672 ||| RB
,  ||| S:7672 E:7674 ||| ,
as  ||| S:7674 E:7677 ||| RB
seen  ||| S:7677 E:7682 ||| VBN
in  ||| S:7682 E:7685 ||| IN
Figure  ||| S:7685 E:7692 ||| NNP
1 ||| S:7692 E:7693 ||| CD
,  ||| S:7693 E:7695 ||| ,
the  ||| S:7695 E:7699 ||| DT
dephosphorylation  ||| S:7699 E:7717 ||| NN
of  ||| S:7717 E:7730 ||| IN
phosphohistone  ||| S:7730 E:7745 ||| NN
by  ||| S:7745 E:7748 ||| IN
the  ||| S:7748 E:7752 ||| DT
catalytic  ||| S:7752 E:7762 ||| JJ
subunit  ||| S:7762 E:7770 ||| NN
of  ||| S:7770 E:7773 ||| IN
purified  ||| S:7773 E:7782 ||| JJ
PP5  ||| S:7782 E:7796 ||| NN
from  ||| S:7796 E:7801 ||| IN
bovine  ||| S:7801 E:7808 ||| JJ
brain  ||| S:7808 E:7814 ||| NN
is  ||| S:7814 E:7817 ||| VBZ
also  ||| S:7817 E:7822 ||| RB
potently  ||| S:7822 E:7831 ||| JJ
inhibited  ||| S:7831 E:7841 ||| NN
by  ||| S:7841 E:7844 ||| IN
okadaic  ||| S:7844 E:7862 ||| JJ
acid ||| S:7862 E:7866 ||| NN
.  ||| S:7866 E:7868 ||| .
Okadaic  ||| S:7868 E:7876 ||| JJ
acid  ||| S:7876 E:7881 ||| NN
inhibits  ||| S:7881 E:7890 ||| VBD
the  ||| S:7890 E:7894 ||| DT
activity  ||| S:7894 E:7903 ||| NN
of  ||| S:7903 E:7906 ||| IN
PP5  ||| S:7906 E:7910 ||| CD
in  ||| S:7910 E:7913 ||| IN
a  ||| S:7913 E:7925 ||| DT
dose-dependent  ||| S:7925 E:7940 ||| JJ
manner ||| S:7940 E:7946 ||| NN
,  ||| S:7946 E:7948 ||| ,
having  ||| S:7948 E:7955 ||| VBG
an  ||| S:7955 E:7958 ||| DT
IC  ||| S:7958 E:7972 ||| NNP
50  ||| S:7972 E:7975 ||| CD
of  ||| S:7975 E:7978 ||| IN
5.58  ||| S:7978 E:7983 ||| CD
+ ||| S:7983 E:7984 ||| CD
/ ||| S:7984 E:7985 ||| CD
-  ||| S:7985 E:7987 ||| :
0.41  ||| S:7987 E:7992 ||| CD
nM ||| S:7992 E:7994 ||| NN
.  ||| S:7994 E:7996 ||| .
Under  ||| S:7996 E:8012 ||| IN
identical  ||| S:8012 E:8022 ||| JJ
assay  ||| S:8022 E:8028 ||| JJ
conditions ||| S:8028 E:8038 ||| NNS
,  ||| S:8038 E:8040 ||| ,
okadaic  ||| S:8040 E:8048 ||| JJ
acid  ||| S:8048 E:8053 ||| NN
is  ||| S:8053 E:8056 ||| VBZ
a  ||| S:8056 E:8058 ||| DT
more  ||| S:8058 E:8063 ||| RBR
potent  ||| S:8063 E:8080 ||| JJ
inhibitor  ||| S:8080 E:8090 ||| NN
of  ||| S:8090 E:8093 ||| IN
PP2A  ||| S:8093 E:8098 ||| NNP
( ||| S:8098 E:8099 ||| -LRB-
IC  ||| S:8099 E:8113 ||| NNP
50  ||| S:8113 E:8116 ||| CD
~  ||| S:8116 E:8118 ||| CD
0.05  ||| S:8118 E:8123 ||| CD
nM ||| S:8123 E:8125 ||| NN
)  ||| S:8125 E:8127 ||| -RRB-
and  ||| S:8127 E:8131 ||| CC
weaker  ||| S:8131 E:8138 ||| JJR
inhibitor  ||| S:8138 E:8148 ||| NN
of  ||| S:8148 E:8161 ||| IN
PP1  ||| S:8161 E:8165 ||| NNP
( ||| S:8165 E:8166 ||| -LRB-
IC  ||| S:8166 E:8180 ||| NNP
50  ||| S:8180 E:8183 ||| CD
~  ||| S:8183 E:8185 ||| CD
45  ||| S:8185 E:8188 ||| CD
nM ||| S:8188 E:8190 ||| NN
) ||| S:8190 E:8191 ||| -RRB-
.  ||| S:8191 E:8193 ||| .
However ||| S:8193 E:8200 ||| RB
,  ||| S:8200 E:8202 ||| ,
the  ||| S:8202 E:8206 ||| DT
activity  ||| S:8206 E:8215 ||| NN
of  ||| S:8215 E:8228 ||| IN
PP5  ||| S:8228 E:8232 ||| CD
against  ||| S:8232 E:8240 ||| IN
histone  ||| S:8240 E:8248 ||| NNS
( ||| S:8248 E:8249 ||| -LRB-
865  ||| S:8249 E:8253 ||| CD
+ ||| S:8253 E:8254 ||| CD
/ ||| S:8254 E:8255 ||| CD
-  ||| S:8255 E:8257 ||| :
31  ||| S:8257 E:8260 ||| CD
nMoles  ||| S:8260 E:8267 ||| JJ
Pi ||| S:8267 E:8269 ||| FW
/ ||| S:8269 E:8270 ||| FW
min ||| S:8270 E:8273 ||| FW
/ ||| S:8273 E:8274 ||| FW
mg  ||| S:8274 E:8277 ||| FW
protein ||| S:8277 E:8284 ||| FW
)  ||| S:8284 E:8296 ||| -RRB-
is  ||| S:8296 E:8299 ||| VBZ
less  ||| S:8299 E:8304 ||| JJR
than  ||| S:8304 E:8309 ||| IN
that  ||| S:8309 E:8314 ||| DT
of  ||| S:8314 E:8317 ||| IN
PP2A ||| S:8317 E:8321 ||| CD
.  ||| S:8321 E:8323 ||| .
Therefore ||| S:8323 E:8332 ||| RB
,  ||| S:8332 E:8334 ||| ,
whereas  ||| S:8334 E:8342 ||| IN
assays  ||| S:8342 E:8359 ||| VBG
conducted  ||| S:8359 E:8369 ||| VBN
with  ||| S:8369 E:8374 ||| IN
PP1  ||| S:8374 E:8378 ||| NNP
and  ||| S:8378 E:8382 ||| CC
PP2A  ||| S:8382 E:8387 ||| NNP
were  ||| S:8387 E:8392 ||| VBD
conducted  ||| S:8392 E:8402 ||| VBN
with  ||| S:8402 E:8407 ||| IN
a  ||| S:8407 E:8419 ||| DT
concentration  ||| S:8419 E:8433 ||| NN
of  ||| S:8433 E:8436 ||| IN
enzyme  ||| S:8436 E:8443 ||| NNS
that  ||| S:8443 E:8448 ||| WDT
is  ||| S:8448 E:8451 ||| VBZ
diluted  ||| S:8451 E:8459 ||| VBN
below  ||| S:8459 E:8465 ||| IN
the  ||| S:8465 E:8479 ||| DT
titration  ||| S:8479 E:8489 ||| JJ
endpoint  ||| S:8489 E:8498 ||| NNS
( ||| S:8498 E:8499 ||| -LRB-
defined  ||| S:8499 E:8507 ||| VBN
as  ||| S:8507 E:8510 ||| IN
the  ||| S:8510 E:8514 ||| DT
concentration  ||| S:8514 E:8528 ||| NN
of  ||| S:8528 E:8541 ||| IN
enzyme  ||| S:8541 E:8548 ||| NN
after  ||| S:8548 E:8554 ||| IN
which  ||| S:8554 E:8560 ||| WDT
further  ||| S:8560 E:8568 ||| RB
dilution  ||| S:8568 E:8577 ||| VB
no  ||| S:8577 E:8580 ||| DT
longer  ||| S:8580 E:8587 ||| RB
affects  ||| S:8587 E:8595 ||| VBZ
the  ||| S:8595 E:8609 ||| DT
IC  ||| S:8609 E:8623 ||| NNP
50  ||| S:8623 E:8626 ||| CD
;  ||| S:8626 E:8628 ||| :
[  ||| S:8628 E:8630 ||| -LRB-
26 ||| S:8630 E:8632 ||| CD
] ||| S:8632 E:8633 ||| CD
)  ||| S:8633 E:8635 ||| -RRB-
because  ||| S:8635 E:8643 ||| IN
the  ||| S:8643 E:8647 ||| DT
activity  ||| S:8647 E:8656 ||| NN
of  ||| S:8656 E:8669 ||| IN
PP5  ||| S:8669 E:8673 ||| CD
upon  ||| S:8673 E:8678 ||| IN
further  ||| S:8678 E:8686 ||| JJ
dilution  ||| S:8686 E:8695 ||| NN
was  ||| S:8695 E:8699 ||| VBD
below  ||| S:8699 E:8705 ||| IN
that  ||| S:8705 E:8710 ||| DT
necessary  ||| S:8710 E:8720 ||| JJ
for  ||| S:8720 E:8734 ||| IN
accurate  ||| S:8734 E:8743 ||| JJ
quantification ||| S:8743 E:8757 ||| NN
,  ||| S:8757 E:8759 ||| ,
we  ||| S:8759 E:8762 ||| PRP
could  ||| S:8762 E:8768 ||| MD
not  ||| S:8768 E:8772 ||| RB
establish  ||| S:8772 E:8782 ||| VB
a  ||| S:8782 E:8784 ||| DT
clear  ||| S:8784 E:8800 ||| JJ
titration  ||| S:8800 E:8810 ||| JJ
endpoint  ||| S:8810 E:8819 ||| NN
with  ||| S:8819 E:8824 ||| IN
PP5 ||| S:8824 E:8827 ||| CD
.  ||| S:8827 E:8829 ||| .
Based  ||| S:8829 E:8835 ||| VBN
on  ||| S:8835 E:8838 ||| IN
titration  ||| S:8838 E:8848 ||| JJ
studies  ||| S:8848 E:8866 ||| NNS
with  ||| S:8866 E:8871 ||| IN
microcystin-LR  ||| S:8871 E:8886 ||| JJ
to  ||| S:8886 E:8889 ||| TO
estimate  ||| S:8889 E:8898 ||| VB
the  ||| S:8898 E:8902 ||| DT
actual  ||| S:8902 E:8909 ||| JJ
amount  ||| S:8909 E:8916 ||| NN
of  ||| S:8916 E:8919 ||| IN
PP5  ||| S:8919 E:8933 ||| CD
in  ||| S:8933 E:8936 ||| IN
the  ||| S:8936 E:8940 ||| DT
reaction ||| S:8940 E:8948 ||| NN
,  ||| S:8948 E:8950 ||| ,
an  ||| S:8950 E:8953 ||| DT
estimate  ||| S:8953 E:8962 ||| NN
of  ||| S:8962 E:8965 ||| IN
the  ||| S:8965 E:8969 ||| DT
K  ||| S:8969 E:8982 ||| NNP
i  ||| S:8982 E:8984 ||| NN
for  ||| S:8984 E:8988 ||| IN
okadaic  ||| S:8988 E:8996 ||| JJ
acid  ||| S:8996 E:9001 ||| NN
is  ||| S:9001 E:9004 ||| VBZ
4.07  ||| S:9004 E:9009 ||| CD
+ ||| S:9009 E:9010 ||| CD
/ ||| S:9010 E:9011 ||| CD
-  ||| S:9011 E:9013 ||| :
0.16  ||| S:9013 E:9028 ||| CD
nM ||| S:9028 E:9030 ||| NN
.  ||| S:9030 E:9032 ||| .
Still ||| S:9032 E:9037 ||| RB
,  ||| S:9037 E:9039 ||| ,
it  ||| S:9039 E:9042 ||| PRP
should  ||| S:9042 E:9049 ||| MD
be  ||| S:9049 E:9052 ||| VB
kept  ||| S:9052 E:9057 ||| VBN
in  ||| S:9057 E:9060 ||| IN
mind  ||| S:9060 E:9065 ||| NN
that  ||| S:9065 E:9070 ||| IN
the  ||| S:9070 E:9074 ||| DT
true  ||| S:9074 E:9079 ||| JJ
K  ||| S:9079 E:9092 ||| NNP
i  ||| S:9092 E:9094 ||| FW
may  ||| S:9094 E:9098 ||| MD
be  ||| S:9098 E:9101 ||| VB
slightly  ||| S:9101 E:9110 ||| RB
lower ||| S:9110 E:9115 ||| JJR
.  ||| S:9115 E:9117 ||| .
Nonetheless ||| S:9117 E:9128 ||| RB
,  ||| S:9128 E:9140 ||| ,
it  ||| S:9140 E:9143 ||| PRP
is  ||| S:9143 E:9146 ||| VBZ
clear  ||| S:9146 E:9152 ||| JJ
that  ||| S:9152 E:9157 ||| IN
PP5  ||| S:9157 E:9161 ||| NNP
is  ||| S:9161 E:9164 ||| VBZ
sensitive  ||| S:9164 E:9174 ||| JJ
to  ||| S:9174 E:9177 ||| TO
inhibition  ||| S:9177 E:9188 ||| VB
by  ||| S:9188 E:9201 ||| IN
okadaic  ||| S:9201 E:9209 ||| JJ
acid  ||| S:9209 E:9214 ||| NN
at  ||| S:9214 E:9217 ||| IN
the  ||| S:9217 E:9221 ||| DT
concentrations  ||| S:9221 E:9236 ||| NNS
that  ||| S:9236 E:9241 ||| WDT
also  ||| S:9241 E:9246 ||| RB
affects  ||| S:9246 E:9254 ||| VBZ
the  ||| S:9254 E:9268 ||| DT
activity  ||| S:9268 E:9277 ||| NN
of  ||| S:9277 E:9280 ||| IN
PP1  ||| S:9280 E:9284 ||| NNP
and  ||| S:9284 E:9288 ||| CC
PP2A ||| S:9288 E:9292 ||| NNP
.  ||| S:9292 E:9294 ||| .
Therefore ||| S:9294 E:9303 ||| RB
,  ||| S:9303 E:9305 ||| ,
when  ||| S:9305 E:9310 ||| WRB
okadaic  ||| S:9310 E:9318 ||| JJ
acid  ||| S:9318 E:9323 ||| NN
is  ||| S:9323 E:9336 ||| VBZ
employed  ||| S:9336 E:9345 ||| VBN
to  ||| S:9345 E:9348 ||| TO
treat  ||| S:9348 E:9354 ||| VB
cells  ||| S:9354 E:9360 ||| NNS
at  ||| S:9360 E:9363 ||| IN
a  ||| S:9363 E:9365 ||| DT
concentration  ||| S:9365 E:9379 ||| NN
of  ||| S:9379 E:9382 ||| IN
> ||| S:9382 E:9383 ||| NNP
1-5  ||| S:9383 E:9387 ||| NNP
nM ||| S:9387 E:9389 ||| NNP
,  ||| S:9389 E:9401 ||| ,
the  ||| S:9401 E:9405 ||| DT
activity  ||| S:9405 E:9414 ||| NN
of  ||| S:9414 E:9417 ||| IN
PP5  ||| S:9417 E:9421 ||| NNP
is  ||| S:9421 E:9424 ||| VBZ
also  ||| S:9424 E:9429 ||| RB
affected ||| S:9429 E:9437 ||| VBN
.  ||| S:9437 E:9467 ||| .
ISIS  ||| S:9467 E:9472 ||| NNP
15534  ||| S:9472 E:9478 ||| CD
promotes  ||| S:9478 E:9487 ||| CD
nuclear  ||| S:9487 E:9495 ||| JJ
localization  ||| S:9495 E:9508 ||| NN
of  ||| S:9508 E:9521 ||| IN
GR  ||| S:9521 E:9534 ||| NNP
To  ||| S:9534 E:9537 ||| TO
determine  ||| S:9537 E:9547 ||| VB
whether  ||| S:9547 E:9555 ||| IN
the  ||| S:9555 E:9559 ||| DT
suppression  ||| S:9559 E:9571 ||| NN
of  ||| S:9571 E:9574 ||| IN
PP5  ||| S:9574 E:9578 ||| CD
activity  ||| S:9578 E:9597 ||| NN
influenced  ||| S:9597 E:9608 ||| VBD
the  ||| S:9608 E:9612 ||| DT
subcellular  ||| S:9612 E:9624 ||| JJ
distribution  ||| S:9624 E:9637 ||| NN
of  ||| S:9637 E:9640 ||| IN
GR ||| S:9640 E:9642 ||| NNP
,  ||| S:9642 E:9644 ||| ,
plasmids  ||| S:9644 E:9663 ||| VBZ
expressing  ||| S:9663 E:9674 ||| VBG
a  ||| S:9674 E:9676 ||| DT
GR-GFP  ||| S:9676 E:9683 ||| JJ
fusion  ||| S:9683 E:9690 ||| NN
protein  ||| S:9690 E:9698 ||| NN
were  ||| S:9698 E:9703 ||| VBD
microinjected  ||| S:9703 E:9727 ||| VBN
into  ||| S:9727 E:9732 ||| IN
cells  ||| S:9732 E:9738 ||| NNS
that  ||| S:9738 E:9743 ||| WDT
were  ||| S:9743 E:9748 ||| VBD
previously  ||| S:9748 E:9759 ||| RB
treated  ||| S:9759 E:9767 ||| VBN
with  ||| S:9767 E:9772 ||| IN
ISIS  ||| S:9772 E:9777 ||| NNP
15534 ||| S:9777 E:9782 ||| CD
.  ||| S:9782 E:9794 ||| .
In  ||| S:9794 E:9797 ||| IN
these  ||| S:9797 E:9803 ||| DT
studies  ||| S:9803 E:9811 ||| NNS
the  ||| S:9811 E:9815 ||| DT
GR-GFP  ||| S:9815 E:9822 ||| JJ
used  ||| S:9822 E:9827 ||| NN
was  ||| S:9827 E:9831 ||| VBD
derived  ||| S:9831 E:9839 ||| VBN
from  ||| S:9839 E:9844 ||| IN
the  ||| S:9844 E:9858 ||| DT
fusion  ||| S:9858 E:9865 ||| NN
of  ||| S:9865 E:9868 ||| IN
GFP  ||| S:9868 E:9872 ||| NNP
to  ||| S:9872 E:9875 ||| TO
a  ||| S:9875 E:9877 ||| DT
GR  ||| S:9877 E:9880 ||| NNP
mutant  ||| S:9880 E:9887 ||| NN
that  ||| S:9887 E:9892 ||| WDT
retained  ||| S:9892 E:9901 ||| VBD
the  ||| S:9901 E:9905 ||| DT
ability  ||| S:9905 E:9913 ||| NN
to  ||| S:9913 E:9926 ||| TO
bind  ||| S:9926 E:9931 ||| VB
agonist ||| S:9931 E:9938 ||| NNS
,  ||| S:9938 E:9940 ||| ,
translocate  ||| S:9940 E:9952 ||| VBG
to  ||| S:9952 E:9955 ||| TO
the  ||| S:9955 E:9959 ||| DT
nucleus ||| S:9959 E:9966 ||| NN
,  ||| S:9966 E:9968 ||| ,
and  ||| S:9968 E:9972 ||| CC
bind  ||| S:9972 E:9977 ||| JJ
DNA ||| S:9977 E:9980 ||| NN
,  ||| S:9980 E:9992 ||| ,
but  ||| S:9992 E:9996 ||| CC
lacked  ||| S:9996 E:10003 ||| VBD
transactivation  ||| S:10003 E:10019 ||| JJ
activity  ||| S:10019 E:10028 ||| NN
[  ||| S:10028 E:10030 ||| -LRB-
27 ||| S:10030 E:10032 ||| CD
] ||| S:10032 E:10033 ||| -RRB-
.  ||| S:10033 E:10035 ||| .
When  ||| S:10035 E:10040 ||| WRB
plasmids  ||| S:10040 E:10059 ||| NNS
expressing  ||| S:10059 E:10070 ||| VBG
the  ||| S:10070 E:10074 ||| DT
GR-GFP  ||| S:10074 E:10081 ||| NN
were  ||| S:10081 E:10086 ||| VBD
injected  ||| S:10086 E:10095 ||| VBN
into  ||| S:10095 E:10100 ||| IN
the  ||| S:10100 E:10104 ||| DT
nuclei  ||| S:10104 E:10111 ||| NN
of  ||| S:10111 E:10124 ||| IN
cells  ||| S:10124 E:10130 ||| NNS
and  ||| S:10130 E:10134 ||| CC
the  ||| S:10134 E:10138 ||| DT
cells  ||| S:10138 E:10144 ||| NNS
were  ||| S:10144 E:10149 ||| VBD
grown  ||| S:10149 E:10155 ||| VBN
in  ||| S:10155 E:10158 ||| IN
serum-containing  ||| S:10158 E:10185 ||| JJ
medium ||| S:10185 E:10191 ||| NN
,  ||| S:10191 E:10193 ||| ,
the  ||| S:10193 E:10197 ||| DT
majority  ||| S:10197 E:10206 ||| NN
of  ||| S:10206 E:10209 ||| IN
the  ||| S:10209 E:10213 ||| DT
expressed  ||| S:10213 E:10223 ||| VBN
GR-GFP  ||| S:10223 E:10230 ||| JJ
localized  ||| S:10230 E:10240 ||| NN
to  ||| S:10240 E:10253 ||| TO
the  ||| S:10253 E:10257 ||| DT
nuclei  ||| S:10257 E:10264 ||| NN
of  ||| S:10264 E:10267 ||| IN
the  ||| S:10267 E:10271 ||| DT
injected  ||| S:10271 E:10280 ||| JJ
cells ||| S:10280 E:10285 ||| NNS
,  ||| S:10285 E:10287 ||| ,
as  ||| S:10287 E:10290 ||| RB
expected  ||| S:10290 E:10299 ||| VBN
due  ||| S:10299 E:10303 ||| JJ
to  ||| S:10303 E:10306 ||| TO
the  ||| S:10306 E:10320 ||| DT
presence  ||| S:10320 E:10329 ||| NN
of  ||| S:10329 E:10332 ||| IN
glucocorticoids  ||| S:10332 E:10348 ||| NN
in  ||| S:10348 E:10351 ||| IN
the  ||| S:10351 E:10355 ||| DT
serum ||| S:10355 E:10360 ||| NN
.  ||| S:10360 E:10362 ||| .
Thus ||| S:10362 E:10366 ||| RB
,  ||| S:10366 E:10368 ||| ,
after  ||| S:10368 E:10384 ||| IN
microinjection ||| S:10384 E:10398 ||| NN
,  ||| S:10398 E:10400 ||| ,
the  ||| S:10400 E:10404 ||| DT
cells  ||| S:10404 E:10410 ||| NNS
were  ||| S:10410 E:10415 ||| VBD
grown  ||| S:10415 E:10421 ||| VBN
in  ||| S:10421 E:10424 ||| IN
medium  ||| S:10424 E:10441 ||| JJ
supplemented  ||| S:10441 E:10454 ||| NN
with  ||| S:10454 E:10459 ||| IN
serum  ||| S:10459 E:10465 ||| NN
for  ||| S:10465 E:10469 ||| IN
4  ||| S:10469 E:10471 ||| CD
to  ||| S:10471 E:10474 ||| TO
6  ||| S:10474 E:10476 ||| CD
hours  ||| S:10476 E:10482 ||| NNS
and  ||| S:10482 E:10486 ||| CC
then  ||| S:10486 E:10491 ||| RB
serum  ||| S:10491 E:10507 ||| VB
starved  ||| S:10507 E:10515 ||| VBN
overnight  ||| S:10515 E:10525 ||| JJ
to  ||| S:10525 E:10528 ||| TO
cause  ||| S:10528 E:10534 ||| VB
the  ||| S:10534 E:10538 ||| DT
redistribution  ||| S:10538 E:10553 ||| NN
of  ||| S:10553 E:10556 ||| IN
GR-GFP ||| S:10556 E:10562 ||| JJ
.  ||| S:10562 E:10574 ||| .
In  ||| S:10574 E:10577 ||| IN
the  ||| S:10577 E:10581 ||| DT
absence  ||| S:10581 E:10589 ||| NN
of  ||| S:10589 E:10592 ||| IN
serum ||| S:10592 E:10597 ||| NN
,  ||| S:10597 E:10599 ||| ,
GR-GFP  ||| S:10599 E:10606 ||| JJ
localized  ||| S:10606 E:10616 ||| NN
throughout  ||| S:10616 E:10627 ||| IN
the  ||| S:10627 E:10641 ||| DT
cells ||| S:10641 E:10646 ||| NNS
,  ||| S:10646 E:10648 ||| ,
with  ||| S:10648 E:10653 ||| IN
equal  ||| S:10653 E:10659 ||| JJ
intensity  ||| S:10659 E:10669 ||| NN
in  ||| S:10669 E:10672 ||| IN
both  ||| S:10672 E:10677 ||| PDT
the  ||| S:10677 E:10681 ||| DT
nucleus  ||| S:10681 E:10689 ||| NN
and  ||| S:10689 E:10703 ||| CC
cytoplasm  ||| S:10703 E:10713 ||| NNS
( ||| S:10713 E:10714 ||| -LRB-
Fig.  ||| S:10714 E:10719 ||| NNP
2A ||| S:10719 E:10721 ||| NNP
) ||| S:10721 E:10722 ||| -RRB-
.  ||| S:10722 E:10724 ||| .
Upon  ||| S:10724 E:10729 ||| IN
treatment  ||| S:10729 E:10739 ||| NN
of  ||| S:10739 E:10742 ||| IN
these  ||| S:10742 E:10748 ||| DT
cells  ||| S:10748 E:10754 ||| NNS
with  ||| S:10754 E:10769 ||| IN
dexamethasone  ||| S:10769 E:10783 ||| NNS
( ||| S:10783 E:10784 ||| -LRB-
500  ||| S:10784 E:10788 ||| CD
nM  ||| S:10788 E:10791 ||| NN
for  ||| S:10791 E:10795 ||| IN
30  ||| S:10795 E:10798 ||| CD
minutes ||| S:10798 E:10805 ||| NNS
)  ||| S:10805 E:10807 ||| -RRB-
the  ||| S:10807 E:10811 ||| DT
GR-GFP  ||| S:10811 E:10828 ||| JJ
efficiently  ||| S:10828 E:10840 ||| JJ
translocated  ||| S:10840 E:10853 ||| NN
to  ||| S:10853 E:10856 ||| TO
the  ||| S:10856 E:10860 ||| DT
nucleus ||| S:10860 E:10867 ||| NN
.  ||| S:10867 E:10869 ||| .
To  ||| S:10869 E:10872 ||| TO
assess  ||| S:10872 E:10879 ||| VB
the  ||| S:10879 E:10893 ||| DT
role  ||| S:10893 E:10898 ||| NN
of  ||| S:10898 E:10901 ||| IN
PP5  ||| S:10901 E:10905 ||| CD
in  ||| S:10905 E:10908 ||| IN
the  ||| S:10908 E:10912 ||| DT
intracellular  ||| S:10912 E:10926 ||| JJ
partitioning  ||| S:10926 E:10939 ||| NN
of  ||| S:10939 E:10942 ||| IN
GR ||| S:10942 E:10944 ||| NNP
,  ||| S:10944 E:10956 ||| ,
cells  ||| S:10956 E:10962 ||| NNS
were  ||| S:10962 E:10967 ||| VBD
treated  ||| S:10967 E:10975 ||| VBN
with  ||| S:10975 E:10980 ||| IN
ISIS  ||| S:10980 E:10985 ||| NNP
15534  ||| S:10985 E:10991 ||| CD
or  ||| S:10991 E:10994 ||| CC
a  ||| S:10994 E:10996 ||| DT
mismatched  ||| S:10996 E:11017 ||| JJ
control  ||| S:11017 E:11025 ||| NN
( ||| S:11025 E:11026 ||| -LRB-
ISIS  ||| S:11026 E:11031 ||| NNP
15521 ||| S:11031 E:11036 ||| CD
)  ||| S:11036 E:11038 ||| -RRB-
at  ||| S:11038 E:11041 ||| IN
a  ||| S:11041 E:11043 ||| DT
concentration  ||| S:11043 E:11057 ||| NN
of  ||| S:11057 E:11060 ||| IN
500  ||| S:11060 E:11064 ||| CD
nM ||| S:11064 E:11066 ||| NN
,  ||| S:11066 E:11068 ||| ,
which  ||| S:11068 E:11084 ||| WDT
essentially  ||| S:11084 E:11096 ||| RB
ablates  ||| S:11096 E:11104 ||| CD
PP5  ||| S:11104 E:11108 ||| CD
expression  ||| S:11108 E:11119 ||| NN
in  ||| S:11119 E:11122 ||| IN
A549  ||| S:11122 E:11127 ||| CD
cells  ||| S:11127 E:11133 ||| NNS
after  ||| S:11133 E:11139 ||| IN
24  ||| S:11139 E:11152 ||| CD
hours  ||| S:11152 E:11158 ||| NNS
[  ||| S:11158 E:11160 ||| -LRB-
24 ||| S:11160 E:11162 ||| CD
,  ||| S:11162 E:11164 ||| ,
25 ||| S:11164 E:11166 ||| CD
] ||| S:11166 E:11167 ||| -RRB-
.  ||| S:11167 E:11169 ||| .
Approximately  ||| S:11169 E:11183 ||| RB
24  ||| S:11183 E:11186 ||| CD
hours  ||| S:11186 E:11192 ||| NNS
after  ||| S:11192 E:11198 ||| IN
antisense  ||| S:11198 E:11218 ||| JJ
treatment ||| S:11218 E:11227 ||| NN
,  ||| S:11227 E:11229 ||| ,
the  ||| S:11229 E:11233 ||| DT
cells  ||| S:11233 E:11239 ||| NNS
were  ||| S:11239 E:11244 ||| VBD
microinjected  ||| S:11244 E:11258 ||| VBN
with  ||| S:11258 E:11263 ||| IN
pGR ||| S:11263 E:11266 ||| NNP
( ||| S:11266 E:11267 ||| -LRB-
Ala ||| S:11267 E:11270 ||| NNP
) ||| S:11270 E:11271 ||| -RRB-
-GFP  ||| S:11271 E:11286 ||| JJ
and  ||| S:11286 E:11290 ||| CC
subjected  ||| S:11290 E:11300 ||| VBN
to  ||| S:11300 E:11303 ||| TO
serum-starvation  ||| S:11303 E:11320 ||| JJ
as  ||| S:11320 E:11323 ||| IN
described  ||| S:11323 E:11333 ||| VBN
above ||| S:11333 E:11338 ||| IN
.  ||| S:11338 E:11340 ||| .
In  ||| S:11340 E:11353 ||| IN
cells  ||| S:11353 E:11359 ||| NNS
treated  ||| S:11359 E:11367 ||| VBN
with  ||| S:11367 E:11372 ||| IN
the  ||| S:11372 E:11376 ||| DT
mismatch  ||| S:11376 E:11385 ||| JJ
control  ||| S:11385 E:11393 ||| NN
prior  ||| S:11393 E:11399 ||| RB
to  ||| S:11399 E:11412 ||| TO
microinjection ||| S:11412 E:11426 ||| VB
,  ||| S:11426 E:11428 ||| ,
GR-GFP  ||| S:11428 E:11435 ||| JJ
expression  ||| S:11435 E:11446 ||| NN
was  ||| S:11446 E:11450 ||| VBD
indistinguishable  ||| S:11450 E:11478 ||| VBN
from  ||| S:11478 E:11483 ||| IN
that  ||| S:11483 E:11488 ||| DT
in  ||| S:11488 E:11491 ||| IN
untreated  ||| S:11491 E:11501 ||| JJ
cells ||| S:11501 E:11506 ||| NNS
:  ||| S:11506 E:11508 ||| :
GR-GFP  ||| S:11508 E:11515 ||| NNP
was  ||| S:11515 E:11519 ||| VBD
distributed  ||| S:11519 E:11541 ||| VBN
evenly  ||| S:11541 E:11548 ||| RB
throughout  ||| S:11548 E:11559 ||| IN
the  ||| S:11559 E:11563 ||| DT
cytoplasm  ||| S:11563 E:11573 ||| NN
and  ||| S:11573 E:11577 ||| CC
nucleus  ||| S:11577 E:11585 ||| NNS
( ||| S:11585 E:11586 ||| -LRB-
Figure  ||| S:11586 E:11593 ||| NNP
2A ||| S:11593 E:11595 ||| NNP
) ||| S:11595 E:11596 ||| -RRB-
.  ||| S:11596 E:11608 ||| .
In  ||| S:11608 E:11611 ||| IN
contrast ||| S:11611 E:11619 ||| NN
,  ||| S:11619 E:11621 ||| ,
following  ||| S:11621 E:11631 ||| VBG
treatment  ||| S:11631 E:11641 ||| NN
with  ||| S:11641 E:11646 ||| IN
ISIS  ||| S:11646 E:11651 ||| NNP
15534 ||| S:11651 E:11656 ||| CD
,  ||| S:11656 E:11658 ||| ,
GR-GFP  ||| S:11658 E:11675 ||| NNP
was  ||| S:11675 E:11679 ||| VBD
localized  ||| S:11679 E:11689 ||| VBN
in  ||| S:11689 E:11692 ||| IN
the  ||| S:11692 E:11696 ||| DT
nucleus  ||| S:11696 E:11704 ||| NN
without  ||| S:11704 E:11712 ||| IN
dexamethasone  ||| S:11712 E:11736 ||| JJ
treatment ||| S:11736 E:11745 ||| NN
.  ||| S:11745 E:11747 ||| .
The  ||| S:11747 E:11751 ||| DT
percentage  ||| S:11751 E:11762 ||| NN
of  ||| S:11762 E:11765 ||| IN
cells  ||| S:11765 E:11771 ||| NNS
displaying  ||| S:11771 E:11792 ||| VBG
predominantly  ||| S:11792 E:11806 ||| RB
nuclear  ||| S:11806 E:11814 ||| JJ
GR-GFP  ||| S:11814 E:11821 ||| JJ
or  ||| S:11821 E:11824 ||| CC
cytoplasmic  ||| S:11824 E:11836 ||| JJ
GR-GFP  ||| S:11836 E:11843 ||| NN
from  ||| S:11843 E:11848 ||| IN
4  ||| S:11848 E:11860 ||| CD
independent  ||| S:11860 E:11872 ||| JJ
experiments  ||| S:11872 E:11884 ||| NNS
were  ||| S:11884 E:11889 ||| VBD
tabulated  ||| S:11889 E:11899 ||| JJ
and  ||| S:11899 E:11903 ||| CC
are  ||| S:11903 E:11907 ||| VBP
presented  ||| S:11907 E:11927 ||| VBN
in  ||| S:11927 E:11930 ||| IN
Figure  ||| S:11930 E:11937 ||| NNP
2B ||| S:11937 E:11939 ||| NNP
.  ||| S:11939 E:11941 ||| .
In  ||| S:11941 E:11944 ||| IN
control  ||| S:11944 E:11952 ||| NN
cells  ||| S:11952 E:11958 ||| NNS
in  ||| S:11958 E:11961 ||| IN
the  ||| S:11961 E:11965 ||| DT
absence  ||| S:11965 E:11973 ||| NN
of  ||| S:11973 E:11986 ||| IN
dexamethasone ||| S:11986 E:11999 ||| NN
,  ||| S:11999 E:12001 ||| ,
10 ||| S:12001 E:12003 ||| CD
%  ||| S:12003 E:12005 ||| NN
of  ||| S:12005 E:12008 ||| IN
the  ||| S:12008 E:12012 ||| DT
cells  ||| S:12012 E:12018 ||| NNS
showed  ||| S:12018 E:12035 ||| VBD
nuclear ||| S:12035 E:12042 ||| JJ
> ||| S:12042 E:12043 ||| CD
cytoplasmic  ||| S:12043 E:12055 ||| JJ
localization  ||| S:12055 E:12068 ||| NN
of  ||| S:12068 E:12071 ||| IN
GR-GFP ||| S:12071 E:12077 ||| JJ
.  ||| S:12077 E:12079 ||| .
Similarly ||| S:12079 E:12088 ||| RB
,  ||| S:12088 E:12100 ||| ,
20 ||| S:12100 E:12102 ||| CD
%  ||| S:12102 E:12104 ||| NN
of  ||| S:12104 E:12107 ||| IN
the  ||| S:12107 E:12111 ||| DT
cells  ||| S:12111 E:12117 ||| NNS
treated  ||| S:12117 E:12125 ||| VBN
with  ||| S:12125 E:12130 ||| IN
mismatch  ||| S:12130 E:12139 ||| JJ
oligonucleotide  ||| S:12139 E:12165 ||| NN
displayed  ||| S:12165 E:12175 ||| VBD
greater  ||| S:12175 E:12183 ||| JJR
nuclear  ||| S:12183 E:12191 ||| JJ
than  ||| S:12191 E:12196 ||| IN
cytoplasmic  ||| S:12196 E:12208 ||| JJ
localization  ||| S:12208 E:12231 ||| NN
of  ||| S:12231 E:12234 ||| IN
GR-GFP ||| S:12234 E:12240 ||| JJ
.  ||| S:12240 E:12242 ||| .
By  ||| S:12242 E:12245 ||| IN
contrast ||| S:12245 E:12253 ||| NN
,  ||| S:12253 E:12255 ||| ,
the  ||| S:12255 E:12259 ||| DT
percentage  ||| S:12259 E:12270 ||| NN
of  ||| S:12270 E:12273 ||| IN
cells  ||| S:12273 E:12279 ||| NNS
showing  ||| S:12279 E:12297 ||| VBG
more  ||| S:12297 E:12302 ||| RBR
nuclear  ||| S:12302 E:12310 ||| JJ
than  ||| S:12310 E:12315 ||| IN
cytoplasmic  ||| S:12315 E:12327 ||| JJ
distribution  ||| S:12327 E:12340 ||| NN
of  ||| S:12340 E:12343 ||| IN
GR-GFP  ||| S:12343 E:12350 ||| NNP
was  ||| S:12350 E:12364 ||| VBD
~  ||| S:12364 E:12366 ||| CD
93 ||| S:12366 E:12368 ||| CD
% ||| S:12368 E:12369 ||| NN
,  ||| S:12369 E:12371 ||| ,
~  ||| S:12371 E:12373 ||| CD
88 ||| S:12373 E:12375 ||| CD
%  ||| S:12375 E:12377 ||| NN
and  ||| S:12377 E:12381 ||| CC
~  ||| S:12381 E:12383 ||| CD
98 ||| S:12383 E:12385 ||| CD
%  ||| S:12385 E:12387 ||| NN
in  ||| S:12387 E:12390 ||| IN
cells  ||| S:12390 E:12396 ||| NNS
treated  ||| S:12396 E:12404 ||| VBN
with  ||| S:12404 E:12409 ||| IN
either  ||| S:12409 E:12426 ||| DT
dexamethasone ||| S:12426 E:12439 ||| NN
,  ||| S:12439 E:12441 ||| ,
ISIS  ||| S:12441 E:12446 ||| NNP
15534 ||| S:12446 E:12451 ||| CD
,  ||| S:12451 E:12453 ||| ,
or  ||| S:12453 E:12456 ||| CC
ISIS  ||| S:12456 E:12461 ||| NNP
15534  ||| S:12461 E:12467 ||| CD
and  ||| S:12467 E:12481 ||| CC
dexamethasone ||| S:12481 E:12494 ||| NN
,  ||| S:12494 E:12496 ||| ,
respectively ||| S:12496 E:12508 ||| RB
.  ||| S:12508 E:12510 ||| .
These  ||| S:12510 E:12516 ||| DT
results  ||| S:12516 E:12524 ||| NNS
suggest  ||| S:12524 E:12532 ||| VBP
that  ||| S:12532 E:12547 ||| IN
PP5  ||| S:12547 E:12551 ||| NNP
plays  ||| S:12551 E:12557 ||| VBZ
a  ||| S:12557 E:12559 ||| DT
role  ||| S:12559 E:12564 ||| NN
in  ||| S:12564 E:12567 ||| IN
the  ||| S:12567 E:12571 ||| DT
nucleo-cytoplasmic  ||| S:12571 E:12590 ||| JJ
partitioning  ||| S:12590 E:12613 ||| NN
of  ||| S:12613 E:12616 ||| IN
GR ||| S:12616 E:12618 ||| NNP
.  ||| S:12618 E:12648 ||| .
Inhibition  ||| S:12648 E:12659 ||| NNP
of  ||| S:12659 E:12662 ||| IN
PP5  ||| S:12662 E:12666 ||| CD
expression  ||| S:12666 E:12677 ||| NN
does  ||| S:12677 E:12682 ||| VBZ
not  ||| S:12682 E:12686 ||| RB
globally  ||| S:12686 E:12705 ||| RB
affect  ||| S:12705 E:12712 ||| VB
nuclear  ||| S:12712 E:12720 ||| JJ
shuttling  ||| S:12720 E:12740 ||| VBG
The  ||| S:12740 E:12744 ||| DT
ability  ||| S:12744 E:12752 ||| NN
of  ||| S:12752 E:12755 ||| IN
ISIS  ||| S:12755 E:12760 ||| NNP
15534  ||| S:12760 E:12766 ||| CD
treatment  ||| S:12766 E:12776 ||| NN
to  ||| S:12776 E:12779 ||| TO
induce  ||| S:12779 E:12786 ||| VB
the  ||| S:12786 E:12800 ||| DT
nuclear  ||| S:12800 E:12808 ||| JJ
accumulation  ||| S:12808 E:12821 ||| NN
of  ||| S:12821 E:12824 ||| IN
GR-GFP  ||| S:12824 E:12831 ||| NNP
suggests  ||| S:12831 E:12840 ||| VBZ
that  ||| S:12840 E:12845 ||| IN
PP5  ||| S:12845 E:12859 ||| NNP
influences  ||| S:12859 E:12870 ||| VBZ
the  ||| S:12870 E:12874 ||| DT
subcellular  ||| S:12874 E:12886 ||| JJ
distribution  ||| S:12886 E:12899 ||| NN
of  ||| S:12899 E:12902 ||| IN
GR ||| S:12902 E:12904 ||| NNP
.  ||| S:12904 E:12916 ||| .
Alternatively ||| S:12916 E:12929 ||| RB
,  ||| S:12929 E:12931 ||| ,
PP5  ||| S:12931 E:12935 ||| NNP
could  ||| S:12935 E:12941 ||| MD
have  ||| S:12941 E:12946 ||| VB
a  ||| S:12946 E:12948 ||| DT
more  ||| S:12948 E:12953 ||| RBR
global  ||| S:12953 E:12960 ||| JJ
role ||| S:12960 E:12964 ||| NN
,  ||| S:12964 E:12976 ||| ,
possibly  ||| S:12976 E:12985 ||| RB
regulating  ||| S:12985 E:12996 ||| VBG
entire  ||| S:12996 E:13003 ||| JJ
nuclear  ||| S:13003 E:13011 ||| JJ
transport  ||| S:13011 E:13021 ||| NN
pathways ||| S:13021 E:13029 ||| NN
.  ||| S:13029 E:13031 ||| .
To  ||| S:13031 E:13044 ||| TO
test  ||| S:13044 E:13049 ||| VB
the  ||| S:13049 E:13053 ||| DT
latter ||| S:13053 E:13059 ||| NN
,  ||| S:13059 E:13061 ||| ,
the  ||| S:13061 E:13065 ||| DT
effect  ||| S:13065 E:13072 ||| NN
of  ||| S:13072 E:13075 ||| IN
PP5  ||| S:13075 E:13079 ||| CD
suppression  ||| S:13079 E:13091 ||| NN
on  ||| S:13091 E:13094 ||| IN
the  ||| S:13094 E:13108 ||| DT
nucleo-cytoplasmic  ||| S:13108 E:13127 ||| JJ
shuttling  ||| S:13127 E:13137 ||| NN
of  ||| S:13137 E:13140 ||| IN
another  ||| S:13140 E:13148 ||| DT
transcription  ||| S:13148 E:13172 ||| JJ
factor ||| S:13172 E:13178 ||| NN
,  ||| S:13178 E:13180 ||| ,
NFAT ||| S:13180 E:13184 ||| NNP
,  ||| S:13184 E:13186 ||| ,
was  ||| S:13186 E:13190 ||| VBD
investigated ||| S:13190 E:13202 ||| VBN
.  ||| S:13202 E:13204 ||| .
In  ||| S:13204 E:13207 ||| IN
these  ||| S:13207 E:13213 ||| DT
studies ||| S:13213 E:13220 ||| NNS
,  ||| S:13220 E:13222 ||| ,
a  ||| S:13222 E:13234 ||| DT
stable  ||| S:13234 E:13241 ||| JJ
GFP-NFAT  ||| S:13241 E:13250 ||| JJ
expressing  ||| S:13250 E:13261 ||| JJ
HeLa  ||| S:13261 E:13266 ||| JJ
cell  ||| S:13266 E:13271 ||| NN
line  ||| S:13271 E:13276 ||| NN
was  ||| S:13276 E:13280 ||| VBD
employed  ||| S:13280 E:13289 ||| VBN
[  ||| S:13289 E:13301 ||| -LRB-
38 ||| S:13301 E:13303 ||| CD
] ||| S:13303 E:13304 ||| -RRB-
.  ||| S:13304 E:13306 ||| .
As  ||| S:13306 E:13309 ||| RB
seen  ||| S:13309 E:13314 ||| VBN
in  ||| S:13314 E:13317 ||| IN
Figure  ||| S:13317 E:13324 ||| NNP
3 ||| S:13324 E:13325 ||| CD
,  ||| S:13325 E:13327 ||| ,
in  ||| S:13327 E:13330 ||| IN
the  ||| S:13330 E:13334 ||| DT
absence  ||| S:13334 E:13342 ||| NN
of  ||| S:13342 E:13345 ||| IN
any  ||| S:13345 E:13349 ||| DT
drug ||| S:13349 E:13353 ||| NN
,  ||| S:13353 E:13355 ||| ,
the  ||| S:13355 E:13369 ||| DT
GFP-NFAT  ||| S:13369 E:13378 ||| JJ
protein  ||| S:13378 E:13386 ||| NN
is  ||| S:13386 E:13389 ||| VBZ
localized  ||| S:13389 E:13399 ||| VBN
entirely  ||| S:13399 E:13408 ||| RB
within  ||| S:13408 E:13415 ||| IN
the  ||| S:13415 E:13429 ||| DT
cytoplasm ||| S:13429 E:13438 ||| NN
.  ||| S:13438 E:13440 ||| .
Upon  ||| S:13440 E:13445 ||| IN
treatment  ||| S:13445 E:13455 ||| NN
with  ||| S:13455 E:13460 ||| IN
the  ||| S:13460 E:13464 ||| DT
calcium  ||| S:13464 E:13472 ||| JJ
ionophore  ||| S:13472 E:13492 ||| JJ
ionomycin ||| S:13492 E:13501 ||| NN
,  ||| S:13501 E:13503 ||| ,
GFP-NFAT  ||| S:13503 E:13512 ||| JJ
translocates  ||| S:13512 E:13525 ||| NNS
rapidly  ||| S:13525 E:13533 ||| RB
to  ||| S:13533 E:13536 ||| TO
the  ||| S:13536 E:13540 ||| DT
nucleus ||| S:13540 E:13547 ||| NN
.  ||| S:13547 E:13559 ||| .
The  ||| S:13559 E:13563 ||| DT
fusion  ||| S:13563 E:13570 ||| NN
protein  ||| S:13570 E:13578 ||| NN
then  ||| S:13578 E:13583 ||| RB
relocates  ||| S:13583 E:13593 ||| VBN
to  ||| S:13593 E:13596 ||| TO
the  ||| S:13596 E:13600 ||| DT
cytoplasm  ||| S:13600 E:13610 ||| NN
if  ||| S:13610 E:13613 ||| IN
the  ||| S:13613 E:13627 ||| DT
drug  ||| S:13627 E:13632 ||| NN
is  ||| S:13632 E:13635 ||| VBZ
washed  ||| S:13635 E:13642 ||| VBN
out  ||| S:13642 E:13646 ||| RP
of  ||| S:13646 E:13649 ||| IN
the  ||| S:13649 E:13653 ||| DT
cells  ||| S:13653 E:13659 ||| NNS
for  ||| S:13659 E:13663 ||| IN
6  ||| S:13663 E:13665 ||| CD
hours ||| S:13665 E:13670 ||| NNS
.  ||| S:13670 E:13672 ||| .
When  ||| S:13672 E:13677 ||| WRB
the  ||| S:13677 E:13691 ||| DT
GFP-NFAT  ||| S:13691 E:13700 ||| JJ
HeLa  ||| S:13700 E:13705 ||| JJ
cells  ||| S:13705 E:13711 ||| NNS
were  ||| S:13711 E:13716 ||| VBD
treated  ||| S:13716 E:13724 ||| VBN
with  ||| S:13724 E:13729 ||| IN
ISIS  ||| S:13729 E:13734 ||| NNP
15534 ||| S:13734 E:13739 ||| CD
,  ||| S:13739 E:13741 ||| ,
the  ||| S:13741 E:13755 ||| DT
distribution  ||| S:13755 E:13768 ||| NN
of  ||| S:13768 E:13771 ||| IN
GFP-NFAT  ||| S:13771 E:13780 ||| NNP
was  ||| S:13780 E:13784 ||| VBD
indistinguishable  ||| S:13784 E:13802 ||| VBN
from  ||| S:13802 E:13817 ||| IN
untreated  ||| S:13817 E:13827 ||| JJ
cells  ||| S:13827 E:13833 ||| NNS
or  ||| S:13833 E:13836 ||| CC
cells  ||| S:13836 E:13842 ||| NNS
treated  ||| S:13842 E:13850 ||| VBN
with  ||| S:13850 E:13855 ||| IN
mismatched  ||| S:13855 E:13866 ||| JJ
control  ||| S:13866 E:13884 ||| NN
oligonucleotides ||| S:13884 E:13900 ||| NN
.  ||| S:13900 E:13902 ||| .
Northern  ||| S:13902 E:13911 ||| JJ
analysis  ||| S:13911 E:13920 ||| NN
confirmed  ||| S:13920 E:13930 ||| VBD
the  ||| S:13930 E:13934 ||| DT
ability  ||| S:13934 E:13952 ||| NN
of  ||| S:13952 E:13955 ||| IN
ISIS  ||| S:13955 E:13960 ||| NNP
15534  ||| S:13960 E:13966 ||| CD
to  ||| S:13966 E:13969 ||| TO
suppress  ||| S:13969 E:13978 ||| VB
PP5  ||| S:13978 E:13982 ||| CD
expression  ||| S:13982 E:13993 ||| NN
in  ||| S:13993 E:13996 ||| IN
Hela  ||| S:13996 E:14001 ||| NNP
cells ||| S:14001 E:14006 ||| NNS
.  ||| S:14006 E:14018 ||| .
Therefore ||| S:14018 E:14027 ||| RB
,  ||| S:14027 E:14029 ||| ,
the  ||| S:14029 E:14033 ||| DT
results  ||| S:14033 E:14041 ||| NNS
indicate  ||| S:14041 E:14050 ||| VBP
that  ||| S:14050 E:14055 ||| DT
suppression  ||| S:14055 E:14067 ||| NN
of  ||| S:14067 E:14070 ||| IN
PP5  ||| S:14070 E:14084 ||| CD
expression  ||| S:14084 E:14095 ||| NN
does  ||| S:14095 E:14100 ||| VBZ
not  ||| S:14100 E:14104 ||| RB
have  ||| S:14104 E:14109 ||| VB
a  ||| S:14109 E:14111 ||| DT
global  ||| S:14111 E:14118 ||| JJ
effect  ||| S:14118 E:14125 ||| NN
on  ||| S:14125 E:14128 ||| IN
all  ||| S:14128 E:14132 ||| DT
nuclear  ||| S:14132 E:14150 ||| JJ
shuttling  ||| S:14150 E:14160 ||| JJ
proteins ||| S:14160 E:14168 ||| NNS
.  ||| S:14168 E:14201 ||| .
Discussion  ||| S:14201 E:14220 ||| NN
Like  ||| S:14220 E:14225 ||| IN
other  ||| S:14225 E:14231 ||| JJ
steroid  ||| S:14231 E:14239 ||| JJ
hormone  ||| S:14239 E:14247 ||| NN
receptors ||| S:14247 E:14256 ||| NNS
,  ||| S:14256 E:14258 ||| ,
GRs  ||| S:14258 E:14262 ||| NNS
are  ||| S:14262 E:14274 ||| VBP
phosphoproteins ||| S:14274 E:14289 ||| VBN
,  ||| S:14289 E:14291 ||| ,
and  ||| S:14291 E:14295 ||| CC
reversible  ||| S:14295 E:14306 ||| JJ
phosphorylation  ||| S:14306 E:14322 ||| NN
of  ||| S:14322 E:14325 ||| IN
specific  ||| S:14325 E:14342 ||| JJ
ser ||| S:14342 E:14345 ||| FW
/ ||| S:14345 E:14346 ||| FW
thr  ||| S:14346 E:14350 ||| FW
residues  ||| S:14350 E:14359 ||| FW
on  ||| S:14359 E:14362 ||| IN
the  ||| S:14362 E:14366 ||| DT
GR  ||| S:14366 E:14369 ||| NNP
or  ||| S:14369 E:14372 ||| CC
associated  ||| S:14372 E:14383 ||| JJ
proteins  ||| S:14383 E:14392 ||| NNS
has  ||| S:14392 E:14396 ||| VBZ
been  ||| S:14396 E:14409 ||| VBN
implicated  ||| S:14409 E:14420 ||| VBN
in  ||| S:14420 E:14423 ||| IN
the  ||| S:14423 E:14427 ||| DT
regulation  ||| S:14427 E:14438 ||| NN
of  ||| S:14438 E:14441 ||| IN
1 ||| S:14441 E:14442 ||| CD
)  ||| S:14442 E:14444 ||| -RRB-
hormone  ||| S:14444 E:14452 ||| NN
binding  ||| S:14452 E:14460 ||| VBG
to  ||| S:14460 E:14463 ||| TO
the  ||| S:14463 E:14475 ||| DT
cytoplasmic  ||| S:14475 E:14487 ||| JJ
GR-complex ||| S:14487 E:14497 ||| NN
,  ||| S:14497 E:14499 ||| ,
2 ||| S:14499 E:14500 ||| LS
)  ||| S:14500 E:14502 ||| -RRB-
the  ||| S:14502 E:14506 ||| DT
translocation  ||| S:14506 E:14520 ||| NN
of  ||| S:14520 E:14523 ||| IN
the  ||| S:14523 E:14527 ||| DT
GR  ||| S:14527 E:14538 ||| NNP
between  ||| S:14538 E:14546 ||| IN
the  ||| S:14546 E:14550 ||| DT
cytoplasm  ||| S:14550 E:14560 ||| NN
and  ||| S:14560 E:14564 ||| CC
the  ||| S:14564 E:14568 ||| DT
nucleus ||| S:14568 E:14575 ||| NN
,  ||| S:14575 E:14577 ||| ,
3 ||| S:14577 E:14578 ||| LS
)  ||| S:14578 E:14580 ||| -RRB-
the  ||| S:14580 E:14584 ||| DT
binding  ||| S:14584 E:14592 ||| NN
of  ||| S:14592 E:14603 ||| IN
ligand  ||| S:14603 E:14610 ||| JJ
activated  ||| S:14610 E:14620 ||| JJ
GR  ||| S:14620 E:14623 ||| NN
to  ||| S:14623 E:14626 ||| TO
consensus  ||| S:14626 E:14636 ||| VB
GRE  ||| S:14636 E:14640 ||| NNP
in  ||| S:14640 E:14643 ||| IN
the  ||| S:14643 E:14647 ||| DT
promoter  ||| S:14647 E:14664 ||| NN
regions  ||| S:14664 E:14672 ||| NNS
of  ||| S:14672 E:14675 ||| IN
GR-responsive  ||| S:14675 E:14689 ||| JJ
genes ||| S:14689 E:14694 ||| NNS
,  ||| S:14694 E:14696 ||| ,
and  ||| S:14696 E:14700 ||| CC
4 ||| S:14700 E:14701 ||| LS
)  ||| S:14701 E:14703 ||| -RRB-
the  ||| S:14703 E:14707 ||| DT
formation  ||| S:14707 E:14717 ||| NN
of  ||| S:14717 E:14720 ||| IN
an  ||| S:14720 E:14731 ||| DT
active  ||| S:14731 E:14738 ||| JJ
transcriptional  ||| S:14738 E:14754 ||| JJ
complex  ||| S:14754 E:14762 ||| NN
[  ||| S:14762 E:14764 ||| -LRB-
1 ||| S:14764 E:14765 ||| CD
,  ||| S:14765 E:14767 ||| ,
2 ||| S:14767 E:14768 ||| CD
,  ||| S:14768 E:14770 ||| ,
5 ||| S:14770 E:14771 ||| CD
,  ||| S:14771 E:14773 ||| ,
6 ||| S:14773 E:14774 ||| CD
,  ||| S:14774 E:14776 ||| ,
7 ||| S:14776 E:14777 ||| CD
,  ||| S:14777 E:14779 ||| ,
8 ||| S:14779 E:14780 ||| CD
,  ||| S:14780 E:14782 ||| ,
28 ||| S:14782 E:14784 ||| CD
,  ||| S:14784 E:14786 ||| ,
29 ||| S:14786 E:14788 ||| CD
,  ||| S:14788 E:14798 ||| ,
30 ||| S:14798 E:14800 ||| CD
,  ||| S:14800 E:14802 ||| ,
31 ||| S:14802 E:14804 ||| CD
] ||| S:14804 E:14805 ||| -RRB-
.  ||| S:14805 E:14807 ||| .
Many  ||| S:14807 E:14812 ||| JJ
of  ||| S:14812 E:14815 ||| IN
the  ||| S:14815 E:14819 ||| DT
kinases  ||| S:14819 E:14827 ||| NN
that  ||| S:14827 E:14832 ||| IN
catalyze  ||| S:14832 E:14841 ||| VBG
the  ||| S:14841 E:14853 ||| DT
phosphorylation  ||| S:14853 E:14869 ||| NN
of  ||| S:14869 E:14872 ||| IN
GRs  ||| S:14872 E:14876 ||| JJ
and  ||| S:14876 E:14880 ||| CC
associated  ||| S:14880 E:14891 ||| JJ
proteins  ||| S:14891 E:14900 ||| NNS
have  ||| S:14900 E:14905 ||| VBP
been  ||| S:14905 E:14918 ||| VBN
identified ||| S:14918 E:14928 ||| VBN
.  ||| S:14928 E:14930 ||| .
However ||| S:14930 E:14937 ||| RB
,  ||| S:14937 E:14939 ||| ,
little  ||| S:14939 E:14946 ||| RB
is  ||| S:14946 E:14949 ||| VBZ
known  ||| S:14949 E:14955 ||| VBN
about  ||| S:14955 E:14961 ||| IN
the  ||| S:14961 E:14965 ||| DT
PPases  ||| S:14965 E:14972 ||| NN
that  ||| S:14972 E:14985 ||| WDT
must  ||| S:14985 E:14990 ||| MD
also  ||| S:14990 E:14995 ||| RB
participate  ||| S:14995 E:15007 ||| VB
in  ||| S:15007 E:15010 ||| IN
the  ||| S:15010 E:15014 ||| DT
regulation  ||| S:15014 E:15025 ||| NN
of  ||| S:15025 E:15028 ||| IN
GR-mediated  ||| S:15028 E:15048 ||| JJ
signaling  ||| S:15048 E:15058 ||| JJ
networks ||| S:15058 E:15066 ||| NNS
.  ||| S:15066 E:15076 ||| .
Several  ||| S:15076 E:15084 ||| JJ
recent  ||| S:15084 E:15091 ||| JJ
studies  ||| S:15091 E:15099 ||| NNS
indicate  ||| S:15099 E:15108 ||| VBP
that  ||| S:15108 E:15113 ||| IN
PP5  ||| S:15113 E:15117 ||| CD
participates  ||| S:15117 E:15130 ||| NN
in  ||| S:15130 E:15141 ||| IN
the  ||| S:15141 E:15145 ||| DT
regulation  ||| S:15145 E:15156 ||| NN
of  ||| S:15156 E:15159 ||| IN
GR-induced  ||| S:15159 E:15170 ||| JJ
gene  ||| S:15170 E:15175 ||| NN
expression ||| S:15175 E:15185 ||| NN
.  ||| S:15185 E:15187 ||| .
First ||| S:15187 E:15192 ||| NNP
,  ||| S:15192 E:15202 ||| ,
dexamethasone-induced  ||| S:15202 E:15224 ||| JJ
transcription  ||| S:15224 E:15238 ||| NN
is  ||| S:15238 E:15241 ||| VBZ
markedly  ||| S:15241 E:15250 ||| RB
enhanced  ||| S:15250 E:15267 ||| VBN
when  ||| S:15267 E:15272 ||| WRB
the  ||| S:15272 E:15276 ||| DT
expression  ||| S:15276 E:15287 ||| NN
of  ||| S:15287 E:15290 ||| IN
PP5  ||| S:15290 E:15294 ||| NNP
is  ||| S:15294 E:15297 ||| VBZ
suppressed  ||| S:15297 E:15308 ||| VBN
by  ||| S:15308 E:15311 ||| IN
treatment  ||| S:15311 E:15321 ||| NN
with  ||| S:15321 E:15334 ||| IN
ISIS  ||| S:15334 E:15339 ||| NNP
15534  ||| S:15339 E:15345 ||| CD
[  ||| S:15345 E:15347 ||| -LRB-
25 ||| S:15347 E:15349 ||| CD
] ||| S:15349 E:15350 ||| -RRB-
.  ||| S:15350 E:15352 ||| .
Second ||| S:15352 E:15358 ||| LS
,  ||| S:15358 E:15360 ||| ,
both  ||| S:15360 E:15365 ||| DT
co-immunoprecipitation  ||| S:15365 E:15396 ||| JJ
studies  ||| S:15396 E:15404 ||| NNS
and  ||| S:15404 E:15408 ||| CC
studies  ||| S:15408 E:15416 ||| NNS
with  ||| S:15416 E:15421 ||| IN
mutant  ||| S:15421 E:15428 ||| JJ
forms  ||| S:15428 E:15434 ||| NNS
of  ||| S:15434 E:15437 ||| IN
PP5  ||| S:15437 E:15441 ||| NNP
indicate  ||| S:15441 E:15450 ||| VBP
that  ||| S:15450 E:15463 ||| IN
PP5  ||| S:15463 E:15467 ||| CD
associates  ||| S:15467 E:15478 ||| NNS
with  ||| S:15478 E:15483 ||| IN
the  ||| S:15483 E:15487 ||| DT
GR-hsp90  ||| S:15487 E:15496 ||| JJ
complex  ||| S:15496 E:15504 ||| NN
[  ||| S:15504 E:15506 ||| -LRB-
22 ||| S:15506 E:15508 ||| CD
,  ||| S:15508 E:15510 ||| ,
23 ||| S:15510 E:15512 ||| CD
] ||| S:15512 E:15513 ||| -RRB-
.  ||| S:15513 E:15523 ||| .
However ||| S:15523 E:15530 ||| RB
,  ||| S:15530 E:15532 ||| ,
binding  ||| S:15532 E:15540 ||| JJ
assays  ||| S:15540 E:15547 ||| NN
revealed  ||| S:15547 E:15556 ||| VBD
that  ||| S:15556 E:15561 ||| IN
the  ||| S:15561 E:15565 ||| DT
suppression  ||| S:15565 E:15577 ||| NN
of  ||| S:15577 E:15588 ||| IN
PP5  ||| S:15588 E:15592 ||| CD
expression  ||| S:15592 E:15603 ||| NN
has  ||| S:15603 E:15607 ||| VBZ
no  ||| S:15607 E:15610 ||| DT
apparent  ||| S:15610 E:15619 ||| JJ
effect  ||| S:15619 E:15626 ||| NN
on  ||| S:15626 E:15629 ||| IN
[  ||| S:15629 E:15631 ||| -LRB-
3H ||| S:15631 E:15633 ||| NNP
] ||| S:15633 E:15634 ||| -RRB-
dexamethasone  ||| S:15634 E:15656 ||| FW
binding  ||| S:15656 E:15664 ||| FW
[  ||| S:15664 E:15666 ||| -LRB-
25 ||| S:15666 E:15668 ||| CD
] ||| S:15668 E:15669 ||| -RRB-
.  ||| S:15669 E:15671 ||| .
Therefore ||| S:15671 E:15680 ||| RB
,  ||| S:15680 E:15682 ||| ,
PP5  ||| S:15682 E:15686 ||| NNP
appears  ||| S:15686 E:15694 ||| VBZ
to  ||| S:15694 E:15697 ||| TO
act  ||| S:15697 E:15701 ||| VB
as  ||| S:15701 E:15704 ||| IN
a  ||| S:15704 E:15714 ||| DT
suppressor  ||| S:15714 E:15725 ||| NN
of  ||| S:15725 E:15728 ||| IN
GR-induced  ||| S:15728 E:15739 ||| JJ
gene  ||| S:15739 E:15744 ||| NN
expression  ||| S:15744 E:15755 ||| NN
via  ||| S:15755 E:15759 ||| IN
a  ||| S:15759 E:15761 ||| DT
mechanism  ||| S:15761 E:15779 ||| NN
that  ||| S:15779 E:15784 ||| WDT
does  ||| S:15784 E:15789 ||| VBZ
not  ||| S:15789 E:15793 ||| RB
alter  ||| S:15793 E:15799 ||| VB
receptor  ||| S:15799 E:15808 ||| JJ
number  ||| S:15808 E:15815 ||| NN
or  ||| S:15815 E:15818 ||| CC
the  ||| S:15818 E:15822 ||| DT
binding  ||| S:15822 E:15830 ||| NN
of  ||| S:15830 E:15841 ||| IN
hormone  ||| S:15841 E:15849 ||| NN
to  ||| S:15849 E:15852 ||| TO
the  ||| S:15852 E:15856 ||| DT
GR ||| S:15856 E:15858 ||| NNP
.  ||| S:15858 E:15860 ||| .
To  ||| S:15860 E:15863 ||| TO
further  ||| S:15863 E:15871 ||| RB
characterize  ||| S:15871 E:15884 ||| VB
the  ||| S:15884 E:15888 ||| DT
relationship  ||| S:15888 E:15909 ||| NN
between  ||| S:15909 E:15917 ||| IN
PP5  ||| S:15917 E:15921 ||| NNP
and  ||| S:15921 E:15925 ||| CC
GR ||| S:15925 E:15927 ||| NNP
,  ||| S:15927 E:15929 ||| ,
in  ||| S:15929 E:15932 ||| IN
the  ||| S:15932 E:15936 ||| DT
present  ||| S:15936 E:15944 ||| JJ
study  ||| S:15944 E:15950 ||| NN
we  ||| S:15950 E:15953 ||| PRP
employed  ||| S:15953 E:15962 ||| VBD
a  ||| S:15962 E:15972 ||| DT
GR-GFP  ||| S:15972 E:15979 ||| JJ
fusion  ||| S:15979 E:15986 ||| NN
protein  ||| S:15986 E:15994 ||| NN
to  ||| S:15994 E:15997 ||| TO
track  ||| S:15997 E:16003 ||| VB
the  ||| S:16003 E:16007 ||| DT
movement  ||| S:16007 E:16016 ||| NN
of  ||| S:16016 E:16019 ||| IN
GRs  ||| S:16019 E:16023 ||| JJ
in  ||| S:16023 E:16026 ||| IN
A549  ||| S:16026 E:16039 ||| CD
cells  ||| S:16039 E:16045 ||| NNS
following  ||| S:16045 E:16055 ||| VBG
treatment  ||| S:16055 E:16065 ||| NN
with  ||| S:16065 E:16070 ||| IN
hormones  ||| S:16070 E:16079 ||| NNS
or  ||| S:16079 E:16082 ||| CC
ISIS  ||| S:16082 E:16087 ||| NNP
15534 ||| S:16087 E:16092 ||| CD
.  ||| S:16092 E:16102 ||| .
These  ||| S:16102 E:16108 ||| DT
studies  ||| S:16108 E:16116 ||| NNS
revealed  ||| S:16116 E:16125 ||| VBD
that  ||| S:16125 E:16130 ||| IN
in  ||| S:16130 E:16133 ||| IN
the  ||| S:16133 E:16137 ||| DT
absence  ||| S:16137 E:16145 ||| NN
of  ||| S:16145 E:16156 ||| IN
glucocorticoids ||| S:16156 E:16171 ||| NN
,  ||| S:16171 E:16173 ||| ,
GR-GFP  ||| S:16173 E:16180 ||| JJ
localized  ||| S:16180 E:16190 ||| NNS
mainly  ||| S:16190 E:16197 ||| RB
in  ||| S:16197 E:16200 ||| IN
the  ||| S:16200 E:16204 ||| DT
cytoplasm ||| S:16204 E:16213 ||| NN
.  ||| S:16213 E:16223 ||| .
As  ||| S:16223 E:16226 ||| RB
expected ||| S:16226 E:16234 ||| VBN
,  ||| S:16234 E:16236 ||| ,
treatment  ||| S:16236 E:16246 ||| NN
with  ||| S:16246 E:16251 ||| IN
dexamethasone  ||| S:16251 E:16265 ||| JJ
results  ||| S:16265 E:16273 ||| NNS
in  ||| S:16273 E:16276 ||| IN
the  ||| S:16276 E:16288 ||| DT
efficient  ||| S:16288 E:16298 ||| JJ
translocation  ||| S:16298 E:16312 ||| NN
of  ||| S:16312 E:16315 ||| IN
GR-GFPs  ||| S:16315 E:16323 ||| JJ
into  ||| S:16323 E:16328 ||| IN
the  ||| S:16328 E:16332 ||| DT
nucleus ||| S:16332 E:16339 ||| NN
.  ||| S:16339 E:16349 ||| .
Nuclear  ||| S:16349 E:16357 ||| JJ
accumulation  ||| S:16357 E:16370 ||| NN
of  ||| S:16370 E:16373 ||| IN
GR-GFP  ||| S:16373 E:16380 ||| NNP
was  ||| S:16380 E:16384 ||| VBD
also  ||| S:16384 E:16389 ||| RB
observed  ||| S:16389 E:16398 ||| VBD
when  ||| S:16398 E:16403 ||| WRB
the  ||| S:16403 E:16415 ||| DT
expression  ||| S:16415 E:16426 ||| NN
of  ||| S:16426 E:16429 ||| IN
PP5  ||| S:16429 E:16433 ||| NNP
was  ||| S:16433 E:16437 ||| VBD
suppressed  ||| S:16437 E:16448 ||| VBN
by  ||| S:16448 E:16451 ||| IN
treatment  ||| S:16451 E:16461 ||| NN
with  ||| S:16461 E:16466 ||| IN
ISIS  ||| S:16466 E:16479 ||| NNP
15534  ||| S:16479 E:16485 ||| CD
after  ||| S:16485 E:16491 ||| IN
~  ||| S:16491 E:16493 ||| CD
24  ||| S:16493 E:16496 ||| CD
hours ||| S:16496 E:16501 ||| NNS
.  ||| S:16501 E:16503 ||| .
This  ||| S:16503 E:16508 ||| DT
translocation  ||| S:16508 E:16522 ||| NN
of  ||| S:16522 E:16525 ||| IN
GR-GFP  ||| S:16525 E:16540 ||| NNP
occurred  ||| S:16540 E:16549 ||| VBD
without  ||| S:16549 E:16557 ||| IN
the  ||| S:16557 E:16561 ||| DT
addition  ||| S:16561 E:16570 ||| NN
of  ||| S:16570 E:16573 ||| IN
glucocorticoids  ||| S:16573 E:16589 ||| NN
and  ||| S:16589 E:16593 ||| CC
in  ||| S:16593 E:16596 ||| IN
the  ||| S:16596 E:16608 ||| DT
presence  ||| S:16608 E:16617 ||| NN
of  ||| S:16617 E:16620 ||| IN
serum  ||| S:16620 E:16626 ||| JJ
free  ||| S:16626 E:16631 ||| JJ
media ||| S:16631 E:16636 ||| NNS
.  ||| S:16636 E:16638 ||| .
Thus ||| S:16638 E:16642 ||| RB
,  ||| S:16642 E:16644 ||| ,
in  ||| S:16644 E:16647 ||| IN
the  ||| S:16647 E:16651 ||| DT
absence  ||| S:16651 E:16659 ||| NN
of  ||| S:16659 E:16670 ||| IN
physiological  ||| S:16670 E:16684 ||| JJ
concentrations  ||| S:16684 E:16699 ||| NNS
of  ||| S:16699 E:16702 ||| IN
PP5 ||| S:16702 E:16705 ||| NNP
,  ||| S:16705 E:16707 ||| ,
GRs  ||| S:16707 E:16711 ||| JJ
accumulate  ||| S:16711 E:16722 ||| NN
in  ||| S:16722 E:16725 ||| IN
the  ||| S:16725 E:16737 ||| DT
nucleus  ||| S:16737 E:16745 ||| NN
of  ||| S:16745 E:16748 ||| IN
A549  ||| S:16748 E:16753 ||| CD
cells ||| S:16753 E:16758 ||| NNS
.  ||| S:16758 E:16760 ||| .
This  ||| S:16760 E:16765 ||| DT
finding  ||| S:16765 E:16773 ||| NN
is  ||| S:16773 E:16776 ||| VBZ
consistent  ||| S:16776 E:16787 ||| JJ
with  ||| S:16787 E:16792 ||| IN
data  ||| S:16792 E:16805 ||| NNS
obtained  ||| S:16805 E:16814 ||| VBN
from  ||| S:16814 E:16819 ||| IN
gel-shift  ||| S:16819 E:16829 ||| JJ
analysis  ||| S:16829 E:16838 ||| NN
and  ||| S:16838 E:16842 ||| CC
transfection  ||| S:16842 E:16855 ||| JJ
studies  ||| S:16855 E:16871 ||| NNS
conducted  ||| S:16871 E:16881 ||| VBN
with  ||| S:16881 E:16886 ||| IN
GR-reporter  ||| S:16886 E:16898 ||| JJ
plasmids ||| S:16898 E:16906 ||| NN
,  ||| S:16906 E:16908 ||| ,
where  ||| S:16908 E:16914 ||| WRB
a  ||| S:16914 E:16916 ||| DT
decrease  ||| S:16916 E:16925 ||| NN
in  ||| S:16925 E:16936 ||| IN
PP5  ||| S:16936 E:16940 ||| CD
levels  ||| S:16940 E:16947 ||| NNS
facilitates  ||| S:16947 E:16959 ||| VBP
the  ||| S:16959 E:16963 ||| DT
association  ||| S:16963 E:16975 ||| NN
of  ||| S:16975 E:16978 ||| IN
GR  ||| S:16978 E:16981 ||| NNP
with  ||| S:16981 E:16986 ||| IN
DNA  ||| S:16986 E:16990 ||| NNP
and  ||| S:16990 E:17002 ||| CC
produces  ||| S:17002 E:17011 ||| VBZ
an  ||| S:17011 E:17014 ||| DT
increase  ||| S:17014 E:17023 ||| NN
in  ||| S:17023 E:17026 ||| IN
GR-transactivation  ||| S:17026 E:17045 ||| NNP
[  ||| S:17045 E:17047 ||| -LRB-
25 ||| S:17047 E:17049 ||| CD
] ||| S:17049 E:17050 ||| -RRB-
.  ||| S:17050 E:17052 ||| .
Together ||| S:17052 E:17060 ||| RB
,  ||| S:17060 E:17070 ||| ,
these  ||| S:17070 E:17076 ||| DT
studies  ||| S:17076 E:17084 ||| NNS
suggest  ||| S:17084 E:17092 ||| VBP
that  ||| S:17092 E:17097 ||| IN
the  ||| S:17097 E:17101 ||| DT
increase  ||| S:17101 E:17110 ||| NN
in  ||| S:17110 E:17113 ||| IN
GR-induced  ||| S:17113 E:17132 ||| JJ
transcriptional  ||| S:17132 E:17148 ||| JJ
activity  ||| S:17148 E:17157 ||| NN
observed  ||| S:17157 E:17166 ||| VBD
when  ||| S:17166 E:17171 ||| WRB
the  ||| S:17171 E:17175 ||| DT
expression  ||| S:17175 E:17186 ||| NN
of  ||| S:17186 E:17197 ||| IN
PP5  ||| S:17197 E:17201 ||| NNP
is  ||| S:17201 E:17204 ||| VBZ
suppressed  ||| S:17204 E:17215 ||| VBN
by  ||| S:17215 E:17218 ||| IN
treatment  ||| S:17218 E:17228 ||| NN
with  ||| S:17228 E:17233 ||| IN
ISIS  ||| S:17233 E:17238 ||| NNP
15534  ||| S:17238 E:17244 ||| CD
results  ||| S:17244 E:17252 ||| NNS
from  ||| S:17252 E:17265 ||| IN
the  ||| S:17265 E:17269 ||| DT
nuclear  ||| S:17269 E:17277 ||| JJ
accumulation  ||| S:17277 E:17290 ||| NN
of  ||| S:17290 E:17293 ||| IN
GR ||| S:17293 E:17295 ||| NNP
.  ||| S:17295 E:17305 ||| .
The  ||| S:17305 E:17309 ||| DT
mechanism  ||| S:17309 E:17319 ||| NN
by  ||| S:17319 E:17322 ||| IN
which  ||| S:17322 E:17328 ||| WDT
PP5  ||| S:17328 E:17332 ||| VBP
suppresses  ||| S:17332 E:17343 ||| VBG
the  ||| S:17343 E:17347 ||| DT
nuclear  ||| S:17347 E:17363 ||| JJ
accumulation  ||| S:17363 E:17376 ||| NN
of  ||| S:17376 E:17379 ||| IN
GR  ||| S:17379 E:17382 ||| NNP
is  ||| S:17382 E:17385 ||| VBZ
not  ||| S:17385 E:17389 ||| RB
clear ||| S:17389 E:17394 ||| JJ
.  ||| S:17394 E:17396 ||| .
The  ||| S:17396 E:17400 ||| DT
current  ||| S:17400 E:17408 ||| JJ
data  ||| S:17408 E:17413 ||| NN
is  ||| S:17413 E:17424 ||| VBZ
consistent  ||| S:17424 E:17435 ||| JJ
with  ||| S:17435 E:17440 ||| IN
PP5  ||| S:17440 E:17444 ||| CD
acting  ||| S:17444 E:17451 ||| VBG
to  ||| S:17451 E:17454 ||| TO
suppress  ||| S:17454 E:17463 ||| VB
the  ||| S:17463 E:17467 ||| DT
nuclear  ||| S:17467 E:17475 ||| JJ
import  ||| S:17475 E:17490 ||| NN
of  ||| S:17490 E:17493 ||| IN
GRs ||| S:17493 E:17496 ||| JJ
.  ||| S:17496 E:17498 ||| .
Alternatively ||| S:17498 E:17511 ||| RB
,  ||| S:17511 E:17513 ||| ,
the  ||| S:17513 E:17517 ||| DT
data  ||| S:17517 E:17522 ||| NN
is  ||| S:17522 E:17525 ||| VBZ
also  ||| S:17525 E:17530 ||| RB
consistent  ||| S:17530 E:17541 ||| JJ
with  ||| S:17541 E:17546 ||| IN
PP5  ||| S:17546 E:17558 ||| CD
acting  ||| S:17558 E:17565 ||| VBG
to  ||| S:17565 E:17568 ||| TO
promote  ||| S:17568 E:17576 ||| VB
the  ||| S:17576 E:17580 ||| DT
nuclear  ||| S:17580 E:17588 ||| JJ
export  ||| S:17588 E:17595 ||| NN
of  ||| S:17595 E:17598 ||| IN
the  ||| S:17598 E:17602 ||| DT
GRs ||| S:17602 E:17605 ||| JJ
.  ||| S:17605 E:17607 ||| .
Because  ||| S:17607 E:17623 ||| IN
the  ||| S:17623 E:17627 ||| DT
effects  ||| S:17627 E:17635 ||| NNS
of  ||| S:17635 E:17638 ||| IN
ISIS  ||| S:17638 E:17643 ||| NNP
15534  ||| S:17643 E:17649 ||| CD
treatment  ||| S:17649 E:17659 ||| NN
are  ||| S:17659 E:17663 ||| VBP
not  ||| S:17663 E:17667 ||| RB
readily  ||| S:17667 E:17683 ||| RB
reversible ||| S:17683 E:17693 ||| JJ
,  ||| S:17693 E:17695 ||| ,
the  ||| S:17695 E:17699 ||| DT
washout  ||| S:17699 E:17707 ||| JJ
experiments  ||| S:17707 E:17719 ||| NNS
needed  ||| S:17719 E:17726 ||| VBN
to  ||| S:17726 E:17729 ||| TO
distinguish  ||| S:17729 E:17749 ||| VB
between  ||| S:17749 E:17757 ||| IN
these  ||| S:17757 E:17763 ||| DT
two  ||| S:17763 E:17767 ||| CD
possibilities  ||| S:17767 E:17781 ||| NNS
cannot  ||| S:17781 E:17788 ||| RB
be  ||| S:17788 E:17791 ||| VB
conducted  ||| S:17791 E:17801 ||| VBN
until  ||| S:17801 E:17807 ||| IN
a  ||| S:17807 E:17817 ||| DT
specific  ||| S:17817 E:17826 ||| JJ
and  ||| S:17826 E:17830 ||| CC
reversible  ||| S:17830 E:17841 ||| JJ
inhibitor  ||| S:17841 E:17851 ||| NN
of  ||| S:17851 E:17854 ||| IN
PP5  ||| S:17854 E:17858 ||| NNP
is  ||| S:17858 E:17861 ||| VBZ
developed ||| S:17861 E:17870 ||| VBN
.  ||| S:17870 E:17880 ||| .
Recent  ||| S:17880 E:17887 ||| JJ
studies  ||| S:17887 E:17895 ||| NNS
indicate  ||| S:17895 E:17904 ||| VBP
that  ||| S:17904 E:17909 ||| IN
okadaic  ||| S:17909 E:17917 ||| JJ
acid  ||| S:17917 E:17922 ||| NN
inhibits  ||| S:17922 E:17939 ||| VBZ
nuclear  ||| S:17939 E:17947 ||| JJ
transport  ||| S:17947 E:17957 ||| NN
mediated  ||| S:17957 E:17966 ||| NN
by  ||| S:17966 E:17969 ||| IN
import  ||| S:17969 E:17976 ||| NN
receptors ||| S:17976 E:17985 ||| NNS
,  ||| S:17985 E:17987 ||| ,
importin  ||| S:17987 E:17996 ||| JJ
β  ||| S:17996 E:18006 ||| NN
and  ||| S:18006 E:18010 ||| CC
transportin ||| S:18010 E:18021 ||| NN
,  ||| S:18021 E:18023 ||| ,
suggesting  ||| S:18023 E:18034 ||| VBG
that  ||| S:18034 E:18039 ||| IN
an  ||| S:18039 E:18042 ||| DT
okadaic  ||| S:18042 E:18050 ||| JJ
acid  ||| S:18050 E:18055 ||| JJ
sensitive  ||| S:18055 E:18073 ||| JJ
phosphatase  ||| S:18073 E:18085 ||| NN
participates  ||| S:18085 E:18098 ||| VBZ
in  ||| S:18098 E:18101 ||| IN
a  ||| S:18101 E:18103 ||| DT
mechanism  ||| S:18103 E:18113 ||| NN
that  ||| S:18113 E:18118 ||| WDT
negatively  ||| S:18118 E:18137 ||| RB
regulates  ||| S:18137 E:18147 ||| VBZ
entire  ||| S:18147 E:18154 ||| JJ
nuclear  ||| S:18154 E:18162 ||| JJ
transport  ||| S:18162 E:18172 ||| NN
pathways  ||| S:18172 E:18181 ||| NNS
[  ||| S:18181 E:18183 ||| -LRB-
32 ||| S:18183 E:18185 ||| CD
] ||| S:18185 E:18186 ||| -RRB-
.  ||| S:18186 E:18188 ||| .
Since  ||| S:18188 E:18202 ||| IN
PP5  ||| S:18202 E:18206 ||| NNP
is  ||| S:18206 E:18209 ||| VBZ
sensitive  ||| S:18209 E:18219 ||| JJ
to  ||| S:18219 E:18222 ||| TO
inhibition  ||| S:18222 E:18233 ||| VB
by  ||| S:18233 E:18236 ||| IN
okadaic  ||| S:18236 E:18244 ||| JJ
acid ||| S:18244 E:18248 ||| NN
,  ||| S:18248 E:18250 ||| ,
we  ||| S:18250 E:18253 ||| PRP
tested  ||| S:18253 E:18268 ||| VBD
the  ||| S:18268 E:18272 ||| DT
possibility  ||| S:18272 E:18284 ||| NN
that  ||| S:18284 E:18289 ||| IN
PP5  ||| S:18289 E:18293 ||| NNP
acted  ||| S:18293 E:18299 ||| VBD
at  ||| S:18299 E:18302 ||| IN
a  ||| S:18302 E:18304 ||| DT
more  ||| S:18304 E:18309 ||| RBR
global  ||| S:18309 E:18316 ||| JJ
level  ||| S:18316 E:18322 ||| NN
by  ||| S:18322 E:18333 ||| IN
assessing  ||| S:18333 E:18343 ||| VBG
the  ||| S:18343 E:18347 ||| DT
effect  ||| S:18347 E:18354 ||| NN
of  ||| S:18354 E:18357 ||| IN
ISIS  ||| S:18357 E:18362 ||| NNP
15534  ||| S:18362 E:18368 ||| CD
on  ||| S:18368 E:18371 ||| IN
the  ||| S:18371 E:18375 ||| DT
cellular  ||| S:18375 E:18392 ||| JJ
distribution  ||| S:18392 E:18405 ||| NN
of  ||| S:18405 E:18408 ||| IN
NFAT-GFP ||| S:18408 E:18416 ||| JJ
.  ||| S:18416 E:18418 ||| .
In  ||| S:18418 E:18421 ||| IN
contrast  ||| S:18421 E:18430 ||| NN
to  ||| S:18430 E:18433 ||| TO
the  ||| S:18433 E:18437 ||| DT
findings  ||| S:18437 E:18454 ||| NNS
obtained  ||| S:18454 E:18463 ||| VBN
with  ||| S:18463 E:18468 ||| IN
GR-GFP ||| S:18468 E:18474 ||| NNP
,  ||| S:18474 E:18476 ||| ,
the  ||| S:18476 E:18480 ||| DT
suppression  ||| S:18480 E:18492 ||| NN
of  ||| S:18492 E:18495 ||| IN
PP5  ||| S:18495 E:18499 ||| CD
expression  ||| S:18499 E:18510 ||| NN
had  ||| S:18510 E:18522 ||| VBD
no  ||| S:18522 E:18525 ||| DT
apparent  ||| S:18525 E:18534 ||| JJ
effect  ||| S:18534 E:18541 ||| NN
on  ||| S:18541 E:18544 ||| IN
calcium  ||| S:18544 E:18552 ||| JJ
induced  ||| S:18552 E:18560 ||| JJ
nuclear  ||| S:18560 E:18568 ||| JJ
import  ||| S:18568 E:18575 ||| NN
or  ||| S:18575 E:18578 ||| CC
the  ||| S:18578 E:18590 ||| DT
subsequent  ||| S:18590 E:18601 ||| JJ
export  ||| S:18601 E:18608 ||| NN
of  ||| S:18608 E:18611 ||| IN
NFAT-GFP  ||| S:18611 E:18620 ||| NNP
( ||| S:18620 E:18621 ||| -LRB-
Figure  ||| S:18621 E:18628 ||| NNP
3 ||| S:18628 E:18629 ||| CD
) ||| S:18629 E:18630 ||| -RRB-
.  ||| S:18630 E:18632 ||| .
Therefore ||| S:18632 E:18641 ||| RB
,  ||| S:18641 E:18643 ||| ,
PP5  ||| S:18643 E:18655 ||| NNP
does  ||| S:18655 E:18660 ||| VBZ
not  ||| S:18660 E:18664 ||| RB
appear  ||| S:18664 E:18671 ||| VB
to  ||| S:18671 E:18674 ||| TO
regulate  ||| S:18674 E:18683 ||| VB
entire  ||| S:18683 E:18690 ||| JJ
nuclear  ||| S:18690 E:18698 ||| JJ
transport  ||| S:18698 E:18716 ||| NN
pathways ||| S:18716 E:18724 ||| NN
.  ||| S:18724 E:18748 ||| .
Conclusions  ||| S:18748 E:18768 ||| NNS
These  ||| S:18768 E:18774 ||| DT
studies  ||| S:18774 E:18782 ||| NNS
indicate  ||| S:18782 E:18791 ||| VBP
that  ||| S:18791 E:18796 ||| IN
PP5  ||| S:18796 E:18800 ||| CD
participates  ||| S:18800 E:18813 ||| NN
in  ||| S:18813 E:18816 ||| IN
the  ||| S:18816 E:18828 ||| DT
regulation  ||| S:18828 E:18839 ||| NN
of  ||| S:18839 E:18842 ||| IN
GR  ||| S:18842 E:18845 ||| NNP
nucleocytoplasmic  ||| S:18845 E:18863 ||| JJ
shuttling ||| S:18863 E:18872 ||| NN
,  ||| S:18872 E:18874 ||| ,
and  ||| S:18874 E:18878 ||| CC
that  ||| S:18878 E:18883 ||| IN
the  ||| S:18883 E:18895 ||| DT
suppression  ||| S:18895 E:18907 ||| NN
of  ||| S:18907 E:18910 ||| IN
PP5  ||| S:18910 E:18914 ||| CD
expression  ||| S:18914 E:18925 ||| NN
results  ||| S:18925 E:18933 ||| NNS
in  ||| S:18933 E:18936 ||| IN
the  ||| S:18936 E:18940 ||| DT
nuclear  ||| S:18940 E:18956 ||| JJ
accumulation  ||| S:18956 E:18969 ||| NN
of  ||| S:18969 E:18972 ||| IN
GR  ||| S:18972 E:18975 ||| NNP
in  ||| S:18975 E:18978 ||| IN
the  ||| S:18978 E:18982 ||| DT
absence  ||| S:18982 E:18990 ||| NN
of  ||| S:18990 E:18993 ||| IN
hormone ||| S:18993 E:19000 ||| NN
.  ||| S:19000 E:19002 ||| .
Therefore ||| S:19002 E:19011 ||| RB
,  ||| S:19011 E:19021 ||| ,
the  ||| S:19021 E:19025 ||| DT
previously  ||| S:19025 E:19036 ||| RB
reported  ||| S:19036 E:19045 ||| VBN
increase  ||| S:19045 E:19054 ||| NN
in  ||| S:19054 E:19057 ||| IN
GR-induced  ||| S:19057 E:19076 ||| JJ
transcriptional  ||| S:19076 E:19092 ||| JJ
activity  ||| S:19092 E:19101 ||| NN
that  ||| S:19101 E:19106 ||| WDT
occurs  ||| S:19106 E:19113 ||| VBZ
after  ||| S:19113 E:19119 ||| IN
ISIS  ||| S:19119 E:19124 ||| NNP
15534  ||| S:19124 E:19138 ||| CD
induced  ||| S:19138 E:19146 ||| JJ
suppression  ||| S:19146 E:19158 ||| NN
of  ||| S:19158 E:19161 ||| IN
PP5  ||| S:19161 E:19165 ||| CD
expression  ||| S:19165 E:19176 ||| NN
likely  ||| S:19176 E:19183 ||| JJ
results  ||| S:19183 E:19191 ||| NNS
from  ||| S:19191 E:19204 ||| IN
the  ||| S:19204 E:19208 ||| DT
nuclear  ||| S:19208 E:19216 ||| JJ
accumulation  ||| S:19216 E:19229 ||| NN
of  ||| S:19229 E:19232 ||| IN
GR  ||| S:19232 E:19235 ||| NNP
in  ||| S:19235 E:19238 ||| IN
a  ||| S:19238 E:19240 ||| DT
form  ||| S:19240 E:19245 ||| NN
that  ||| S:19245 E:19250 ||| WDT
is  ||| S:19250 E:19253 ||| VBZ
capable  ||| S:19253 E:19261 ||| JJ
of  ||| S:19261 E:19272 ||| IN
binding  ||| S:19272 E:19280 ||| JJ
DNA  ||| S:19280 E:19284 ||| NN
yet  ||| S:19284 E:19288 ||| RB
still  ||| S:19288 E:19294 ||| RB
requires  ||| S:19294 E:19303 ||| VBZ
agonist  ||| S:19303 E:19311 ||| VBN
to  ||| S:19311 E:19314 ||| TO
elicit  ||| S:19314 E:19321 ||| FW
maximal  ||| S:19321 E:19337 ||| FW
transcriptional  ||| S:19337 E:19353 ||| FW
activation ||| S:19353 E:19363 ||| FW
.  ||| S:19363 E:19365 ||| .
Still ||| S:19365 E:19370 ||| RB
,  ||| S:19370 E:19372 ||| ,
it  ||| S:19372 E:19375 ||| PRP
is  ||| S:19375 E:19378 ||| VBZ
not  ||| S:19378 E:19382 ||| RB
yet  ||| S:19382 E:19386 ||| RB
clear  ||| S:19386 E:19392 ||| JJ
if  ||| S:19392 E:19403 ||| IN
PP5  ||| S:19403 E:19407 ||| CD
acts  ||| S:19407 E:19412 ||| NNS
to  ||| S:19412 E:19415 ||| TO
suppress  ||| S:19415 E:19424 ||| VB
the  ||| S:19424 E:19428 ||| DT
nuclear  ||| S:19428 E:19436 ||| JJ
accumulation  ||| S:19436 E:19449 ||| NN
or  ||| S:19449 E:19452 ||| CC
to  ||| S:19452 E:19463 ||| TO
facilitate  ||| S:19463 E:19474 ||| VB
the  ||| S:19474 E:19478 ||| DT
nuclear  ||| S:19478 E:19486 ||| JJ
export  ||| S:19486 E:19493 ||| NN
of  ||| S:19493 E:19496 ||| IN
GRs ||| S:19496 E:19499 ||| JJ
.  ||| S:19499 E:19501 ||| .
Thus ||| S:19501 E:19505 ||| RB
,  ||| S:19505 E:19507 ||| ,
the  ||| S:19507 E:19511 ||| DT
precise  ||| S:19511 E:19527 ||| JJ
molecular  ||| S:19527 E:19537 ||| JJ
mechanism  ||| S:19537 E:19547 ||| NN
by  ||| S:19547 E:19550 ||| IN
which  ||| S:19550 E:19556 ||| WDT
PP5  ||| S:19556 E:19560 ||| VBP
suppresses  ||| S:19560 E:19571 ||| VBG
the  ||| S:19571 E:19575 ||| DT
nuclear  ||| S:19575 E:19591 ||| JJ
accumulation  ||| S:19591 E:19604 ||| NN
of  ||| S:19604 E:19607 ||| IN
GR  ||| S:19607 E:19610 ||| NNP
remains  ||| S:19610 E:19618 ||| VBZ
to  ||| S:19618 E:19621 ||| TO
be  ||| S:19621 E:19624 ||| VB
elucidated ||| S:19624 E:19634 ||| NNS
.  ||| S:19634 E:19658 ||| .
Materials  ||| S:19658 E:19668 ||| NNS
and  ||| S:19668 E:19672 ||| CC
Methods  ||| S:19672 E:19699 ||| NNP
Reagents  ||| S:19699 E:19718 ||| NNP
Tissue  ||| S:19718 E:19725 ||| NNP
culture  ||| S:19725 E:19733 ||| NN
medium ||| S:19733 E:19739 ||| NN
,  ||| S:19739 E:19741 ||| ,
Lipofectin  ||| S:19741 E:19752 ||| NNP
®and  ||| S:19752 E:19757 ||| NNP
TRIzol  ||| S:19757 E:19764 ||| NNP
®were  ||| S:19764 E:19780 ||| NNP
purchased  ||| S:19780 E:19790 ||| VBD
from  ||| S:19790 E:19795 ||| IN
Life  ||| S:19795 E:19800 ||| NNP
Technologies  ||| S:19800 E:19813 ||| NNPS
( ||| S:19813 E:19814 ||| -LRB-
Gaithersburg ||| S:19814 E:19826 ||| NNP
,  ||| S:19826 E:19828 ||| ,
MD ||| S:19828 E:19830 ||| NNP
) ||| S:19830 E:19831 ||| -RRB-
.  ||| S:19831 E:19843 ||| .
DECEprime™  ||| S:19843 E:19854 ||| NNP
II  ||| S:19854 E:19857 ||| NNP
DNA  ||| S:19857 E:19861 ||| NNP
labeling ||| S:19861 E:19869 ||| NN
,  ||| S:19869 E:19871 ||| ,
and  ||| S:19871 E:19875 ||| CC
MAXIscript™  ||| S:19875 E:19898 ||| CD
in  ||| S:19898 E:19901 ||| IN
vitro  ||| S:19901 E:19907 ||| JJ
transcription  ||| S:19907 E:19921 ||| JJ
kits  ||| S:19921 E:19926 ||| NNS
were  ||| S:19926 E:19941 ||| VBD
purchased  ||| S:19941 E:19951 ||| VBN
from  ||| S:19951 E:19956 ||| IN
Ambion  ||| S:19956 E:19963 ||| NNP
Inc ||| S:19963 E:19966 ||| NNP
.  ||| S:19966 E:19968 ||| .
( ||| S:19968 E:19969 ||| -LRB-
Austin ||| S:19969 E:19975 ||| NNP
,  ||| S:19975 E:19977 ||| ,
TX ||| S:19977 E:19979 ||| NNP
) ||| S:19979 E:19980 ||| -RRB-
.  ||| S:19980 E:19982 ||| .
[ ||| S:19982 E:19983 ||| -LRB-
α-  ||| S:19983 E:19986 ||| NNP
32P ||| S:19986 E:19989 ||| NNP
] ||| S:19989 E:19990 ||| -RRB-
dATP  ||| S:19990 E:19995 ||| JJ
and  ||| S:19995 E:20009 ||| CC
[ ||| S:20009 E:20010 ||| -LRB-
α-  ||| S:20010 E:20013 ||| NNP
32P ||| S:20013 E:20016 ||| NNP
] ||| S:20016 E:20017 ||| -RRB-
UTP  ||| S:20017 E:20021 ||| NNP
were  ||| S:20021 E:20026 ||| VBD
purchased  ||| S:20026 E:20036 ||| VBN
from  ||| S:20036 E:20041 ||| IN
Dupont  ||| S:20041 E:20048 ||| NNP
NEN  ||| S:20048 E:20052 ||| NNP
( ||| S:20052 E:20053 ||| -LRB-
Boston ||| S:20053 E:20059 ||| NNP
,  ||| S:20059 E:20061 ||| ,
MA ||| S:20061 E:20063 ||| NNP
) ||| S:20063 E:20064 ||| -RRB-
.  ||| S:20064 E:20076 ||| .
Protein  ||| S:20076 E:20084 ||| NN
kinase  ||| S:20084 E:20091 ||| VBD
A  ||| S:20091 E:20093 ||| DT
( ||| S:20093 E:20094 ||| -LRB-
3 ||| S:20094 E:20095 ||| LS
' ||| S:20095 E:20096 ||| :
: ||| S:20096 E:20097 ||| :
5 ||| S:20097 E:20098 ||| CD
' ||| S:20098 E:20099 ||| POS
-cyclic  ||| S:20099 E:20107 ||| JJ
AMP  ||| S:20107 E:20111 ||| NNP
dependent ||| S:20111 E:20120 ||| JJ
) ||| S:20120 E:20121 ||| -RRB-
,  ||| S:20121 E:20133 ||| ,
phosphorylase  ||| S:20133 E:20147 ||| FW
b  ||| S:20147 E:20149 ||| FW
( ||| S:20149 E:20150 ||| -LRB-
EC  ||| S:20150 E:20153 ||| NNP
2.4.1.1 ||| S:20153 E:20160 ||| NNP
) ||| S:20160 E:20161 ||| -RRB-
,  ||| S:20161 E:20163 ||| ,
crude  ||| S:20163 E:20169 ||| JJ
histone  ||| S:20169 E:20177 ||| NNS
( ||| S:20177 E:20178 ||| -LRB-
type  ||| S:20178 E:20183 ||| NN
2AS ||| S:20183 E:20186 ||| CD
)  ||| S:20186 E:20198 ||| -RRB-
and  ||| S:20198 E:20202 ||| CC
p-nitrophenyl  ||| S:20202 E:20216 ||| JJ
phosphate  ||| S:20216 E:20226 ||| NNS
( ||| S:20226 E:20227 ||| -LRB-
PNPP ||| S:20227 E:20231 ||| NNP
)  ||| S:20231 E:20233 ||| -RRB-
were  ||| S:20233 E:20238 ||| VBD
obtained  ||| S:20238 E:20247 ||| VBN
from  ||| S:20247 E:20262 ||| IN
Sigma  ||| S:20262 E:20268 ||| NNP
Chemical  ||| S:20268 E:20277 ||| NNP
Company ||| S:20277 E:20284 ||| NNP
.  ||| S:20284 E:20314 ||| .
Cell  ||| S:20314 E:20319 ||| NNP
Culture  ||| S:20319 E:20337 ||| NNP
A549  ||| S:20337 E:20342 ||| NNP
lung  ||| S:20342 E:20347 ||| NN
carcinoma  ||| S:20347 E:20357 ||| NN
cells  ||| S:20357 E:20363 ||| NNS
were  ||| S:20363 E:20368 ||| VBD
obtained  ||| S:20368 E:20377 ||| VBN
from  ||| S:20377 E:20382 ||| IN
the  ||| S:20382 E:20396 ||| DT
American  ||| S:20396 E:20405 ||| NNP
Type  ||| S:20405 E:20410 ||| NNP
Tissue  ||| S:20410 E:20417 ||| NNP
Collection ||| S:20417 E:20427 ||| NNP
.  ||| S:20427 E:20429 ||| .
A  ||| S:20429 E:20431 ||| DT
stable  ||| S:20431 E:20438 ||| JJ
HeLa  ||| S:20438 E:20443 ||| JJ
cell  ||| S:20443 E:20448 ||| NN
line  ||| S:20448 E:20463 ||| NN
expressing  ||| S:20463 E:20474 ||| VBG
GFP-NFAT  ||| S:20474 E:20483 ||| NN
was  ||| S:20483 E:20487 ||| VBD
generously  ||| S:20487 E:20498 ||| RB
provided  ||| S:20498 E:20507 ||| VBN
by  ||| S:20507 E:20510 ||| IN
Larry  ||| S:20510 E:20526 ||| NNP
Gerace  ||| S:20526 E:20533 ||| NNP
( ||| S:20533 E:20534 ||| -LRB-
The  ||| S:20534 E:20538 ||| DT
Scripps  ||| S:20538 E:20546 ||| NNP
Research  ||| S:20546 E:20555 ||| NNP
Institute ||| S:20555 E:20564 ||| NNP
,  ||| S:20564 E:20566 ||| ,
La  ||| S:20566 E:20569 ||| NNP
Jolla ||| S:20569 E:20574 ||| NNP
,  ||| S:20574 E:20576 ||| ,
CA ||| S:20576 E:20578 ||| NNP
) ||| S:20578 E:20579 ||| -RRB-
.  ||| S:20579 E:20591 ||| .
HeLa  ||| S:20591 E:20596 ||| NNP
and  ||| S:20596 E:20600 ||| CC
A549  ||| S:20600 E:20605 ||| CD
cells  ||| S:20605 E:20611 ||| NNS
were  ||| S:20611 E:20616 ||| VBD
grown  ||| S:20616 E:20622 ||| VBN
in  ||| S:20622 E:20625 ||| IN
Dulbecco ||| S:20625 E:20633 ||| NNP
's  ||| S:20633 E:20636 ||| POS
modified  ||| S:20636 E:20655 ||| JJ
Eagle ||| S:20655 E:20660 ||| NNP
's  ||| S:20660 E:20663 ||| POS
medium  ||| S:20663 E:20670 ||| NN
containing  ||| S:20670 E:20681 ||| VBG
1  ||| S:20681 E:20683 ||| CD
g  ||| S:20683 E:20685 ||| NN
of  ||| S:20685 E:20688 ||| IN
glucose ||| S:20688 E:20695 ||| FW
/ ||| S:20695 E:20696 ||| FW
liter  ||| S:20696 E:20702 ||| FW
( ||| S:20702 E:20703 ||| -LRB-
DMEM ||| S:20703 E:20707 ||| NNP
)  ||| S:20707 E:20709 ||| -RRB-
and  ||| S:20709 E:20723 ||| CC
10  ||| S:20723 E:20726 ||| CD
%  ||| S:20726 E:20728 ||| NN
heat-inactivated  ||| S:20728 E:20745 ||| NNP
FBS ||| S:20745 E:20748 ||| NNP
.  ||| S:20748 E:20750 ||| .
All  ||| S:20750 E:20754 ||| DT
cell  ||| S:20754 E:20759 ||| NN
cultures  ||| S:20759 E:20768 ||| NNS
were  ||| S:20768 E:20783 ||| VBD
routinely  ||| S:20783 E:20793 ||| RB
passed  ||| S:20793 E:20800 ||| VBN
when  ||| S:20800 E:20805 ||| WRB
90-95 ||| S:20805 E:20810 ||| JJ
%  ||| S:20810 E:20812 ||| NN
confluent ||| S:20812 E:20821 ||| NN
.  ||| S:20821 E:20851 ||| .
Oligonucleotide  ||| S:20851 E:20867 ||| NNP
Synthesis  ||| S:20867 E:20877 ||| NNP
Assay  ||| S:20877 E:20883 ||| NNP
for  ||| S:20883 E:20887 ||| IN
Oligonucleotide  ||| S:20887 E:20913 ||| NNP
Inhibition  ||| S:20913 E:20924 ||| NNP
of  ||| S:20924 E:20927 ||| IN
PP5  ||| S:20927 E:20931 ||| NNP
Expression  ||| S:20931 E:20952 ||| NNP
2 ||| S:20952 E:20953 ||| ,
' ||| S:20953 E:20954 ||| ''
-  ||| S:20954 E:20967 ||| :
O  ||| S:20967 E:20969 ||| NNP
- ||| S:20969 E:20970 ||| :
( ||| S:20970 E:20971 ||| -LRB-
2-methoxy ||| S:20971 E:20980 ||| NNP
) ||| S:20980 E:20981 ||| -RRB-
ethylphosphothioate  ||| S:20981 E:21011 ||| JJ
oligonucleotides  ||| S:21011 E:21028 ||| NN
were  ||| S:21028 E:21033 ||| VBD
synthesized  ||| S:21033 E:21045 ||| JJ
and  ||| S:21045 E:21049 ||| CC
purified  ||| S:21049 E:21058 ||| NN
as  ||| S:21058 E:21071 ||| IN
previously  ||| S:21071 E:21082 ||| RB
described  ||| S:21082 E:21092 ||| VBN
[  ||| S:21092 E:21094 ||| -LRB-
33 ||| S:21094 E:21096 ||| CD
] ||| S:21096 E:21097 ||| -RRB-
.  ||| S:21097 E:21099 ||| .
To  ||| S:21099 E:21102 ||| TO
suppress  ||| S:21102 E:21111 ||| VB
the  ||| S:21111 E:21115 ||| DT
expression  ||| S:21115 E:21126 ||| NN
of  ||| S:21126 E:21139 ||| IN
PP5 ||| S:21139 E:21142 ||| NNP
,  ||| S:21142 E:21144 ||| ,
the  ||| S:21144 E:21148 ||| DT
indicated  ||| S:21148 E:21158 ||| JJ
cells  ||| S:21158 E:21164 ||| NNS
were  ||| S:21164 E:21169 ||| VBD
plated  ||| S:21169 E:21176 ||| VBN
in  ||| S:21176 E:21179 ||| IN
60  ||| S:21179 E:21182 ||| CD
mm  ||| S:21182 E:21185 ||| CD
dished  ||| S:21185 E:21192 ||| NNS
and  ||| S:21192 E:21206 ||| CC
cultured  ||| S:21206 E:21215 ||| NN
in  ||| S:21215 E:21218 ||| IN
DMEM  ||| S:21218 E:21223 ||| NNP
containing  ||| S:21223 E:21234 ||| VBG
10 ||| S:21234 E:21236 ||| CD
%  ||| S:21236 E:21238 ||| NN
FCS ||| S:21238 E:21241 ||| NNP
.  ||| S:21241 E:21243 ||| .
When  ||| S:21243 E:21248 ||| WRB
the  ||| S:21248 E:21252 ||| DT
cells  ||| S:21252 E:21258 ||| NNS
were  ||| S:21258 E:21273 ||| VBD
about  ||| S:21273 E:21279 ||| IN
70 ||| S:21279 E:21281 ||| CD
%  ||| S:21281 E:21283 ||| NN
confluent ||| S:21283 E:21292 ||| NN
,  ||| S:21292 E:21294 ||| ,
they  ||| S:21294 E:21299 ||| PRP
were  ||| S:21299 E:21304 ||| VBD
treated  ||| S:21304 E:21312 ||| VBN
with  ||| S:21312 E:21327 ||| IN
oligonucleotides  ||| S:21327 E:21344 ||| NN
as  ||| S:21344 E:21347 ||| IN
previously  ||| S:21347 E:21358 ||| RB
described  ||| S:21358 E:21368 ||| VBN
[  ||| S:21368 E:21370 ||| -LRB-
24 ||| S:21370 E:21372 ||| CD
,  ||| S:21372 E:21374 ||| ,
25 ||| S:21374 E:21376 ||| CD
] ||| S:21376 E:21377 ||| -RRB-
.  ||| S:21377 E:21389 ||| .
Briefly ||| S:21389 E:21396 ||| RB
,  ||| S:21396 E:21398 ||| ,
cells  ||| S:21398 E:21404 ||| NNS
were  ||| S:21404 E:21409 ||| VBD
washed  ||| S:21409 E:21416 ||| VBN
with  ||| S:21416 E:21421 ||| IN
DMEM ||| S:21421 E:21425 ||| NNP
.  ||| S:21425 E:21427 ||| .
A  ||| S:21427 E:21429 ||| DT
solution  ||| S:21429 E:21438 ||| NN
( ||| S:21438 E:21439 ||| -LRB-
1  ||| S:21439 E:21441 ||| CD
ml ||| S:21441 E:21443 ||| CD
)  ||| S:21443 E:21455 ||| -RRB-
of  ||| S:21455 E:21458 ||| IN
DMEM  ||| S:21458 E:21463 ||| NNP
containing  ||| S:21463 E:21474 ||| VBG
the  ||| S:21474 E:21478 ||| DT
oligonucleotides  ||| S:21478 E:21495 ||| NN
at  ||| S:21495 E:21498 ||| IN
the  ||| S:21498 E:21502 ||| DT
indicated  ||| S:21502 E:21522 ||| JJ
concentration  ||| S:21522 E:21536 ||| NN
and  ||| S:21536 E:21540 ||| CC
15  ||| S:21540 E:21543 ||| CD
μg ||| S:21543 E:21545 ||| FW
/ ||| S:21545 E:21546 ||| FW
ml  ||| S:21546 E:21549 ||| FW
DOTMA ||| S:21549 E:21554 ||| FW
/ ||| S:21554 E:21555 ||| FW
DOPE  ||| S:21555 E:21560 ||| FW
( ||| S:21560 E:21561 ||| -LRB-
Lipofectin  ||| S:21561 E:21572 ||| NNP
® ||| S:21572 E:21573 ||| NNP
;  ||| S:21573 E:21585 ||| :
GIBCO-BRL ||| S:21585 E:21594 ||| NNP
)  ||| S:21594 E:21596 ||| -RRB-
was  ||| S:21596 E:21600 ||| VBD
then  ||| S:21600 E:21605 ||| RB
added ||| S:21605 E:21610 ||| VBD
.  ||| S:21610 E:21612 ||| .
After  ||| S:21612 E:21618 ||| IN
incubating  ||| S:21618 E:21629 ||| VBG
the  ||| S:21629 E:21633 ||| DT
cells  ||| S:21633 E:21639 ||| NNS
at  ||| S:21639 E:21652 ||| IN
37°C  ||| S:21652 E:21657 ||| CD
for  ||| S:21657 E:21661 ||| IN
4  ||| S:21661 E:21663 ||| CD
hours ||| S:21663 E:21668 ||| NNS
,  ||| S:21668 E:21670 ||| ,
the  ||| S:21670 E:21674 ||| DT
cells  ||| S:21674 E:21680 ||| NNS
were  ||| S:21680 E:21685 ||| VBD
washed  ||| S:21685 E:21692 ||| VBN
and  ||| S:21692 E:21696 ||| CC
cultured  ||| S:21696 E:21705 ||| NN
in  ||| S:21705 E:21718 ||| IN
fresh  ||| S:21718 E:21724 ||| JJ
DMEM  ||| S:21724 E:21729 ||| NNS
containing  ||| S:21729 E:21740 ||| VBG
10 ||| S:21740 E:21742 ||| CD
%  ||| S:21742 E:21744 ||| NN
FCS  ||| S:21744 E:21748 ||| NN
for  ||| S:21748 E:21752 ||| IN
17  ||| S:21752 E:21755 ||| CD
hours ||| S:21755 E:21760 ||| NNS
.  ||| S:21760 E:21762 ||| .
The  ||| S:21762 E:21766 ||| DT
cells  ||| S:21766 E:21782 ||| NNS
were  ||| S:21782 E:21787 ||| VBD
then  ||| S:21787 E:21792 ||| RB
harvested ||| S:21792 E:21801 ||| VBN
,  ||| S:21801 E:21803 ||| ,
and  ||| S:21803 E:21807 ||| CC
total  ||| S:21807 E:21813 ||| JJ
RNA  ||| S:21813 E:21817 ||| NNP
was  ||| S:21817 E:21821 ||| VBD
extracted  ||| S:21821 E:21831 ||| VBN
with  ||| S:21831 E:21846 ||| IN
TRIzol  ||| S:21846 E:21853 ||| NNP
Reagent  ||| S:21853 E:21861 ||| NNP
( ||| S:21861 E:21862 ||| -LRB-
GIBCO-BRL ||| S:21862 E:21871 ||| NNP
)  ||| S:21871 E:21873 ||| -RRB-
according  ||| S:21873 E:21883 ||| VBG
to  ||| S:21883 E:21886 ||| TO
the  ||| S:21886 E:21890 ||| DT
methods  ||| S:21890 E:21898 ||| NNS
of  ||| S:21898 E:21911 ||| IN
the  ||| S:21911 E:21915 ||| DT
manufacturer ||| S:21915 E:21927 ||| NN
.  ||| S:21927 E:21929 ||| .
Total  ||| S:21929 E:21935 ||| JJ
RNA  ||| S:21935 E:21939 ||| NNP
( ||| S:21939 E:21940 ||| -LRB-
20  ||| S:21940 E:21943 ||| CD
μg ||| S:21943 E:21945 ||| CD
)  ||| S:21945 E:21947 ||| -RRB-
was  ||| S:21947 E:21951 ||| VBD
fractionated  ||| S:21951 E:21964 ||| VBN
on  ||| S:21964 E:21977 ||| IN
1 ||| S:21977 E:21978 ||| CD
%  ||| S:21978 E:21980 ||| NN
agarose  ||| S:21980 E:21988 ||| NNS
gels  ||| S:21988 E:21993 ||| VBP
containing  ||| S:21993 E:22004 ||| VBG
formaldehyde  ||| S:22004 E:22017 ||| NNS
and  ||| S:22017 E:22021 ||| CC
transferred  ||| S:22021 E:22043 ||| VBN
to  ||| S:22043 E:22046 ||| TO
DURLON-UV  ||| S:22046 E:22056 ||| NNP
( ||| S:22056 E:22057 ||| -LRB-
Stratagene ||| S:22057 E:22067 ||| NNP
)  ||| S:22067 E:22069 ||| -RRB-
nylon  ||| S:22069 E:22075 ||| JJ
membranes ||| S:22075 E:22084 ||| NN
.  ||| S:22084 E:22086 ||| .
Following  ||| S:22086 E:22096 ||| VBG
UV  ||| S:22096 E:22109 ||| NNP
cross-linking ||| S:22109 E:22122 ||| NNP
,  ||| S:22122 E:22124 ||| ,
the  ||| S:22124 E:22128 ||| DT
filters  ||| S:22128 E:22136 ||| NNS
were  ||| S:22136 E:22141 ||| VBD
hybridized  ||| S:22141 E:22152 ||| VBN
with  ||| S:22152 E:22157 ||| IN
a  ||| S:22157 E:22159 ||| DT
[  ||| S:22159 E:22171 ||| -LRB-
32P ||| S:22171 E:22174 ||| NNP
] ||| S:22174 E:22175 ||| -RRB-
probe  ||| S:22175 E:22181 ||| NN
for  ||| S:22181 E:22185 ||| IN
human  ||| S:22185 E:22191 ||| JJ
PP5 ||| S:22191 E:22194 ||| NN
.  ||| S:22194 E:22196 ||| .
The  ||| S:22196 E:22200 ||| DT
human  ||| S:22200 E:22206 ||| JJ
PP5  ||| S:22206 E:22210 ||| CD
cDNA  ||| S:22210 E:22215 ||| JJ
probe  ||| S:22215 E:22221 ||| NN
was  ||| S:22221 E:22235 ||| VBD
generated  ||| S:22235 E:22245 ||| VBN
from  ||| S:22245 E:22250 ||| IN
the  ||| S:22250 E:22254 ||| DT
full  ||| S:22254 E:22259 ||| JJ
length  ||| S:22259 E:22266 ||| NN
coding  ||| S:22266 E:22273 ||| NN
region  ||| S:22273 E:22280 ||| NN
of  ||| S:22280 E:22283 ||| IN
PP5  ||| S:22283 E:22287 ||| NNP
and  ||| S:22287 E:22291 ||| CC
[  ||| S:22291 E:22303 ||| -LRB-
32P ||| S:22303 E:22306 ||| NNP
] ||| S:22306 E:22307 ||| -RRB-
labeled  ||| S:22307 E:22315 ||| VBN
with  ||| S:22315 E:22320 ||| IN
DECAprime  ||| S:22320 E:22330 ||| NNP
®DNA  ||| S:22330 E:22335 ||| NNP
Labeling  ||| S:22335 E:22344 ||| NNP
Kit  ||| S:22344 E:22348 ||| NNP
( ||| S:22348 E:22349 ||| -LRB-
Ambion ||| S:22349 E:22355 ||| NNP
)  ||| S:22355 E:22367 ||| -RRB-
according  ||| S:22367 E:22377 ||| VBG
to  ||| S:22377 E:22380 ||| TO
the  ||| S:22380 E:22384 ||| DT
manufacturer ||| S:22384 E:22396 ||| NN
's  ||| S:22396 E:22399 ||| POS
protocol ||| S:22399 E:22407 ||| NN
.  ||| S:22407 E:22409 ||| .
Hybridization  ||| S:22409 E:22433 ||| NNP
was  ||| S:22433 E:22437 ||| VBD
performed  ||| S:22437 E:22447 ||| VBN
in  ||| S:22447 E:22450 ||| IN
the  ||| S:22450 E:22454 ||| DT
presence  ||| S:22454 E:22463 ||| NN
of  ||| S:22463 E:22466 ||| IN
50 ||| S:22466 E:22468 ||| CD
%  ||| S:22468 E:22470 ||| NN
formamide  ||| S:22470 E:22480 ||| NN
at  ||| S:22480 E:22483 ||| IN
42°C  ||| S:22483 E:22498 ||| CD
for  ||| S:22498 E:22502 ||| IN
16  ||| S:22502 E:22505 ||| CD
hours ||| S:22505 E:22510 ||| NNS
.  ||| S:22510 E:22512 ||| .
Following  ||| S:22512 E:22522 ||| VBG
hybridization ||| S:22522 E:22535 ||| NN
,  ||| S:22535 E:22537 ||| ,
the  ||| S:22537 E:22541 ||| DT
membrane  ||| S:22541 E:22550 ||| NN
was  ||| S:22550 E:22564 ||| VBD
subjected  ||| S:22564 E:22574 ||| VBN
to  ||| S:22574 E:22577 ||| TO
two  ||| S:22577 E:22581 ||| CD
low  ||| S:22581 E:22585 ||| JJ
stringency  ||| S:22585 E:22596 ||| JJ
washes  ||| S:22596 E:22603 ||| NNS
( ||| S:22603 E:22604 ||| -LRB-
2  ||| S:22604 E:22606 ||| CD
×  ||| S:22606 E:22608 ||| CD
SSC ||| S:22608 E:22611 ||| NNP
)  ||| S:22611 E:22613 ||| -RRB-
at  ||| S:22613 E:22616 ||| IN
room  ||| S:22616 E:22631 ||| NN
temperature  ||| S:22631 E:22643 ||| NN
and  ||| S:22643 E:22647 ||| CC
then  ||| S:22647 E:22652 ||| RB
two  ||| S:22652 E:22656 ||| CD
high  ||| S:22656 E:22661 ||| JJ
stringency  ||| S:22661 E:22672 ||| JJ
washes  ||| S:22672 E:22679 ||| NNS
( ||| S:22679 E:22680 ||| -LRB-
0.1  ||| S:22680 E:22684 ||| CD
×  ||| S:22684 E:22696 ||| CD
SSC ||| S:22696 E:22699 ||| CD
/ ||| S:22699 E:22700 ||| CD
0.5 ||| S:22700 E:22703 ||| CD
%  ||| S:22703 E:22705 ||| NN
SDS ||| S:22705 E:22708 ||| NNP
)  ||| S:22708 E:22710 ||| -RRB-
at  ||| S:22710 E:22713 ||| IN
55°C ||| S:22713 E:22717 ||| CD
.  ||| S:22717 E:22719 ||| .
Hybridization  ||| S:22719 E:22733 ||| NNP
was  ||| S:22733 E:22737 ||| VBD
visualized  ||| S:22737 E:22748 ||| VBN
by  ||| S:22748 E:22761 ||| IN
autoradiography ||| S:22761 E:22776 ||| NN
,  ||| S:22776 E:22778 ||| ,
and  ||| S:22778 E:22782 ||| CC
the  ||| S:22782 E:22786 ||| DT
filters  ||| S:22786 E:22794 ||| NNS
were  ||| S:22794 E:22799 ||| VBD
then  ||| S:22799 E:22804 ||| RB
stripped  ||| S:22804 E:22813 ||| VBN
and  ||| S:22813 E:22827 ||| CC
reprobed  ||| S:22827 E:22836 ||| NN
with  ||| S:22836 E:22841 ||| IN
a  ||| S:22841 E:22843 ||| DT
[  ||| S:22843 E:22845 ||| -LRB-
32P ||| S:22845 E:22848 ||| NNP
] ||| S:22848 E:22849 ||| -RRB-
labeled  ||| S:22849 E:22857 ||| FW
glyceraldehyde-3-phosphate  ||| S:22857 E:22894 ||| FW
dehydrogenase  ||| S:22894 E:22908 ||| FW
( ||| S:22908 E:22909 ||| -LRB-
GAPDH ||| S:22909 E:22914 ||| NNP
)  ||| S:22914 E:22916 ||| -RRB-
cDNA  ||| S:22916 E:22921 ||| JJ
probe  ||| S:22921 E:22927 ||| NN
to  ||| S:22927 E:22930 ||| TO
confirm  ||| S:22930 E:22938 ||| VB
equal  ||| S:22938 E:22954 ||| JJ
loading ||| S:22954 E:22961 ||| NN
.  ||| S:22961 E:22963 ||| .
Quantification  ||| S:22963 E:22978 ||| NNP
of  ||| S:22978 E:22981 ||| IN
hybridization  ||| S:22981 E:22995 ||| JJ
signals  ||| S:22995 E:23003 ||| NNS
was  ||| S:23003 E:23017 ||| VBD
achieved  ||| S:23017 E:23026 ||| VBN
by  ||| S:23026 E:23029 ||| IN
analysis  ||| S:23029 E:23038 ||| NN
of  ||| S:23038 E:23041 ||| IN
the  ||| S:23041 E:23045 ||| DT
scanned  ||| S:23045 E:23053 ||| JJ
autoradiograms  ||| S:23053 E:23068 ||| NNS
using  ||| S:23068 E:23084 ||| VBG
the  ||| S:23084 E:23088 ||| DT
NIH  ||| S:23088 E:23092 ||| NNP
Image  ||| S:23092 E:23098 ||| NNP
program  ||| S:23098 E:23106 ||| NN
( ||| S:23106 E:23107 ||| -LRB-
ImagePC ||| S:23107 E:23114 ||| NNP
) ||| S:23114 E:23115 ||| -RRB-
.  ||| S:23115 E:23145 ||| .
Preparation  ||| S:23145 E:23157 ||| NN
of  ||| S:23157 E:23160 ||| IN
phosphoprotein  ||| S:23160 E:23175 ||| FW
substrates  ||| S:23175 E:23196 ||| FW
Histone  ||| S:23196 E:23204 ||| FW
( ||| S:23204 E:23205 ||| -LRB-
type  ||| S:23205 E:23210 ||| NN
2AS  ||| S:23210 E:23214 ||| NN
from  ||| S:23214 E:23219 ||| IN
Sigma ||| S:23219 E:23224 ||| NNP
)  ||| S:23224 E:23226 ||| -RRB-
was  ||| S:23226 E:23230 ||| VBD
phosphorylated  ||| S:23230 E:23245 ||| VBN
with  ||| S:23245 E:23260 ||| IN
cAMP-dependent  ||| S:23260 E:23275 ||| JJ
protein  ||| S:23275 E:23283 ||| NN
kinase  ||| S:23283 E:23290 ||| NNS
( ||| S:23290 E:23291 ||| -LRB-
protein  ||| S:23291 E:23299 ||| FW
kinase  ||| S:23299 E:23306 ||| FW
A ||| S:23306 E:23307 ||| NNP
)  ||| S:23307 E:23309 ||| -RRB-
as  ||| S:23309 E:23322 ||| RB
described  ||| S:23322 E:23332 ||| VBN
previously  ||| S:23332 E:23343 ||| RB
[  ||| S:23343 E:23345 ||| -LRB-
34 ||| S:23345 E:23347 ||| CD
] ||| S:23347 E:23348 ||| -RRB-
.  ||| S:23348 E:23350 ||| .
Briefly ||| S:23350 E:23357 ||| RB
,  ||| S:23357 E:23359 ||| ,
20  ||| S:23359 E:23362 ||| CD
mg  ||| S:23362 E:23365 ||| NN
of  ||| S:23365 E:23368 ||| IN
histone  ||| S:23368 E:23376 ||| NN
was  ||| S:23376 E:23390 ||| VBD
incubated  ||| S:23390 E:23400 ||| VBN
with  ||| S:23400 E:23405 ||| IN
1  ||| S:23405 E:23407 ||| CD
mg  ||| S:23407 E:23410 ||| NN
of  ||| S:23410 E:23413 ||| IN
protein  ||| S:23413 E:23421 ||| NN
kinase  ||| S:23421 E:23428 ||| VBD
A ||| S:23428 E:23429 ||| DT
,  ||| S:23429 E:23431 ||| ,
in  ||| S:23431 E:23434 ||| IN
a  ||| S:23434 E:23436 ||| DT
20  ||| S:23436 E:23439 ||| CD
mM  ||| S:23439 E:23452 ||| JJ
Tris-Cl  ||| S:23452 E:23460 ||| JJ
buffer  ||| S:23460 E:23467 ||| NN
( ||| S:23467 E:23468 ||| -LRB-
pH  ||| S:23468 E:23471 ||| NNP
7.4 ||| S:23471 E:23474 ||| CD
)  ||| S:23474 E:23476 ||| -RRB-
containing  ||| S:23476 E:23487 ||| VBG
1  ||| S:23487 E:23489 ||| CD
mCi  ||| S:23489 E:23493 ||| NNS
[  ||| S:23493 E:23495 ||| -LRB-
32P ||| S:23495 E:23498 ||| NNP
] ||| S:23498 E:23499 ||| -RRB-
ATP  ||| S:23499 E:23503 ||| NNP
( ||| S:23503 E:23504 ||| -LRB-
150  ||| S:23504 E:23518 ||| CD
μM  ||| S:23518 E:23521 ||| JJ
ATP ||| S:23521 E:23524 ||| NNP
) ||| S:23524 E:23525 ||| -RRB-
,  ||| S:23525 E:23527 ||| ,
100  ||| S:23527 E:23531 ||| CD
μM  ||| S:23531 E:23534 ||| JJ
cAMP ||| S:23534 E:23538 ||| NN
,  ||| S:23538 E:23540 ||| ,
5  ||| S:23540 E:23542 ||| CD
mM  ||| S:23542 E:23545 ||| JJ
DTT ||| S:23545 E:23548 ||| NNP
,  ||| S:23548 E:23550 ||| ,
and  ||| S:23550 E:23554 ||| CC
5  ||| S:23554 E:23556 ||| CD
mM  ||| S:23556 E:23559 ||| JJ
MgCl  ||| S:23559 E:23575 ||| JJ
2  ||| S:23575 E:23577 ||| CD
in  ||| S:23577 E:23580 ||| IN
a  ||| S:23580 E:23582 ||| DT
final  ||| S:23582 E:23588 ||| JJ
volume  ||| S:23588 E:23595 ||| NN
of  ||| S:23595 E:23598 ||| IN
4  ||| S:23598 E:23600 ||| CD
ml ||| S:23600 E:23602 ||| NNS
.  ||| S:23602 E:23604 ||| .
The  ||| S:23604 E:23618 ||| DT
reaction  ||| S:23618 E:23627 ||| NN
was  ||| S:23627 E:23631 ||| VBD
allowed  ||| S:23631 E:23639 ||| VBN
to  ||| S:23639 E:23642 ||| TO
continue  ||| S:23642 E:23651 ||| VB
for  ||| S:23651 E:23655 ||| IN
3.5  ||| S:23655 E:23659 ||| CD
to  ||| S:23659 E:23662 ||| TO
4  ||| S:23662 E:23664 ||| CD
hrs  ||| S:23664 E:23668 ||| NN
at  ||| S:23668 E:23671 ||| IN
30°C  ||| S:23671 E:23686 ||| NNP
and  ||| S:23686 E:23690 ||| CC
terminated  ||| S:23690 E:23701 ||| VBN
by  ||| S:23701 E:23704 ||| IN
the  ||| S:23704 E:23708 ||| DT
addition  ||| S:23708 E:23717 ||| NN
of  ||| S:23717 E:23720 ||| IN
1.3  ||| S:23720 E:23724 ||| CD
ml  ||| S:23724 E:23727 ||| NN
of  ||| S:23727 E:23730 ||| IN
100 ||| S:23730 E:23733 ||| CD
%  ||| S:23733 E:23735 ||| NN
TCA ||| S:23735 E:23738 ||| NNP
.  ||| S:23738 E:23740 ||| .
The  ||| S:23740 E:23754 ||| DT
precipitated  ||| S:23754 E:23767 ||| JJ
phosphohistone  ||| S:23767 E:23782 ||| NN
was  ||| S:23782 E:23786 ||| VBD
collected  ||| S:23786 E:23796 ||| VBN
by  ||| S:23796 E:23809 ||| IN
centrifugation  ||| S:23809 E:23824 ||| NN
at  ||| S:23824 E:23827 ||| IN
3000  ||| S:23827 E:23832 ||| CD
×  ||| S:23832 E:23834 ||| CD
g  ||| S:23834 E:23836 ||| NN
for  ||| S:23836 E:23840 ||| IN
5  ||| S:23840 E:23842 ||| CD
min ||| S:23842 E:23845 ||| NNS
.  ||| S:23845 E:23847 ||| .
The  ||| S:23847 E:23851 ||| DT
supernatant  ||| S:23851 E:23863 ||| NN
was  ||| S:23863 E:23877 ||| VBD
discarded ||| S:23877 E:23886 ||| VBN
,  ||| S:23886 E:23888 ||| ,
and  ||| S:23888 E:23892 ||| CC
the  ||| S:23892 E:23896 ||| DT
pellet  ||| S:23896 E:23903 ||| NN
was  ||| S:23903 E:23907 ||| VBD
redissolved  ||| S:23907 E:23919 ||| VBN
in  ||| S:23919 E:23922 ||| IN
4  ||| S:23922 E:23924 ||| CD
ml  ||| S:23924 E:23927 ||| NN
of  ||| S:23927 E:23930 ||| IN
1  ||| S:23930 E:23932 ||| CD
M  ||| S:23932 E:23944 ||| NNP
Tris-Cl  ||| S:23944 E:23952 ||| NNP
( ||| S:23952 E:23953 ||| -LRB-
pH  ||| S:23953 E:23956 ||| NNP
8.2 ||| S:23956 E:23959 ||| CD
) ||| S:23959 E:23960 ||| -RRB-
.  ||| S:23960 E:23962 ||| .
TCA  ||| S:23962 E:23966 ||| NNP
was  ||| S:23966 E:23970 ||| VBD
added  ||| S:23970 E:23976 ||| VBN
to  ||| S:23976 E:23979 ||| TO
precipitate  ||| S:23979 E:23991 ||| VB
the  ||| S:23991 E:24005 ||| DT
phosphohistone ||| S:24005 E:24019 ||| NN
,  ||| S:24019 E:24021 ||| ,
and  ||| S:24021 E:24025 ||| CC
this  ||| S:24025 E:24030 ||| DT
precipitation-resuspension  ||| S:24030 E:24057 ||| JJ
wash  ||| S:24057 E:24072 ||| NN
was  ||| S:24072 E:24076 ||| VBD
repeated  ||| S:24076 E:24085 ||| VBN
5  ||| S:24085 E:24087 ||| CD
times ||| S:24087 E:24092 ||| NNS
.  ||| S:24092 E:24094 ||| .
The  ||| S:24094 E:24098 ||| DT
pellet  ||| S:24098 E:24105 ||| NN
produced  ||| S:24105 E:24114 ||| VBN
upon  ||| S:24114 E:24119 ||| IN
the  ||| S:24119 E:24123 ||| DT
sixth  ||| S:24123 E:24139 ||| JJ
TCA  ||| S:24139 E:24143 ||| NNP
precipitation  ||| S:24143 E:24157 ||| NN
was  ||| S:24157 E:24161 ||| VBD
washed  ||| S:24161 E:24168 ||| VBN
2  ||| S:24168 E:24170 ||| CD
times  ||| S:24170 E:24176 ||| NNS
with  ||| S:24176 E:24181 ||| IN
4  ||| S:24181 E:24183 ||| CD
ml  ||| S:24183 E:24186 ||| NN
of  ||| S:24186 E:24199 ||| IN
ethanol ||| S:24199 E:24206 ||| NN
: ||| S:24206 E:24207 ||| :
ethyl  ||| S:24207 E:24213 ||| FW
ether  ||| S:24213 E:24219 ||| FW
( ||| S:24219 E:24220 ||| -LRB-
1 ||| S:24220 E:24221 ||| LS
: ||| S:24221 E:24222 ||| :
4 ||| S:24222 E:24223 ||| LS
;  ||| S:24223 E:24225 ||| :
v ||| S:24225 E:24226 ||| CD
: ||| S:24226 E:24227 ||| :
v ||| S:24227 E:24228 ||| LS
)  ||| S:24228 E:24230 ||| -RRB-
and  ||| S:24230 E:24234 ||| CC
then  ||| S:24234 E:24239 ||| RB
2  ||| S:24239 E:24241 ||| CD
additional  ||| S:24241 E:24262 ||| JJ
times  ||| S:24262 E:24268 ||| NNS
with  ||| S:24268 E:24273 ||| IN
acidified  ||| S:24273 E:24283 ||| JJ
ethanol ||| S:24283 E:24290 ||| NN
: ||| S:24290 E:24291 ||| :
ethyl  ||| S:24291 E:24297 ||| FW
ether  ||| S:24297 E:24303 ||| FW
( ||| S:24303 E:24304 ||| -LRB-
1 ||| S:24304 E:24305 ||| LS
: ||| S:24305 E:24306 ||| :
4 ||| S:24306 E:24307 ||| LS
;  ||| S:24307 E:24309 ||| :
0.1  ||| S:24309 E:24313 ||| CD
N  ||| S:24313 E:24325 ||| NNP
HCl ||| S:24325 E:24328 ||| NNP
) ||| S:24328 E:24329 ||| -RRB-
.  ||| S:24329 E:24331 ||| .
The  ||| S:24331 E:24335 ||| DT
washed  ||| S:24335 E:24342 ||| JJ
histone  ||| S:24342 E:24350 ||| NN
was  ||| S:24350 E:24354 ||| VBD
allowed  ||| S:24354 E:24362 ||| VBN
to  ||| S:24362 E:24365 ||| TO
air  ||| S:24365 E:24369 ||| VB
dry  ||| S:24369 E:24373 ||| JJ
and  ||| S:24373 E:24377 ||| CC
was  ||| S:24377 E:24391 ||| VBD
then  ||| S:24391 E:24396 ||| RB
resuspended  ||| S:24396 E:24408 ||| VBN
in  ||| S:24408 E:24411 ||| IN
5  ||| S:24411 E:24413 ||| CD
mM  ||| S:24413 E:24416 ||| JJ
Tris-Cl  ||| S:24416 E:24424 ||| NN
( ||| S:24424 E:24425 ||| -LRB-
pH  ||| S:24425 E:24428 ||| NNP
7.4 ||| S:24428 E:24431 ||| CD
) ||| S:24431 E:24432 ||| -RRB-
.  ||| S:24432 E:24434 ||| .
This  ||| S:24434 E:24439 ||| DT
procedure  ||| S:24439 E:24459 ||| NN
yields  ||| S:24459 E:24466 ||| NNS
phosphohistone  ||| S:24466 E:24481 ||| VBN
with  ||| S:24481 E:24486 ||| IN
a  ||| S:24486 E:24488 ||| DT
specific  ||| S:24488 E:24497 ||| JJ
activity  ||| S:24497 E:24506 ||| NN
>  ||| S:24506 E:24508 ||| CD
4.5  ||| S:24508 E:24512 ||| CD
×  ||| S:24512 E:24524 ||| CD
10  ||| S:24524 E:24527 ||| CD
6CPM ||| S:24527 E:24531 ||| CD
/ ||| S:24531 E:24532 ||| CD
nMole  ||| S:24532 E:24538 ||| JJ
incorporated  ||| S:24538 E:24551 ||| JJ
phosphate ||| S:24551 E:24560 ||| NN
.  ||| S:24560 E:24590 ||| .
Determination  ||| S:24590 E:24604 ||| NN
of  ||| S:24604 E:24607 ||| IN
phosphatase  ||| S:24607 E:24619 ||| JJ
activity  ||| S:24619 E:24638 ||| NN
Phosphatase  ||| S:24638 E:24650 ||| NNP
activity  ||| S:24650 E:24659 ||| NN
against  ||| S:24659 E:24667 ||| IN
phosphohistone  ||| S:24667 E:24682 ||| NN
was  ||| S:24682 E:24696 ||| VBD
determined  ||| S:24696 E:24707 ||| VBN
by  ||| S:24707 E:24710 ||| IN
the  ||| S:24710 E:24714 ||| DT
quantification  ||| S:24714 E:24729 ||| NN
of  ||| S:24729 E:24732 ||| IN
[  ||| S:24732 E:24734 ||| -LRB-
32P ||| S:24734 E:24737 ||| NNP
]  ||| S:24737 E:24739 ||| -RRB-
liberation  ||| S:24739 E:24760 ||| NN
from  ||| S:24760 E:24765 ||| IN
phosphohistone  ||| S:24765 E:24780 ||| VBG
as  ||| S:24780 E:24783 ||| RB
described  ||| S:24783 E:24793 ||| VBN
previously  ||| S:24793 E:24804 ||| RB
[  ||| S:24804 E:24806 ||| -LRB-
34 ||| S:24806 E:24808 ||| CD
] ||| S:24808 E:24809 ||| -RRB-
.  ||| S:24809 E:24821 ||| .
Assays ||| S:24821 E:24827 ||| NNP
,  ||| S:24827 E:24829 ||| ,
80  ||| S:24829 E:24832 ||| CD
μl  ||| S:24832 E:24835 ||| CD
total  ||| S:24835 E:24841 ||| JJ
volume ||| S:24841 E:24847 ||| NN
,  ||| S:24847 E:24849 ||| ,
containing  ||| S:24849 E:24860 ||| VBG
50  ||| S:24860 E:24863 ||| CD
mM  ||| S:24863 E:24866 ||| JJ
Tris-HCl ||| S:24866 E:24874 ||| NN
,  ||| S:24874 E:24876 ||| ,
pH  ||| S:24876 E:24889 ||| JJ
7.4 ||| S:24889 E:24892 ||| CD
,  ||| S:24892 E:24894 ||| ,
0.5  ||| S:24894 E:24898 ||| CD
mM  ||| S:24898 E:24901 ||| JJ
DTT ||| S:24901 E:24904 ||| NNP
,  ||| S:24904 E:24906 ||| ,
1  ||| S:24906 E:24908 ||| CD
mM  ||| S:24908 E:24911 ||| JJ
EDTA ||| S:24911 E:24915 ||| NNP
,  ||| S:24915 E:24917 ||| ,
100  ||| S:24917 E:24921 ||| CD
μM  ||| S:24921 E:24924 ||| JJ
oleic  ||| S:24924 E:24930 ||| JJ
acid  ||| S:24930 E:24935 ||| NN
( ||| S:24935 E:24936 ||| -LRB-
assay  ||| S:24936 E:24952 ||| FW
buffer ||| S:24952 E:24958 ||| FW
)  ||| S:24958 E:24960 ||| -RRB-
and  ||| S:24960 E:24964 ||| CC
[  ||| S:24964 E:24966 ||| -LRB-
32P ||| S:24966 E:24969 ||| NNP
] ||| S:24969 E:24970 ||| -RRB-
phosphoprotein  ||| S:24970 E:24985 ||| NNS
( ||| S:24985 E:24986 ||| -LRB-
1-2  ||| S:24986 E:24990 ||| NNP
μM  ||| S:24990 E:24993 ||| NNP
PO  ||| S:24993 E:25007 ||| NNP
4  ||| S:25007 E:25009 ||| CD
) ||| S:25009 E:25010 ||| -RRB-
,  ||| S:25010 E:25012 ||| ,
were  ||| S:25012 E:25017 ||| VBD
conducted  ||| S:25017 E:25027 ||| VBN
at  ||| S:25027 E:25030 ||| IN
37°C  ||| S:25030 E:25035 ||| NNP
as  ||| S:25035 E:25048 ||| RB
described  ||| S:25048 E:25058 ||| VBN
previously  ||| S:25058 E:25069 ||| RB
[  ||| S:25069 E:25071 ||| -LRB-
34 ||| S:25071 E:25073 ||| CD
]  ||| S:25073 E:25075 ||| -RRB-
using  ||| S:25075 E:25081 ||| VBG
PP5  ||| S:25081 E:25085 ||| CD
purified  ||| S:25085 E:25094 ||| NN
from  ||| S:25094 E:25099 ||| IN
bovine  ||| S:25099 E:25116 ||| JJ
brain ||| S:25116 E:25121 ||| NN
.  ||| S:25121 E:25123 ||| .
The  ||| S:25123 E:25127 ||| DT
serine ||| S:25127 E:25133 ||| FW
/ ||| S:25133 E:25134 ||| FW
threonine  ||| S:25134 E:25144 ||| FW
protein  ||| S:25144 E:25152 ||| FW
phosphatase  ||| S:25152 E:25164 ||| FW
type  ||| S:25164 E:25169 ||| NN
5  ||| S:25169 E:25181 ||| CD
( ||| S:25181 E:25182 ||| -LRB-
PP5 ||| S:25182 E:25185 ||| NNP
)  ||| S:25185 E:25187 ||| -RRB-
was  ||| S:25187 E:25191 ||| VBD
purified  ||| S:25191 E:25200 ||| VBN
from  ||| S:25200 E:25205 ||| IN
bovine  ||| S:25205 E:25212 ||| JJ
brain  ||| S:25212 E:25218 ||| NN
according  ||| S:25218 E:25228 ||| VBG
to  ||| S:25228 E:25231 ||| TO
the  ||| S:25231 E:25245 ||| DT
following  ||| S:25245 E:25255 ||| JJ
procedure ||| S:25255 E:25264 ||| NN
:  ||| S:25264 E:25266 ||| :
a  ||| S:25266 E:25268 ||| DT
bovine  ||| S:25268 E:25275 ||| JJ
brain  ||| S:25275 E:25281 ||| NN
was  ||| S:25281 E:25285 ||| VBD
homogenized  ||| S:25285 E:25297 ||| VBN
in  ||| S:25297 E:25300 ||| IN
~  ||| S:25300 E:25312 ||| CD
3  ||| S:25312 E:25314 ||| CD
volumes  ||| S:25314 E:25322 ||| NNS
of  ||| S:25322 E:25325 ||| IN
buffer  ||| S:25325 E:25332 ||| VBG
A  ||| S:25332 E:25334 ||| DT
( ||| S:25334 E:25335 ||| -LRB-
50  ||| S:25335 E:25338 ||| CD
mM  ||| S:25338 E:25341 ||| JJ
HEPES  ||| S:25341 E:25347 ||| NNP
pH  ||| S:25347 E:25350 ||| NNP
7.5  ||| S:25350 E:25354 ||| CD
4°C ||| S:25354 E:25357 ||| CD
,  ||| S:25357 E:25359 ||| ,
1  ||| S:25359 E:25361 ||| CD
mM  ||| S:25361 E:25364 ||| JJ
EDTA ||| S:25364 E:25368 ||| NNP
,  ||| S:25368 E:25380 ||| ,
10  ||| S:25380 E:25383 ||| CD
mM  ||| S:25383 E:25386 ||| JJ
PMSF  ||| S:25386 E:25391 ||| NNP
and  ||| S:25391 E:25395 ||| CC
0.1 ||| S:25395 E:25398 ||| CD
%  ||| S:25398 E:25400 ||| NN
2-mercaptoethanol ||| S:25400 E:25417 ||| CD
)  ||| S:25417 E:25419 ||| -RRB-
and  ||| S:25419 E:25423 ||| CC
subjected  ||| S:25423 E:25433 ||| VBN
to  ||| S:25433 E:25446 ||| TO
centrifugation  ||| S:25446 E:25461 ||| VB
at  ||| S:25461 E:25464 ||| IN
15,000  ||| S:25464 E:25471 ||| CD
g  ||| S:25471 E:25473 ||| NN
for  ||| S:25473 E:25477 ||| IN
40  ||| S:25477 E:25480 ||| CD
min.  ||| S:25480 E:25485 ||| CD
followed  ||| S:25485 E:25494 ||| VBN
by  ||| S:25494 E:25497 ||| IN
a  ||| S:25497 E:25509 ||| DT
45 ||| S:25509 E:25511 ||| CD
% ||| S:25511 E:25512 ||| NN
-60 ||| S:25512 E:25515 ||| CD
%  ||| S:25515 E:25517 ||| NN
ammonium  ||| S:25517 E:25526 ||| NN
sulfate  ||| S:25526 E:25534 ||| NN
fractionation  ||| S:25534 E:25548 ||| NN
of  ||| S:25548 E:25551 ||| IN
the  ||| S:25551 E:25565 ||| DT
supernatant ||| S:25565 E:25576 ||| NN
.  ||| S:25576 E:25578 ||| .
The  ||| S:25578 E:25582 ||| DT
pellets  ||| S:25582 E:25590 ||| NN
from  ||| S:25590 E:25595 ||| IN
the  ||| S:25595 E:25599 ||| DT
ammonium  ||| S:25599 E:25608 ||| JJ
sulfate  ||| S:25608 E:25626 ||| JJ
fractionation  ||| S:25626 E:25640 ||| NN
were  ||| S:25640 E:25645 ||| VBD
resuspended  ||| S:25645 E:25657 ||| VBN
in  ||| S:25657 E:25660 ||| IN
60  ||| S:25660 E:25663 ||| CD
ml  ||| S:25663 E:25666 ||| NN
of  ||| S:25666 E:25669 ||| IN
buffer  ||| S:25669 E:25676 ||| JJ
B  ||| S:25676 E:25678 ||| NNP
( ||| S:25678 E:25679 ||| -LRB-
20  ||| S:25679 E:25692 ||| CD
mM  ||| S:25692 E:25695 ||| JJ
HEPES  ||| S:25695 E:25701 ||| NNP
pH  ||| S:25701 E:25704 ||| NNP
8.5  ||| S:25704 E:25708 ||| CD
4°C ||| S:25708 E:25711 ||| CD
,  ||| S:25711 E:25713 ||| ,
1  ||| S:25713 E:25715 ||| CD
mM  ||| S:25715 E:25718 ||| JJ
EDTA ||| S:25718 E:25722 ||| NNP
,  ||| S:25722 E:25724 ||| ,
and  ||| S:25724 E:25728 ||| CC
0.1 ||| S:25728 E:25731 ||| CD
%  ||| S:25731 E:25743 ||| NN
2-mercaptoethanol ||| S:25743 E:25760 ||| CD
) ||| S:25760 E:25761 ||| -RRB-
,  ||| S:25761 E:25763 ||| ,
desalted  ||| S:25763 E:25772 ||| VBG
on  ||| S:25772 E:25775 ||| IN
a  ||| S:25775 E:25777 ||| DT
G-25  ||| S:25777 E:25782 ||| JJ
sephadex  ||| S:25782 E:25791 ||| JJ
column  ||| S:25791 E:25808 ||| NN
equilibrated  ||| S:25808 E:25821 ||| NN
with  ||| S:25821 E:25826 ||| IN
buffer  ||| S:25826 E:25833 ||| JJ
B ||| S:25833 E:25834 ||| NNP
,  ||| S:25834 E:25836 ||| ,
then  ||| S:25836 E:25841 ||| RB
subjected  ||| S:25841 E:25851 ||| VBN
to  ||| S:25851 E:25854 ||| TO
sequential  ||| S:25854 E:25875 ||| VB
chromatography  ||| S:25875 E:25890 ||| VBN
on  ||| S:25890 E:25893 ||| IN
a  ||| S:25893 E:25895 ||| DT
5  ||| S:25895 E:25897 ||| CD
ml  ||| S:25897 E:25900 ||| CD
HiTrap  ||| S:25900 E:25907 ||| JJ
Heparin  ||| S:25907 E:25915 ||| JJ
column  ||| S:25915 E:25932 ||| NN
( ||| S:25932 E:25933 ||| -LRB-
Pharmacia ||| S:25933 E:25942 ||| NNP
) ||| S:25942 E:25943 ||| -RRB-
,  ||| S:25943 E:25945 ||| ,
a  ||| S:25945 E:25947 ||| DT
5  ||| S:25947 E:25949 ||| CD
ml  ||| S:25949 E:25952 ||| CD
HiTrap  ||| S:25952 E:25959 ||| JJ
Q  ||| S:25959 E:25961 ||| NNP
column  ||| S:25961 E:25968 ||| NN
( ||| S:25968 E:25969 ||| -LRB-
Pharmacia ||| S:25969 E:25978 ||| NNP
)  ||| S:25978 E:25980 ||| -RRB-
and  ||| S:25980 E:25984 ||| CC
a  ||| S:25984 E:25996 ||| DT
HiTrap  ||| S:25996 E:26003 ||| JJ
SP  ||| S:26003 E:26006 ||| NNP
column  ||| S:26006 E:26013 ||| NN
( ||| S:26013 E:26014 ||| -LRB-
Pharmacia ||| S:26014 E:26023 ||| NNP
)  ||| S:26023 E:26025 ||| -RRB-
respectively ||| S:26025 E:26037 ||| RB
.  ||| S:26037 E:26039 ||| .
The  ||| S:26039 E:26043 ||| DT
eluate  ||| S:26043 E:26060 ||| NN
from  ||| S:26060 E:26065 ||| IN
the  ||| S:26065 E:26069 ||| DT
SP  ||| S:26069 E:26072 ||| NNP
column  ||| S:26072 E:26079 ||| NN
was  ||| S:26079 E:26083 ||| VBD
then  ||| S:26083 E:26088 ||| RB
diluted  ||| S:26088 E:26096 ||| VBN
5-fold  ||| S:26096 E:26103 ||| CD
with  ||| S:26103 E:26108 ||| IN
buffer  ||| S:26108 E:26115 ||| JJ
C  ||| S:26115 E:26127 ||| NNP
( ||| S:26127 E:26128 ||| -LRB-
20  ||| S:26128 E:26131 ||| CD
mM  ||| S:26131 E:26134 ||| JJ
tris  ||| S:26134 E:26139 ||| JJ
pH  ||| S:26139 E:26142 ||| JJ
8.5 ||| S:26142 E:26145 ||| CD
,  ||| S:26145 E:26147 ||| ,
1  ||| S:26147 E:26149 ||| CD
mM  ||| S:26149 E:26152 ||| JJ
EDTA  ||| S:26152 E:26157 ||| NNP
and  ||| S:26157 E:26161 ||| CC
0.1 ||| S:26161 E:26164 ||| CD
%  ||| S:26164 E:26166 ||| NN
2-mercaptoethanol ||| S:26166 E:26183 ||| CD
)  ||| S:26183 E:26195 ||| -RRB-
and  ||| S:26195 E:26199 ||| CC
subjected  ||| S:26199 E:26209 ||| VBN
to  ||| S:26209 E:26212 ||| TO
anion-exchange  ||| S:26212 E:26227 ||| JJ
chromatography  ||| S:26227 E:26242 ||| NN
on  ||| S:26242 E:26245 ||| IN
a  ||| S:26245 E:26257 ||| DT
BioScale  ||| S:26257 E:26266 ||| JJ
Q  ||| S:26266 E:26268 ||| NNP
column  ||| S:26268 E:26275 ||| NN
( ||| S:26275 E:26276 ||| -LRB-
2  ||| S:26276 E:26278 ||| CD
ml  ||| S:26278 E:26281 ||| NN
from  ||| S:26281 E:26286 ||| IN
BioRad ||| S:26286 E:26292 ||| NNP
) ||| S:26292 E:26293 ||| -RRB-
.  ||| S:26293 E:26295 ||| .
All  ||| S:26295 E:26299 ||| DT
steps  ||| S:26299 E:26305 ||| NNS
in  ||| S:26305 E:26308 ||| IN
the  ||| S:26308 E:26322 ||| DT
purification  ||| S:26322 E:26335 ||| JJ
procedure  ||| S:26335 E:26345 ||| NN
were  ||| S:26345 E:26350 ||| VBD
performed  ||| S:26350 E:26360 ||| VBN
at  ||| S:26360 E:26363 ||| IN
4°C  ||| S:26363 E:26367 ||| CD
except  ||| S:26367 E:26374 ||| IN
for  ||| S:26374 E:26388 ||| IN
the  ||| S:26388 E:26392 ||| DT
last  ||| S:26392 E:26397 ||| JJ
step  ||| S:26397 E:26402 ||| NN
which  ||| S:26402 E:26408 ||| WDT
was  ||| S:26408 E:26412 ||| VBD
performed  ||| S:26412 E:26422 ||| VBN
at  ||| S:26422 E:26425 ||| IN
23°C ||| S:26425 E:26429 ||| CD
.  ||| S:26429 E:26431 ||| .
PP5  ||| S:26431 E:26435 ||| NNP
activity  ||| S:26435 E:26454 ||| NN
was  ||| S:26454 E:26458 ||| VBD
followed  ||| S:26458 E:26467 ||| VBN
during  ||| S:26467 E:26474 ||| IN
the  ||| S:26474 E:26478 ||| DT
purification  ||| S:26478 E:26491 ||| NN
by  ||| S:26491 E:26494 ||| IN
assaying  ||| S:26494 E:26503 ||| NN
for  ||| S:26503 E:26517 ||| IN
trypsin-stimulated  ||| S:26517 E:26536 ||| JJ
phosphohydrolase  ||| S:26536 E:26553 ||| JJ
activity  ||| S:26553 E:26562 ||| NN
at  ||| S:26562 E:26565 ||| IN
37°C  ||| S:26565 E:26570 ||| FW
vs.  ||| S:26570 E:26584 ||| FW
p-nitrophenyl  ||| S:26584 E:26598 ||| FW
phosphate  ||| S:26598 E:26608 ||| FW
in  ||| S:26608 E:26611 ||| IN
200  ||| S:26611 E:26615 ||| CD
μl  ||| S:26615 E:26618 ||| CD
reactions  ||| S:26618 E:26628 ||| NNS
containing ||| S:26628 E:26638 ||| VBG
:  ||| S:26638 E:26650 ||| :
25  ||| S:26650 E:26653 ||| CD
mM  ||| S:26653 E:26656 ||| JJ
tris  ||| S:26656 E:26661 ||| JJ
pH  ||| S:26661 E:26664 ||| JJ
8.3 ||| S:26664 E:26667 ||| CD
,  ||| S:26667 E:26669 ||| ,
25  ||| S:26669 E:26672 ||| CD
mM  ||| S:26672 E:26675 ||| JJ
MgCl  ||| S:26675 E:26691 ||| JJ
2  ||| S:26691 E:26693 ||| CD
,  ||| S:26693 E:26695 ||| ,
1  ||| S:26695 E:26697 ||| CD
mM  ||| S:26697 E:26700 ||| JJ
DTT  ||| S:26700 E:26704 ||| NNP
and  ||| S:26704 E:26708 ||| CC
10  ||| S:26708 E:26711 ||| CD
mM  ||| S:26711 E:26714 ||| JJ
p-nitrophenyl  ||| S:26714 E:26738 ||| JJ
phosphate ||| S:26738 E:26747 ||| NN
.  ||| S:26747 E:26759 ||| .
Dephosphorylation  ||| S:26759 E:26777 ||| JJ
reactions  ||| S:26777 E:26787 ||| NNS
were  ||| S:26787 E:26792 ||| VBD
routinely  ||| S:26792 E:26802 ||| RB
conducted  ||| S:26802 E:26822 ||| VBN
for  ||| S:26822 E:26826 ||| IN
10  ||| S:26826 E:26829 ||| CD
minutes  ||| S:26829 E:26837 ||| NNS
and  ||| S:26837 E:26841 ||| CC
initiated  ||| S:26841 E:26851 ||| VBN
with  ||| S:26851 E:26856 ||| IN
the  ||| S:26856 E:26860 ||| DT
addition  ||| S:26860 E:26869 ||| NN
of  ||| S:26869 E:26882 ||| IN
substrate ||| S:26882 E:26891 ||| NN
.  ||| S:26891 E:26893 ||| .
The  ||| S:26893 E:26897 ||| DT
dephosphorylation  ||| S:26897 E:26915 ||| NN
of  ||| S:26915 E:26918 ||| IN
substrate  ||| S:26918 E:26928 ||| NN
was  ||| S:26928 E:26932 ||| VBD
kept  ||| S:26932 E:26937 ||| VBN
to  ||| S:26937 E:26950 ||| TO
less  ||| S:26950 E:26955 ||| JJR
than  ||| S:26955 E:26960 ||| IN
10  ||| S:26960 E:26963 ||| CD
%  ||| S:26963 E:26965 ||| NN
of  ||| S:26965 E:26968 ||| IN
the  ||| S:26968 E:26972 ||| DT
total  ||| S:26972 E:26978 ||| JJ
phosphorylated  ||| S:26978 E:26993 ||| JJ
substrate ||| S:26993 E:27002 ||| NN
,  ||| S:27002 E:27004 ||| ,
and  ||| S:27004 E:27018 ||| CC
the  ||| S:27018 E:27022 ||| DT
reaction  ||| S:27022 E:27031 ||| NN
was  ||| S:27031 E:27035 ||| VBD
linear  ||| S:27035 E:27042 ||| VBN
with  ||| S:27042 E:27047 ||| IN
respect  ||| S:27047 E:27055 ||| NN
to  ||| S:27055 E:27058 ||| TO
enzyme  ||| S:27058 E:27075 ||| VB
concentration  ||| S:27075 E:27089 ||| NN
and  ||| S:27089 E:27093 ||| CC
time.  ||| S:27093 E:27099 ||| NNP
[  ||| S:27099 E:27101 ||| -LRB-
32P ||| S:27101 E:27104 ||| NNP
] ||| S:27104 E:27105 ||| -RRB-
phosphate  ||| S:27105 E:27115 ||| JJ
liberated  ||| S:27115 E:27125 ||| NN
by  ||| S:27125 E:27128 ||| IN
the  ||| S:27128 E:27142 ||| DT
enzymes  ||| S:27142 E:27150 ||| NN
was  ||| S:27150 E:27154 ||| VBD
extracted  ||| S:27154 E:27164 ||| VBN
as  ||| S:27164 E:27167 ||| IN
a  ||| S:27167 E:27169 ||| DT
phosphomolybdate  ||| S:27169 E:27186 ||| JJ
complex  ||| S:27186 E:27194 ||| NN
and  ||| S:27194 E:27208 ||| CC
measured  ||| S:27208 E:27217 ||| VBN
according  ||| S:27217 E:27227 ||| VBG
to  ||| S:27227 E:27230 ||| TO
the  ||| S:27230 E:27234 ||| DT
methods  ||| S:27234 E:27242 ||| NNS
of  ||| S:27242 E:27245 ||| IN
Killilea  ||| S:27245 E:27254 ||| NNP
et  ||| S:27254 E:27257 ||| FW
al.  ||| S:27257 E:27261 ||| FW
[  ||| S:27261 E:27273 ||| -LRB-
35 ||| S:27273 E:27275 ||| CD
] ||| S:27275 E:27276 ||| -RRB-
.  ||| S:27276 E:27278 ||| .
Inhibition  ||| S:27278 E:27289 ||| NNP
of  ||| S:27289 E:27292 ||| IN
phosphatase  ||| S:27292 E:27304 ||| JJ
activity  ||| S:27304 E:27313 ||| NN
by  ||| S:27313 E:27316 ||| IN
okadaic  ||| S:27316 E:27324 ||| JJ
acid  ||| S:27324 E:27339 ||| NN
was  ||| S:27339 E:27343 ||| VBD
determined  ||| S:27343 E:27354 ||| VBN
by  ||| S:27354 E:27357 ||| IN
adding  ||| S:27357 E:27364 ||| VBG
the  ||| S:27364 E:27368 ||| DT
inhibitors  ||| S:27368 E:27379 ||| NN
to  ||| S:27379 E:27382 ||| TO
the  ||| S:27382 E:27386 ||| DT
enzyme  ||| S:27386 E:27403 ||| JJ
mixture  ||| S:27403 E:27411 ||| NN
10  ||| S:27411 E:27414 ||| CD
minutes  ||| S:27414 E:27422 ||| NNS
prior  ||| S:27422 E:27428 ||| RB
to  ||| S:27428 E:27431 ||| TO
initiating  ||| S:27431 E:27442 ||| VB
the  ||| S:27442 E:27446 ||| DT
reaction  ||| S:27446 E:27455 ||| NN
with  ||| S:27455 E:27470 ||| IN
the  ||| S:27470 E:27474 ||| DT
addition  ||| S:27474 E:27483 ||| NN
of  ||| S:27483 E:27486 ||| IN
substrate ||| S:27486 E:27495 ||| NN
.  ||| S:27495 E:27525 ||| .
GR-GFP  ||| S:27525 E:27532 ||| JJ
expression  ||| S:27532 E:27543 ||| NN
vectors  ||| S:27543 E:27561 ||| VBD
A  ||| S:27561 E:27563 ||| DT
mutant  ||| S:27563 E:27570 ||| JJ
rat  ||| S:27570 E:27574 ||| NN
glucocorticoid  ||| S:27574 E:27589 ||| NN
receptor  ||| S:27589 E:27598 ||| NN
that  ||| S:27598 E:27603 ||| WDT
retained  ||| S:27603 E:27622 ||| VBD
hormone  ||| S:27622 E:27630 ||| JJ
binding ||| S:27630 E:27637 ||| NN
,  ||| S:27637 E:27639 ||| ,
nuclear  ||| S:27639 E:27647 ||| JJ
translocation  ||| S:27647 E:27661 ||| JJ
activity ||| S:27661 E:27669 ||| NN
,  ||| S:27669 E:27671 ||| ,
and  ||| S:27671 E:27685 ||| CC
specific  ||| S:27685 E:27694 ||| JJ
DNA  ||| S:27694 E:27698 ||| NN
binding  ||| S:27698 E:27706 ||| JJ
activity ||| S:27706 E:27714 ||| NN
,  ||| S:27714 E:27716 ||| ,
but  ||| S:27716 E:27720 ||| CC
was  ||| S:27720 E:27724 ||| VBD
incapable  ||| S:27724 E:27734 ||| VBN
of  ||| S:27734 E:27747 ||| IN
transactivation  ||| S:27747 E:27763 ||| NN
was  ||| S:27763 E:27767 ||| VBD
fused  ||| S:27767 E:27773 ||| VBN
to  ||| S:27773 E:27776 ||| TO
a  ||| S:27776 E:27778 ||| DT
S65T  ||| S:27778 E:27783 ||| JJ
mutant  ||| S:27783 E:27790 ||| NN
of  ||| S:27790 E:27793 ||| IN
green  ||| S:27793 E:27809 ||| JJ
fluorescent  ||| S:27809 E:27821 ||| JJ
protein  ||| S:27821 E:27829 ||| NN
to  ||| S:27829 E:27832 ||| TO
create  ||| S:27832 E:27839 ||| VB
pGR ||| S:27839 E:27842 ||| JJ
( ||| S:27842 E:27843 ||| -LRB-
Ala ||| S:27843 E:27846 ||| NNP
) ||| S:27846 E:27847 ||| -RRB-
-GFP ||| S:27847 E:27851 ||| JJ
.  ||| S:27851 E:27853 ||| .
GR ||| S:27853 E:27855 ||| NNP
( ||| S:27855 E:27856 ||| -LRB-
Ala ||| S:27856 E:27859 ||| NNP
) ||| S:27859 E:27860 ||| -RRB-
-GFP  ||| S:27860 E:27875 ||| JJ
expression  ||| S:27875 E:27886 ||| NN
is  ||| S:27886 E:27889 ||| VBZ
driven  ||| S:27889 E:27896 ||| VBN
by  ||| S:27896 E:27899 ||| IN
the  ||| S:27899 E:27903 ||| DT
CMV  ||| S:27903 E:27907 ||| NNP
immediate  ||| S:27907 E:27917 ||| JJ
early  ||| S:27917 E:27923 ||| JJ
promoter  ||| S:27923 E:27942 ||| NN
and  ||| S:27942 E:27946 ||| CC
enhancer ||| S:27946 E:27954 ||| NN
.  ||| S:27954 E:27956 ||| .
All  ||| S:27956 E:27960 ||| DT
manipulations  ||| S:27960 E:27974 ||| NN
were  ||| S:27974 E:27979 ||| VBD
performed  ||| S:27979 E:27989 ||| VBN
as  ||| S:27989 E:28002 ||| RB
described ||| S:28002 E:28011 ||| VBN
,  ||| S:28011 E:28013 ||| ,
and  ||| S:28013 E:28017 ||| CC
all  ||| S:28017 E:28021 ||| DT
constructs  ||| S:28021 E:28032 ||| NN
were  ||| S:28032 E:28037 ||| VBD
confirmed  ||| S:28037 E:28047 ||| VBN
by  ||| S:28047 E:28060 ||| IN
sequencing  ||| S:28060 E:28071 ||| NNS
[  ||| S:28071 E:28073 ||| -LRB-
36 ||| S:28073 E:28075 ||| CD
] ||| S:28075 E:28076 ||| -RRB-
.  ||| S:28076 E:28078 ||| .
Protein-free  ||| S:28078 E:28091 ||| JJ
plasmid  ||| S:28091 E:28099 ||| JJ
DNA  ||| S:28099 E:28103 ||| NN
was  ||| S:28103 E:28107 ||| VBD
purified  ||| S:28107 E:28126 ||| VBN
using  ||| S:28126 E:28132 ||| VBG
Qiagen  ||| S:28132 E:28139 ||| JJ
maxiprep  ||| S:28139 E:28148 ||| JJ
columns  ||| S:28148 E:28156 ||| NNS
( ||| S:28156 E:28157 ||| -LRB-
San  ||| S:28157 E:28161 ||| NNP
Diego ||| S:28161 E:28166 ||| NNP
,  ||| S:28166 E:28168 ||| ,
CA ||| S:28168 E:28170 ||| NNP
)  ||| S:28170 E:28172 ||| -RRB-
and  ||| S:28172 E:28186 ||| CC
contained  ||| S:28186 E:28196 ||| VBD
predominantly  ||| S:28196 E:28210 ||| RB
supercoiled  ||| S:28210 E:28222 ||| JJ
plasmid  ||| S:28222 E:28230 ||| NN
with  ||| S:28230 E:28235 ||| IN
no  ||| S:28235 E:28248 ||| DT
contaminating  ||| S:28248 E:28262 ||| JJ
RNA  ||| S:28262 E:28266 ||| NNP
or  ||| S:28266 E:28269 ||| CC
low  ||| S:28269 E:28273 ||| JJ
molecular  ||| S:28273 E:28283 ||| JJ
weight  ||| S:28283 E:28300 ||| NN
contaminants ||| S:28300 E:28312 ||| NN
.  ||| S:28312 E:28342 ||| .
GFP-GR  ||| S:28342 E:28349 ||| JJ
translocation  ||| S:28349 E:28373 ||| JJ
Cells  ||| S:28373 E:28379 ||| NNP
were  ||| S:28379 E:28384 ||| VBD
plated  ||| S:28384 E:28391 ||| VBN
on  ||| S:28391 E:28394 ||| IN
etched  ||| S:28394 E:28401 ||| JJ
coverslips  ||| S:28401 E:28412 ||| NN
and  ||| S:28412 E:28416 ||| CC
grown  ||| S:28416 E:28422 ||| VBN
until  ||| S:28422 E:28438 ||| IN
the  ||| S:28438 E:28442 ||| DT
cultures  ||| S:28442 E:28451 ||| NNS
were  ||| S:28451 E:28456 ||| VBD
~  ||| S:28456 E:28458 ||| CD
70  ||| S:28458 E:28461 ||| CD
%  ||| S:28461 E:28463 ||| NN
confluent ||| S:28463 E:28472 ||| NN
.  ||| S:28472 E:28474 ||| .
The  ||| S:28474 E:28478 ||| DT
cells  ||| S:28478 E:28484 ||| NNS
were  ||| S:28484 E:28489 ||| VBD
then  ||| S:28489 E:28504 ||| RB
either  ||| S:28504 E:28511 ||| RB
treated  ||| S:28511 E:28519 ||| VBN
with  ||| S:28519 E:28524 ||| IN
oligonucleotides  ||| S:28524 E:28541 ||| VBG
as  ||| S:28541 E:28544 ||| RB
described  ||| S:28544 E:28554 ||| VBN
above  ||| S:28554 E:28570 ||| IN
or  ||| S:28570 E:28573 ||| CC
left  ||| S:28573 E:28578 ||| VBD
untreated ||| S:28578 E:28587 ||| VBN
.  ||| S:28587 E:28589 ||| .
Eighteen  ||| S:28589 E:28598 ||| JJ
hours  ||| S:28598 E:28604 ||| NNS
later ||| S:28604 E:28609 ||| RB
,  ||| S:28609 E:28611 ||| ,
purified  ||| S:28611 E:28630 ||| JJ
protein-free  ||| S:28630 E:28643 ||| JJ
pGR ||| S:28643 E:28646 ||| NN
( ||| S:28646 E:28647 ||| -LRB-
Ala ||| S:28647 E:28650 ||| NNP
) ||| S:28650 E:28651 ||| -RRB-
-GFP  ||| S:28651 E:28656 ||| NNP
suspended  ||| S:28656 E:28666 ||| VBD
in  ||| S:28666 E:28669 ||| IN
phosphate-buffered  ||| S:28669 E:28698 ||| JJ
saline  ||| S:28698 E:28705 ||| NNS
( ||| S:28705 E:28706 ||| -LRB-
0.25  ||| S:28706 E:28711 ||| CD
mg ||| S:28711 E:28713 ||| CD
/ ||| S:28713 E:28714 ||| CD
ml ||| S:28714 E:28716 ||| CD
)  ||| S:28716 E:28718 ||| -RRB-
was  ||| S:28718 E:28722 ||| VBD
microinjected  ||| S:28722 E:28736 ||| VBN
into  ||| S:28736 E:28741 ||| IN
the  ||| S:28741 E:28745 ||| DT
nuclei  ||| S:28745 E:28752 ||| NN
of  ||| S:28752 E:28765 ||| IN
the  ||| S:28765 E:28769 ||| DT
cells  ||| S:28769 E:28775 ||| NNS
[  ||| S:28775 E:28777 ||| -LRB-
37 ||| S:28777 E:28779 ||| CD
] ||| S:28779 E:28780 ||| -RRB-
.  ||| S:28780 E:28782 ||| .
Typically ||| S:28782 E:28791 ||| RB
,  ||| S:28791 E:28793 ||| ,
150-200  ||| S:28793 E:28801 ||| CD
cells  ||| S:28801 E:28807 ||| NNS
were  ||| S:28807 E:28812 ||| VBD
injected  ||| S:28812 E:28831 ||| VBN
for  ||| S:28831 E:28835 ||| IN
each  ||| S:28835 E:28840 ||| DT
condition ||| S:28840 E:28849 ||| NN
.  ||| S:28849 E:28851 ||| .
After  ||| S:28851 E:28857 ||| IN
microinjection  ||| S:28857 E:28872 ||| VBG
the  ||| S:28872 E:28876 ||| DT
cells  ||| S:28876 E:28882 ||| NNS
were  ||| S:28882 E:28897 ||| VBD
incubated  ||| S:28897 E:28907 ||| VBN
in  ||| S:28907 E:28910 ||| IN
medium  ||| S:28910 E:28917 ||| NN
containing  ||| S:28917 E:28928 ||| VBG
10 ||| S:28928 E:28930 ||| CD
%  ||| S:28930 E:28932 ||| NN
FBS  ||| S:28932 E:28936 ||| NN
for  ||| S:28936 E:28940 ||| IN
6  ||| S:28940 E:28942 ||| CD
hours  ||| S:28942 E:28948 ||| NNS
at  ||| S:28948 E:28961 ||| IN
37°C ||| S:28961 E:28965 ||| CD
.  ||| S:28965 E:28967 ||| .
The  ||| S:28967 E:28971 ||| DT
cells  ||| S:28971 E:28977 ||| NNS
were  ||| S:28977 E:28982 ||| VBD
then  ||| S:28982 E:28987 ||| RB
washed  ||| S:28987 E:28994 ||| VBN
several  ||| S:28994 E:29002 ||| JJ
times  ||| S:29002 E:29008 ||| NNS
with  ||| S:29008 E:29023 ||| IN
serum-free  ||| S:29023 E:29034 ||| JJ
media  ||| S:29034 E:29040 ||| NNS
and  ||| S:29040 E:29044 ||| CC
placed  ||| S:29044 E:29051 ||| VBN
in  ||| S:29051 E:29054 ||| IN
serum  ||| S:29054 E:29060 ||| JJ
deficient  ||| S:29060 E:29070 ||| JJ
media  ||| S:29070 E:29076 ||| NNS
for  ||| S:29076 E:29090 ||| IN
14  ||| S:29090 E:29093 ||| CD
hours  ||| S:29093 E:29099 ||| NNS
to  ||| S:29099 E:29102 ||| TO
prevent  ||| S:29102 E:29110 ||| VB
GFP-GR  ||| S:29110 E:29117 ||| JJ
translocation  ||| S:29117 E:29131 ||| NN
to  ||| S:29131 E:29134 ||| TO
the  ||| S:29134 E:29138 ||| DT
nucleus ||| S:29138 E:29145 ||| NN
,  ||| S:29145 E:29157 ||| ,
prior  ||| S:29157 E:29163 ||| RB
to  ||| S:29163 E:29166 ||| TO
treatment  ||| S:29166 E:29176 ||| NN
with  ||| S:29176 E:29181 ||| IN
500  ||| S:29181 E:29185 ||| CD
nM  ||| S:29185 E:29188 ||| JJ
dexamethasone  ||| S:29188 E:29202 ||| NNS
( ||| S:29202 E:29203 ||| -LRB-
30  ||| S:29203 E:29206 ||| CD
min. ||| S:29206 E:29210 ||| CD
)  ||| S:29210 E:29212 ||| -RRB-
or  ||| S:29212 E:29225 ||| CC
with  ||| S:29225 E:29230 ||| IN
vehicle  ||| S:29230 E:29238 ||| NN
alone ||| S:29238 E:29243 ||| RB
.  ||| S:29243 E:29245 ||| .
The  ||| S:29245 E:29249 ||| DT
cells  ||| S:29249 E:29255 ||| NNS
were  ||| S:29255 E:29260 ||| VBD
washed  ||| S:29260 E:29267 ||| VBN
3  ||| S:29267 E:29269 ||| CD
times  ||| S:29269 E:29275 ||| NNS
with  ||| S:29275 E:29290 ||| IN
PBS ||| S:29290 E:29293 ||| NNP
,  ||| S:29293 E:29295 ||| ,
fixed  ||| S:29295 E:29301 ||| VBN
by  ||| S:29301 E:29304 ||| IN
incubation  ||| S:29304 E:29315 ||| NN
in  ||| S:29315 E:29318 ||| IN
PBS  ||| S:29318 E:29322 ||| NNP
supplemented  ||| S:29322 E:29335 ||| NN
with  ||| S:29335 E:29340 ||| IN
4  ||| S:29340 E:29342 ||| CD
%  ||| S:29342 E:29354 ||| NN
paraformaldehyde  ||| S:29354 E:29371 ||| NN
for  ||| S:29371 E:29375 ||| IN
10  ||| S:29375 E:29378 ||| CD
min  ||| S:29378 E:29382 ||| NNS
and  ||| S:29382 E:29386 ||| CC
washed  ||| S:29386 E:29393 ||| VBD
again  ||| S:29393 E:29399 ||| RB
3  ||| S:29399 E:29401 ||| CD
times  ||| S:29401 E:29407 ||| NNS
with  ||| S:29407 E:29422 ||| IN
PBS  ||| S:29422 E:29426 ||| NNP
before  ||| S:29426 E:29433 ||| IN
mounting  ||| S:29433 E:29442 ||| VBG
on  ||| S:29442 E:29445 ||| IN
slides  ||| S:29445 E:29452 ||| NNS
with  ||| S:29452 E:29457 ||| IN
DABCO ||| S:29457 E:29462 ||| NNP
/ ||| S:29462 E:29463 ||| NNP
DAPI  ||| S:29463 E:29468 ||| NNP
mounting  ||| S:29468 E:29487 ||| VBG
solution ||| S:29487 E:29495 ||| NN
.  ||| S:29495 E:29497 ||| .
GR-GFP  ||| S:29497 E:29504 ||| JJ
expression  ||| S:29504 E:29515 ||| NN
and  ||| S:29515 E:29519 ||| CC
localization  ||| S:29519 E:29532 ||| NNS
were  ||| S:29532 E:29547 ||| VBD
monitored  ||| S:29547 E:29557 ||| VBN
by  ||| S:29557 E:29560 ||| IN
fluorescence  ||| S:29560 E:29573 ||| JJ
microscopy ||| S:29573 E:29583 ||| NN
.  ||| S:29583 E:29585 ||| .
Nuclei  ||| S:29585 E:29592 ||| NNP
were  ||| S:29592 E:29607 ||| VBD
localized  ||| S:29607 E:29617 ||| VBN
by  ||| S:29617 E:29620 ||| IN
DAPI  ||| S:29620 E:29625 ||| NNP
staining ||| S:29625 E:29633 ||| NN
.  ||| S:29633 E:29635 ||| .
Images  ||| S:29635 E:29642 ||| NNS
were  ||| S:29642 E:29647 ||| VBD
captured  ||| S:29647 E:29656 ||| VBN
with  ||| S:29656 E:29661 ||| IN
an  ||| S:29661 E:29674 ||| DT
Optronics  ||| S:29674 E:29684 ||| NNP
cooled  ||| S:29684 E:29691 ||| VBD
CCD  ||| S:29691 E:29695 ||| NNP
camera  ||| S:29695 E:29702 ||| NN
and  ||| S:29702 E:29706 ||| CC
imported  ||| S:29706 E:29715 ||| VBN
into  ||| S:29715 E:29720 ||| IN
Adobe  ||| S:29720 E:29736 ||| NNP
Photoshop ||| S:29736 E:29745 ||| NNP
.  ||| S:29745 E:29747 ||| .
The  ||| S:29747 E:29751 ||| DT
experiments  ||| S:29751 E:29763 ||| NNS
were  ||| S:29763 E:29768 ||| VBD
repeated  ||| S:29768 E:29777 ||| VBN
4  ||| S:29777 E:29779 ||| CD
times  ||| S:29779 E:29785 ||| NNS
( ||| S:29785 E:29786 ||| -LRB-
6  ||| S:29786 E:29788 ||| CD
for  ||| S:29788 E:29802 ||| IN
control ||| S:29802 E:29809 ||| NN
) ||| S:29809 E:29810 ||| -RRB-
.  ||| S:29810 E:29812 ||| .
One-way  ||| S:29812 E:29820 ||| JJ
ANOVA  ||| S:29820 E:29826 ||| NNP
was  ||| S:29826 E:29830 ||| VBD
performed  ||| S:29830 E:29840 ||| VBN
to  ||| S:29840 E:29843 ||| TO
determine  ||| S:29843 E:29863 ||| VB
statistical  ||| S:29863 E:29875 ||| JJ
significance  ||| S:29875 E:29888 ||| NN
of  ||| S:29888 E:29891 ||| IN
the  ||| S:29891 E:29895 ||| DT
results  ||| S:29895 E:29903 ||| NNS
using  ||| S:29903 E:29909 ||| VBG
Instat  ||| S:29909 E:29916 ||| NNP
2.03  ||| S:29916 E:29931 ||| NNP
( ||| S:29931 E:29932 ||| -LRB-
GraphPad  ||| S:29932 E:29941 ||| NNP
Software ||| S:29941 E:29949 ||| NNP
,  ||| S:29949 E:29951 ||| ,
San  ||| S:29951 E:29955 ||| NNP
Diego ||| S:29955 E:29960 ||| NNP
,  ||| S:29960 E:29962 ||| ,
CA ||| S:29962 E:29964 ||| NNP
) ||| S:29964 E:29965 ||| -RRB-
.  ||| S:29965 E:29995 ||| .
GFP-NFAT  ||| S:29995 E:30004 ||| JJ
nuclear  ||| S:30004 E:30012 ||| JJ
shuttling  ||| S:30012 E:30022 ||| FW
assay  ||| S:30022 E:30038 ||| FW
Stably-transfected  ||| S:30038 E:30057 ||| FW
HeLa  ||| S:30057 E:30062 ||| FW
cells  ||| S:30062 E:30068 ||| FW
expressing  ||| S:30068 E:30079 ||| FW
GFP-NFAT  ||| S:30079 E:30088 ||| FW
[  ||| S:30088 E:30100 ||| -LRB-
38 ||| S:30100 E:30102 ||| CD
]  ||| S:30102 E:30104 ||| -RRB-
were  ||| S:30104 E:30109 ||| VBD
grown  ||| S:30109 E:30115 ||| VBN
on  ||| S:30115 E:30118 ||| IN
glass  ||| S:30118 E:30124 ||| NN
coverslips  ||| S:30124 E:30135 ||| NN
to  ||| S:30135 E:30138 ||| TO
approximately  ||| S:30138 E:30152 ||| RB
30 ||| S:30152 E:30154 ||| CD
%  ||| S:30154 E:30166 ||| NN
confluency  ||| S:30166 E:30177 ||| NNS
and  ||| S:30177 E:30181 ||| CC
either  ||| S:30181 E:30188 ||| RB
left  ||| S:30188 E:30193 ||| VBN
untreated  ||| S:30193 E:30203 ||| NNS
or  ||| S:30203 E:30206 ||| CC
treated  ||| S:30206 E:30214 ||| VBN
with ||| S:30214 E:30218 ||| IN
,  ||| S:30218 E:30230 ||| ,
ISIS  ||| S:30230 E:30235 ||| NNP
15534 ||| S:30235 E:30240 ||| CD
,  ||| S:30240 E:30242 ||| ,
or  ||| S:30242 E:30245 ||| CC
ISIS  ||| S:30245 E:30250 ||| NNP
15521  ||| S:30250 E:30256 ||| CD
( ||| S:30256 E:30257 ||| -LRB-
a  ||| S:30257 E:30259 ||| DT
mismatched  ||| S:30259 E:30270 ||| JJ
oligonucleotide  ||| S:30270 E:30296 ||| JJ
control  ||| S:30296 E:30304 ||| NN
for  ||| S:30304 E:30308 ||| IN
ISIS  ||| S:30308 E:30313 ||| NNP
15534 ||| S:30313 E:30318 ||| CD
)  ||| S:30318 E:30320 ||| -RRB-
in  ||| S:30320 E:30323 ||| IN
the  ||| S:30323 E:30327 ||| DT
absence  ||| S:30327 E:30335 ||| NN
of  ||| S:30335 E:30338 ||| IN
serum  ||| S:30338 E:30344 ||| VBG
as  ||| S:30344 E:30357 ||| RB
described  ||| S:30357 E:30367 ||| VBN
above ||| S:30367 E:30372 ||| IN
.  ||| S:30372 E:30374 ||| .
Four  ||| S:30374 E:30379 ||| CD
hours  ||| S:30379 E:30385 ||| NNS
later ||| S:30385 E:30390 ||| RB
,  ||| S:30390 E:30392 ||| ,
FBS  ||| S:30392 E:30396 ||| NNP
was  ||| S:30396 E:30400 ||| VBD
added  ||| S:30400 E:30406 ||| VBN
to  ||| S:30406 E:30409 ||| TO
10 ||| S:30409 E:30411 ||| CD
%  ||| S:30411 E:30423 ||| NN
and  ||| S:30423 E:30427 ||| CC
the  ||| S:30427 E:30431 ||| DT
cells  ||| S:30431 E:30437 ||| NNS
were  ||| S:30437 E:30442 ||| VBD
grown  ||| S:30442 E:30448 ||| VBN
for  ||| S:30448 E:30452 ||| IN
an  ||| S:30452 E:30455 ||| DT
additional  ||| S:30455 E:30466 ||| JJ
24  ||| S:30466 E:30469 ||| CD
hours ||| S:30469 E:30474 ||| NNS
.  ||| S:30474 E:30476 ||| .
The  ||| S:30476 E:30490 ||| DT
cells  ||| S:30490 E:30496 ||| NNS
were  ||| S:30496 E:30501 ||| VBD
then  ||| S:30501 E:30506 ||| RB
treated  ||| S:30506 E:30514 ||| VBN
with  ||| S:30514 E:30519 ||| IN
1  ||| S:30519 E:30521 ||| CD
μM  ||| S:30521 E:30524 ||| JJ
ionomycin  ||| S:30524 E:30534 ||| NN
for  ||| S:30534 E:30538 ||| IN
30  ||| S:30538 E:30551 ||| CD
minutes ||| S:30551 E:30558 ||| NNS
,  ||| S:30558 E:30560 ||| ,
after  ||| S:30560 E:30566 ||| IN
which  ||| S:30566 E:30572 ||| WDT
time  ||| S:30572 E:30577 ||| NN
they  ||| S:30577 E:30582 ||| PRP
were  ||| S:30582 E:30587 ||| VBD
either  ||| S:30587 E:30594 ||| RB
fixed  ||| S:30594 E:30610 ||| VBN
immediately  ||| S:30610 E:30622 ||| RB
or  ||| S:30622 E:30625 ||| CC
washed  ||| S:30625 E:30632 ||| JJ
extensively  ||| S:30632 E:30644 ||| NN
with  ||| S:30644 E:30649 ||| IN
PBS  ||| S:30649 E:30653 ||| NNP
and  ||| S:30653 E:30657 ||| CC
incubated  ||| S:30657 E:30677 ||| NN
for  ||| S:30677 E:30681 ||| IN
6  ||| S:30681 E:30683 ||| CD
hours  ||| S:30683 E:30689 ||| NNS
in  ||| S:30689 E:30692 ||| IN
medium  ||| S:30692 E:30699 ||| NN
lacking  ||| S:30699 E:30707 ||| VBG
the  ||| S:30707 E:30711 ||| DT
drug  ||| S:30711 E:30716 ||| NN
( ||| S:30716 E:30717 ||| -LRB-
"washout ||| S:30717 E:30725 ||| NNP
" ||| S:30725 E:30726 ||| ''
) ||| S:30726 E:30727 ||| -RRB-
.  ||| S:30727 E:30739 ||| .
Control  ||| S:30739 E:30747 ||| NN
cells  ||| S:30747 E:30753 ||| NNS
were  ||| S:30753 E:30758 ||| VBD
not  ||| S:30758 E:30762 ||| RB
incubated  ||| S:30762 E:30772 ||| VBN
with  ||| S:30772 E:30777 ||| IN
ionomycin ||| S:30777 E:30786 ||| NN
.  ||| S:30786 E:30788 ||| .
GFP-NFAT  ||| S:30788 E:30807 ||| JJ
localization  ||| S:30807 E:30820 ||| NN
was  ||| S:30820 E:30824 ||| VBD
monitored  ||| S:30824 E:30834 ||| VBN
by  ||| S:30834 E:30837 ||| IN
fluorescence  ||| S:30837 E:30850 ||| JJ
microscopy ||| S:30850 E:30860 ||| NN
,  ||| S:30860 E:30872 ||| ,
and  ||| S:30872 E:30876 ||| CC
images  ||| S:30876 E:30883 ||| NNS
were  ||| S:30883 E:30888 ||| VBD
captured  ||| S:30888 E:30897 ||| VBN
with  ||| S:30897 E:30902 ||| IN
an  ||| S:30902 E:30905 ||| DT
Optronics  ||| S:30905 E:30915 ||| NNP
cooled  ||| S:30915 E:30922 ||| VBD
CCD  ||| S:30922 E:30936 ||| NNP
camera  ||| S:30936 E:30943 ||| NN
and  ||| S:30943 E:30947 ||| CC
imported  ||| S:30947 E:30956 ||| VBN
into  ||| S:30956 E:30961 ||| IN
Adobe  ||| S:30961 E:30967 ||| NNP
Photoshop ||| S:30967 E:30976 ||| NNP
.  ||| S:30976 E:31002 ||| .
